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Abstract 
 
The paper, composed for Worcester Polytechnic Institute, examines the various 
implications and possible solutions of Alzheimer’s disease in society. It begins with a 
briefing on the numerous physiological characteristics of the disease and continues with a 
dissertation of the current treatments and possible future treatments, with the aid of early 
detection techniques. Furthermore, the paper also discusses the relationship of the disease 
with other disorders and assesses the socioeconomic impacts of Alzheimer’s presently, 
with a conjecture on possible future techniques.  
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Executive Summary 
This Interactive Qualifying Project investigates the current fields of pathology, 
detection techniques, treatments, and prevention methods of Alzheimer’s disease.	  
Alzheimer’s disease (AD) is a neurodegenerative disorder that occurs mainly in older 
people, and it is the most common cause of dementia. As of the 2009 Alzheimer’s 
Report, there is an estimate of 36 million people living with dementia worldwide, and its 
prevalence is only increasing with an estimated 115 million diagnosed by 2050. There are 
currently no known cures or preventions, and the only definitive way to diagnosis 
Alzheimer’s is through a post-mortem autopsy. The autopsy allows for the analysis of the 
excess presence of amyloid plaques and neurofibrillary tangles in the brain.	  
The presence of large amounts of amyloid plaques, made from β-amyloid 
proteins (Aβ), and neurofibrillary tangles, made from tau proteins, were the very first 
diagnostic characteristics of the disease. These were first visualized and determined by a 
young and accomplished German doctor named Alois Alzheimer in the brain slices of the 
very first patient with Alzheimer’s disease, Auguste D. As the years progressed and the 
research into the disorder intensified, another possible characteristic of AD surfaced: the 
disruption of calcium homeostasis in neurons. This characteristic came to be identified as 
a possible cause when researchers established a greater understanding of the role calcium 
plays in memory formation and activation of apoptosis, otherwise known as cell death, as 
well as its continual presence in neurons of AD patients. 
The combination of large concentrations of amyloid plaques and neurofibrillary 
tangles, along with the disruption of calcium homeostasis in the neurons, results in 
interference of normal neuronal functions that is caused by damages to the synapses. 
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Other causes include the destruction of the cellular trafficking system, the extensive 
production of reactive oxygen species leading to oxidative stress, the inability of the 
neuron to correct cellular damages, and later the activation of apoptosis. All of this 
manifests itself in the form of cortical atrophy, memory loss, decrease in cellular energy 
metabolism, smaller brain size, and psychiatric disturbances. 
Although there has been great progress in understanding the characteristics of 
the disease and how it manifests itself, there has been limited understanding in the risk 
factors of AD. Nevertheless, there are diseases such as Type II diabetes and Down’s 
syndrome, which have similar characteristics to Alzheimer’s. There are several 
environmental, genetic, and evolutionary risk factors associated with the diseases, 
whether it is diabetes or Down’s syndrome. As a result, it may be a disadvantage for the 
patients since they are at a higher risk for contracting the other two disorders in addition 
to having Alzheimer’s. Conversely, the similarities may allow for a faster treatment and 
better opportunities to detect and treat Alzheimer’s and other deadly disorders using the 
same tests. Not only is there a very limited knowledge in the possible risk factors of AD, 
but also there is also no detection technique that can 100% accurately diagnose the 
disease as well as differentiate it from other diseases. 
The current detection techniques that show potential in distinguishing AD from 
normal controls and other types of dementia are biochemical markers and neuroimaging 
methods. In biochemical AD markers, there are two major categories: cerebrospinal fluid 
(CSF) and plasma markers. Studies report several CSF biomarkers showing consistent 
results in the concentrations observed in AD patients as well as in predicting the 
conversion from normal or mild cognitive impairment (MCI) patients to AD. 
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Furthermore, combinations of CSF markers, specifically Aβ42 and tau, prove particularly 
promising as potential diagnostic and prognostic biomarkers with accurate sensitivity and 
specificity. Plasma markers, on the other hand, provide either mixed results or no changes 
in the levels of several proteins. Although plasma markers are difficult to distinguish AD 
from controls and to predict progression from MCI to AD, some proteomic studies of 
plasma and serum are promising. 
Along with biochemical markers, neuroimaging techniques are used 
increasingly to detect brain changes associated with AD, and thus have potential as 
markers of disease progression, monitors of therapeutic effects, and predictors of future 
dementia prior to symptoms. These imaging markers include computed tomography 
(CT), magnetic resonance imaging (MRI, functional MRI, positron emission tomography 
(PET), and single photon emission computed tomography (SPECT). Each imaging 
marker offers positive and negative predictive values and the appropriate sensitivity and 
specificity. 
Yet, given the amalgamation of the various pathophysiological causes and 
mechanisms of the disease, it is unlikely that any of these markers will detect specifically 
for AD alone. Therefore, recent studies focus on developing compounds for the in vivo 
imaging of brain amyloid, neurofibrillary tangles, and activated microglia. Because AD 
pathology precedes the onset of AD symptoms by many years, “molecular” imaging 
agents would allow for early diagnosis and for the monitoring of disease progression and 
treatment efficacy. Therefore, it is likely that combinations of CSF/plasma and imaging 
measures will be required to accurately diagnose the disease early. 
The field in Alzheimer’s research focuses not only on understanding the 
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pathology of AD and detecting it at its earliest stage, but also on finding treatments for 
patients suffering from AD. Currently, there are a number of treatments available to 
patients suffering from Alzheimer’s disease. The most common treatment for AD patients 
is two classes of drugs known as acetylcholinesterase (AChE) inhibitors and NMDA 
modulators. Although these treatments relieve many of the symptoms of AD and improve 
cognitive function in several patients, there is a major problem with the current standards 
of treatment. These therapies do not actually treat the underlying causes of the disease; 
they only offer a temporary reprieve from the debilitating conditions of AD. Therefore, 
scientists strive to find new, disease-modifying treatments for AD patients, as research 
has grown exponentially in recent years. A disease-modifying treatment is the ideal 
approach to Alzheimer’s therapy. If AD was detected early in patients, even with the 
current standards of care, doctors would not be able to stop the disease from eventually 
taking its toll. If a disease-modifying therapy was successful, it is then possible that the 
disease could be prevented outright if it was detected early enough. 
Research for potential treatments and even possible “cures” for Alzheimer’s 
disease has exploded in the last decade. There is large amount of research devoted to the 
idea of Aβ modulation, which refers to altering toxic Aβ, which can be achieved through 
inhibition of secretase proteins in the brain. Aβ itself can also be modulated to prevent 
aggregation of these molecules into toxic oligomers, which contribute to 
neurodegeneration. These kinds of modulation treatments are expanding to include things 
such as removing trace metals from Aβ, which is an innovative field of research that has 
only grown recently. There is a large amount of research devoted to AD immunotherapy 
as well, but the mechanics of this treatment are not fully understood, which is a serious 
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issue with attempting to understand how this therapy would work clinically. In addition, 
there are lesser-known research areas devoted to treating things such as tau tangles and 
apolipoprotein E gene (APOE). Although not as high profile as Aβ modulation and 
immunotherapy, these areas are worth exploring as possible treatments. Yet many of 
these treatments are only minimally successful in early clinical trials, and their 
mechanisms are not fully understood. Unfortunately, the search for a true disease-
modifying treatment for AD continues, and the world still remains relatively far away 
from having a commercial treatment. 
One of the major negative impacts of Alzheimer’s disease is the socioeconomic 
effect on humanity. Socially, the patient is unable to associate with anyone due to the 
neurodegenerative effects of AD, and thus is forced to live with uncertainty and solitude. 
Furthermore, the family of the patient has to deal with being away from their loved ones 
and having to pay a large sum of money just to allow the patient to live a relatively 
normal life. The lives of the caretakers are also impacted since they need to adhere to the 
patients’ every need, as the patients are unable to perform simple daily tasks. 
Economically, there is an enormous impact of AD on a personal level and on the 
government. The research, care, and treatment for Alzheimer’s accounts for a tremendous 
amount of money and it is one of the most expensive diseases to treat and follow up on. 
Therefore, the future treatments and prevention techniques need to be less expensive, so 
that the families are not constantly in a state of debt solely for the ones they love. 
         Prevention techniques have been developed in Alzheimer’s, which include 
neurological tests and early detection. However, the techniques are not as effective as 
they should be. Being one of the deadliest diseases in the world, Alzheimer’s needs to be 
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stopped at a genetic level. There are inhibitors that block the risk factors and prevent the 
onset early on. Some of the ones discussed include anti-amyloid therapy and the research 
performed by scientists at Alzheimer’s Disease Neuroimaging Initiative (ADNI). 
Additionally, some of the techniques need to be improved and newer techniques need to 
be developed in order to completely stop the onset through the earliest possible detection 
of the disease. In the end there is a cascading effect of AD on the society as the 
development of the biomarkers leads to early detection, which ultimately leads to 
treatment of the disease. Moreover, all of the scientific factors correlate with the 
socioeconomic factors of AD as well. Ultimately, there need to be steps taken to 
minimize the negative impacts of AD while maximizing the efforts towards positive 
results. 
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Chapter 1: Characteristics of Alzheimer’s Disease 
Alzheimer’s disease (AD) is a very common cause of dementia among the elderly 
with its prevalence greatly increasing after the age of 80 years though in very few cases 
younger people can get AD as well. There are two types of AD: familial and sporadic. 
Familial Alzheimer’s disease (FAD) involves gene mutations and is often passed down 
from parent to offspring, making it the main cause of early onset AD that occurs between 
the age of 40 and 60 years. Sporadic Alzheimer’s disease, the most common form of AD, 
has no clear mode of causation and often occurs unpredictably, resulting in late onset AD 
that occurs after the age of 60. The most prominent physical trait of AD is cerebral 
atrophy, predominantly in the medial temporal lobe, extensive loss of neurons, and the 
formation of extracellular senile plaques and intracellular neurofibrillary tangles. 
The cerebral atrophy characteristic of AD, which is the weakening and the 
decrease in brain size, is not enough to diagnose AD because it does not distinguish 
normal aging from the disease.1 This is one of the reasons why currently the only 
definitive way to diagnosis Alzheimer’s is through a post-mortem autopsy.2 It is the 
microscopic examination of the brain tissues through a post-mortem autopsy that features 
the characteristics of the disease: “a cerebral cortex peppered with neurofibrillary tangles 
and senile plaques.”1 
Senile plaques, also known as amyloid plaques, are composed of β-amyloid 
proteins (Aβ) that is formed from the cleavage of β-amyloid precursor proteins (APP) and 
are present on the outside of the neurons. Neurofibrillary tangles, on the other hand, are 
composed of hyperphosphorylated tau proteins that have dissociated from it attachment 
on the microtubules and are present on the inside of the neurons.3 Both amyloid plaques 
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and neurofibrillary tangles are present in low amounts in all aging individuals including 
normal adults and even in young adults.  However when a certain density of amyloid 
plaques and neurofibrillary tangles accumulate in the brain, it progresses into AD.1,3  
Neurofibrillary tangles are present in many neurodegenerative diseases where it is 
assumed that they are closely involved in neuronal death  but only amyloid plaques are 
found in AD, which is why many researchers considered amyloid plaques to be the cause 
of AD.4  
In addition to amyloid plaques and neurofibrillary tangles, it has been shown that 
the neurons of AD patients also exhibit calcium disruption, mitochondrial dysfunction, 
metabolic interference, oxidative stress, and protein misfolding, all of which eventually 
leads to the activation of apoptosis, or cell death. All of these factors occur normally as 
an individual age. However, in AD they are all abnormally elevated or expressed. 
Alzheimer’s is a progressive neurodegenerative disease and because there is 
currently no cure, individuals with AD will have the disease for the rest of their lives. 
Therefore, neurons of the brain gradually die over a course of many years with fairly 
“small number of neurons dying at any one time”. The neuronal death that is associated 
with AD is similar, but not identical, to the neuronal death associated with normal aging, 
which suggests that AD pathology is “not simply an acceleration of normal brain aging.”5 
In the following sections, the two prominent characteristics of AD (amyloid plaques and 
neurofibrillary tangles) as well as the newly observed characteristic, calcium homeostasis 
disruption, will be discussed in further details.  
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1.1 Amyloid Plaques 
The β-amyloid precursor protein (APP) is a transmembrane glycoprotein that 
extends the lipid bilayer of a cell and contains a β-amyloid (Aβ) section. This Aβ section 
is located within the membrane, extending from outside the cell to the inside of the 
plasma membrane.3 APP is expressed in all cells in the body and is present not only on 
the plasma membrane but also on the endoplasmic reticulum (ER) as well as the Golgi 
apparatus. The protein comes in different sizes ranging from 695 to 770 amino acids with 
the larger N terminus on the exterior of the membrane while the smaller C terminus is in 
the interior. The most common form is the one that contains 695 amino acids and is 
mostly produced by neurons.5 The protein is abundantly expressed in the brain and highly 
conserved throughout evolution, demonstrating the important role it plays in human 
development.6 Figure 1 illustrates the proteolytic processing of APP that it can undergo. 
 
 
 
Figure 1: The Different Cleavage Pathways of Amyloid Precursor Protein (APP)4 
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Three different protease enzymes (α-secretase, β-secretase, and γ-secretase) 
cleave the β-amyloid precursor protein at different locations within the Aβ section.  The 
enzyme β-secretase, also known as β-site APP cleaving enzyme (BACE1), cleaves the 
Aβ section that is located outside the cell while α-secretase cleaves the middle section, 
and γ-secretase cleaves the section that is inside the plasma membrane.3,4 If α-secretase 
cleaves the Aβ section no Aβ is formed because it disrupts the entire Aβ section, dividing 
the Aβ section into a sAPPα and a p3 fragment.4  However, if β-secretase cleaves the Aβ 
section and that is followed by γ-secretase cleavage of the products then Aβ is formed, 
producing amyloidogenic Aβ proteins that aggregate together and form insoluble plaques 
outside of the neurons.3  
When α-secretase cleaves APP, it forms an extracellular secreted fragment, 
sAPPα, that is released from presynaptic terminals. sAPPα functions to increase synaptic 
plasticity, regulate neuronal excitability, promote learning and memory as well as 
enhance a neuron’s resistance to oxidative stress and metabolic abnormalities. Since there 
is greater concentration of β-secretase and γ-secretase activity in AD, this promotes an 
increase in formation of Aβ and a decrease in formation of sAPPα. This decrease in 
sAPPα production would mean less amounts of sAPPα present to promote neurons 
resistance to oxidative stress and metabolic abnormalities and along with the increased 
concentration of Aβ, which exhibits its own neurotoxicity, further stimulates neuronal 
death.  
When APP is cleaved by β-secretase, the fragment produced can be cleaved by γ-
secretase to produce Aβ and an APP intracellular domain (AICD), or by caspase, an 
enzyme that mediates apoptosis, to produce a neurotoxic peptide to initiate cell death. 
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The AICD itself can also be further cleaved by caspase to produce the same neurotoxic 
peptide. The AICD acts as a gene expression regulator including genes involved in 
apoptosis and is formed regardless of what secretase pathway is undertaken.4,5  
The enzyme γ-secretase is an integral membrane protein that cleaves “APP within 
the borders of the transmembrane domain” at multiple sites, producing many peptides of 
varying lengths from 39 to 42 amino acid residues. Even though γ-secretase can cleave 
APP at many sites, the majority of the Aβ produced are either 40 amino acids or 42 
amino acids long. It is composed of 4 separate protein fragments: presenilin 1 (PS1), 
nicastrin, APH-1, and presenilin 2 (PS2).7 The γ-secretase active site requires presenilin 1 
(PS1) and can cleave several different proteins including APP and Notch-1. Notch-1 is a 
receptor on the cell that gets cleaved by γ-secretase when activated by a ligand and plays 
a role in regulating gene expression. This Notch signaling is especially important during 
development as it regulates cell fate.5 
Of the two types of Aβ, the most common form is the 40 amino acid variant 
(Aβ40) and it is also the non-amyloidogenic one, meaning that it does not aggregate 
together to form the amyloid plaques.6 Mutations in the presenilin (PS) genes shift the 
cleavage of APP to where more of the amyloidogenic Aβ42 is produced compared to 
Aβ40.7 In normal neurons, the APP produces Aβ in the hippocampus, which facilitates 
learning and memory formation. In normal individuals, the Aβ peptides are produced at 
low concentrations with higher amounts of Aβ40 and lower amounts of Aβ42.  In brains 
affected by AD, the Aβ peptides are produced at a high level with higher concentrations 
of Aβ42 and lower concentrations of Aβ40.6 The 42 amino acid variant (Aβ42) is the 
longer form of β-amyloid and displays enhanced neurotoxicity because of its greater 
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ability to form insoluble amyloid plaques due to its size, making it highly 
amyloidogenic.8 When they aggregate together along with glycosaminoglycan, a complex 
sugar polymer, they form the senile plaques that characterize AD.1 
In the brain, APP and Aβ42 play an essential role in normal brain development. 
Studies have implicated that APP and its metabolites like Aβ42 are normally involved in 
cell signaling, synapse formation, cell adhesion, regulating neuronal survival, neurite 
extension, synaptic plasticity and ironically learning and memory.5,6 
In experiments with transgenic animals that involved inhibiting APP or removing 
its expression, it caused impairments in avoidance learning and memory. In APP 
knockout mice, their spatial and avoidance learning as well as memory were impaired. In 
Drosophila, the removal of the homolog for APP caused “impaired avoidance learning 
that can be rescued by the expression of the human APP gene.” When APP was bonded 
or blocked by antibodies or antisense-mediated blockade in chicks during the early phase 
of memory development, it disrupted inhibitory avoidance. On the contrast, in studies 
that involved administering secreted APP into the ventricular areas of the brain, it 
resulted in memory enhancement as well as a reduction of amnesia in the transgenic 
animals.6 
Similarly to APP, Aβ42 also functions to facilitate memory formation by binding 
to nicotinic acetylcholine receptors (nAchr), a transmembrane protein that mediates rapid 
transduction to initiate memory development. In experiments involving Aβ42 where anti-
Aβ antibodies (anti-Aβ) were injected into rats before they were trained to associate a 
mild foot shock with an avoidance of a certain area, it disrupted both their short term 
(STM) and long-term (LTM) memories compared to rats that had the control monoclonal 
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antibody (mAb). Both forms of memory were not restored until they were retrained 9 
days later. These results are presented in graph A and graph B respectively in figure 2. 
However if the anti-Aβ were injected after they were trained, it had no effect on their 
memory retention as illustrated in graph C of figure 2.6  
 
 
 
Figure 2: Avoidance Tests Conducted on Rats with Anti-Aβ Antibodies (anti-Aβ) Before 
or After a Training for Short-Term and Long-Term6 
 
In contrast to the experiments discussed above that tested to see what would 
happen if the function of Aβ42 was inhibiting, another experiment was conducted to see 
what would happen to memory and learning if Aβ42 were injected into the rats. To test 
the effects of Aβ42 on amnesia, a memory test was conducted 24 hours after the training 
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on rats that had control monoclonal antibody (mAb) with Aβ42, mAb with scramble (sc) 
peptide, anti-Aβ with Aβ42, and anti-Aβ with sc peptide. Figure 3 illustrate the results of 
the test. The rats that had the control mAb with Aβ42 showed “significantly enhanced 
memory retention compared to those that received mAb and scrambled peptide.” The rats 
that had anti-Aβ with scramble peptide had a substantial memory impairment compared 
to those that received anti-Aβ with Aβ42. In both cases the rats that had anti-Aβ along 
with either peptides had memory retentions that was both lower than the rats that had 
mAb with either peptides. The memory test was again conducted after 5 days and the 
same results were produced. Both experiments, the avoidance test and the memory test, 
show that Aβ peptides, including Aβ42 in low concentrations, facilitate both short-term 
and long-term learning and memory developments.6   
 
 
Figure 3: Memory Tests Conducted on Rats using Control Monoclonal Antibody (mAb), 
Scramble (sc) Peptide, Anti-Aβ Antibodies (anti-Aβ), and β-Amyloid42 (Aβ42)6 
 
Even though APP and Aβ42 are important and necessary for facilitating learning 
and memory formation as demonstrated through the experiments discussed above, what 
causes them from becoming beneficial to becoming harmful to the brain is when neurons 
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can no longer control the amount of APP and Aβ42 produced, resulting in high 
concentrations of both proteins. In all cells, including neurons, when it is unable to 
function normally it cannot properly regulate and maintain its cellular processes such as 
correcting sudden mutations in DNA and proteins as well as proper protein formation. 
This inability to control APP and Aβ42 production can be caused by gene mutations and 
environmental factors. With the neurons not functioning properly, the APP and Aβ42 
formed are not correctly folded or assembled. Therefore the cells are not only continually 
forming large amounts of the proteins but they are also misfolded and malfunctioning 
proteins. This accumulation of altered proteins is the most common pathogenic 
mechanism that several neurodegenerative disorders exhibit including AD.9  
In addition to mutations in the APP gene, mutations in the Aβ peptide can also 
cause the misfolding of the protein, changing its conformation from the α-helix native 
structure to a β-sheet configuration, and foster self-aggregation, which leads to the 
formation of the insoluble accumulation of the plaques in AD individuals.9,10 The 
misfolded protein can even interfere with the function of other normal proteins.10 Cells 
have an ubiquitin-proteasome system (UPS) whose purpose is to degrade “misfolded, 
unassembled, or damaged proteins” by being bound to ubiquitin, a small protein that acts 
as a signal for degradation. When a misfolded protein is overly expressed, it is able to 
aggregate together forming a stable complex that resists the binding of ubiquitin thereby 
inhibiting UPS. If ubiquitin was mutated that would also inhibit UPS by making the 
protein unable to recognize misfolded or damaged proteins. Defects in ubiquitination of 
cerebral proteins as well as a large percentage of mutant ubiquitin were found in AD 
individuals.9 Therefore, when Aβ is soluble and in low concentrations it has neurotrophic 
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properties that nourishes the neurons while when it is aggregated and in high 
concentration, Aβ has neurotoxic properties.7 
1.2 Neurofibrillary Tangles 
Tau protein is normally and abundantly produced in neurons as microtubule- 
associated proteins that bind to tubulin and promote microtubule assembly.3 The protein 
is made of “alternatively spliced cytoplasmic proteins” that contains three or four 
microtubule-binding domains and it co-assembles tubulin with microtubules in order to 
stabilize the structure as well as helps form the “cross bridges between adjacent 
microtubules.”10  
If the tau proteins dissociate from the microtubules, they accumulate in the 
neuronal cell body and aggregate together in the cytoplasm forming paired helical 
filaments. These helical filaments are the components of the neurofibrillary tangles, one 
of the characteristics of AD. What causes the tau protein to detach from the microtubules 
is the hyperphosphorylation of the protein, most particularly at the sites that flank the 
regions of the microtubule binding domains.3 Therefore, the tau proteins detachment 
from the microtubules destabilize the cytoskeleton and promote the formation of 
neurofibrillary tangles as illustrated in figure 4.10  
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Figure 4: The Proper Function of Tau Protein and the Process of Neurofibrillary Tangle 
Formation11 
 
What can promote the tau protein to be highly phosphorylated are mutations in 
the tau gene that can cause modification in the protein’s function by either reducing the 
ability of the microtubules to form or by altering the protein’s structure. The alteration of 
the proteins’ structure can decrease tau’s affinity to the microtubules thereby leading to 
the cytoskeleton instability. As a result, the freely floating tau proteins in the cytosol can 
become highly phosphorylated and aggregate into neurotoxic fibrils. When tau is 
phosphorylated it also becomes more resistant to proteases. Therefore, the tau protein 
cannot be degraded and it stays longer within the cell making it more readily to form 
paired helical filaments.3  
When neurofibrillary tangles form, it shows that the neurons are unable to 
properly maintain its cytoskeleton, which is required to support the numerous complex 
cellular processes. The development of a few neurofibrillary tangles is normal within an 
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aging brain. However, it is the large amount of tangles and its distribution that contribute 
to the increased amount of neuronal death in AD.1 What accounts for this high 
concentration of tangles in AD patients compared to a normal brain is the fact that 
phosphorylation of the tau protein is at a much higher extent in an AD brain than in a 
normal brain.3 
Even though the high concentrations of tangles are present throughout the brain, 
some neurons in parts of the brain are more affected by the tangles than others, most 
notably in the hippocampus. The hippocampus is involved in memory storage and its 
prevalence in being affected by neurofibrillary tangles accounts for the symptoms of AD 
involving memory loss with daily activities, familiar faces, and loss of words.1  
Along with mutations in the tau gene, altered calcium homeostasis and the 
resulting activation of kinases can also cause hyperphosporylation of tau as well as 
promote high oxidative modifications on the neurofibrillary tangles.5,10 This continuous 
observation of high oxidative modifications in the brain of AD patients presented a new 
characteristic of AD that is slowly being recognized and that is calcium homeostasis 
disruption. 
1.3 Calcium Homeostasis Disruption  
Calcium ions (Ca2+) are involved in transcription of genes, synaptic transmission, 
synaptic plasticity, exocytosis, and other cellular processes.7 They also play a key role in 
storing and erasing memories. During the day, brief high concentration spikes of Ca2+ 
triggers the process of long-term potentiation (LTP), which is involved in temporary 
memory stores. The information in the temporary memory stores is then transferred to the 
permanent memory stores and erased when smaller elevation in Ca2+ activates the process 
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of long-term depression (LTD) during sleep. Figure 5 illustrates the process of memory 
storage. The high concentration of Ca2+ that is needed to activate LTP is derived from 
Ca2+ entering the NMDA receptors, which are Ca2+  channels on the cell, while the lower 
concentrations of Ca2+ needed to active LTD is the Ca2+ released from the ER by 
ryanodine receptors (RYR) and inositol 1,4,5-trisphophate (InsP3) receptors. The high 
levels of Ca2+ cause protein phosphorylation of receptors and associated proteins and 
promote their insertion onto the plasma membrane to stimulate LTP. The low levels of 
Ca2+ cause dephosphorylation and the retrieval of those receptors and the associated 
proteins to activate LTD. When Ca2+ is released from the ER to generate a signal, a 
portion of the Ca2+ is taken up by the mitochondria, which act as cytosolic buffers. After 
the signal has been produced and the cell is in the recovery phase, the Ca2+ is returned 
back to the ER.12  
 
 
Figure 5: The Process of Storing and Erasing Memories in Relation to Calcium 
Concentrations in Normal and AD Brains12 
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Increased calcium level in neurons is normal as an individual age. However, in 
AD there is an constant abnormal disruption of calcium levels caused by the interference 
of the main intracellular calcium regulating stores (mitochondria and endoplasmic 
reticulum) and the calcium channels on the plasma membrane.4,7 This constant elevated 
level of calcium also illustrated in figure 5. The abnormal production of amyloid plaques 
causes a change in Ca2+ homeostasis that affects the Ca2+ signaling pathways, thereby 
altering the mechanisms involved in learning and memory along with initiating the 
progressive decline in memory and the increase in neuronal death.  
The APP intracellular domain (AICD), which is the peptide that is located inside 
the cell when APP is cleaved by γ-secretase, is a transcription factor. It promotes an 
increase production of ryanodine receptors (RYR) that function to amplify inositol 1,4,5-
trisphophate (InsP3) in order to release calcium from the ER. The AICD also decreases 
the transcription of the Ca2+ buffer calbindin, which functions to reduce Ca2+ signals that 
can be induced by β amyloids and heightened by mutated presenilin.12  
When the ER calcium stores are destabilized, it leads to negatively influencing 
synaptic plasticity that results in memory deterioration and neurodegeneration.7 The Aβ 
oligomers cause an influx of extracellular calcium into the cell and increase the level of 
calcium in the cytoplasm by weakening or thinning the plasma membrane or by forming 
small annular structures on the membrane that resemble pores. They can also stimulate 
the opening of calcium channels like NMDA receptors on the plasma membrane and 
RYR and InsP3 receptors on the ER to allow the increase influx of calcium into the 
cytoplasm.4 The increased production of oxidative stress caused by the continual 
formation of Aβ plaques also interferes with membrane calcium pumps and channels, 
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further promoting calcium influx into the cell.5 This constant inflow of calcium into the 
neurons with no mechanism to relieve the stress, creates a permanent elevated resting 
level of Ca2+  that promotes the constant activation of LTD. This constant activation of 
LTD quickly and continuously delete memories in the temporary memory stores before 
they can be transferred to the permanent memory stores as illustrated in figure 5.12 Based 
on this mechanism that is involved in the constant activation of LTD, it only affects the 
ability to learn new things. Therefore it would have no impact on knowledge already 
learned. However, the cerebral atrophy as well as the damages to the hippocampus and 
the frontal and temporal lobes of the brain that is caused by the high activation of 
apoptosis can effectively deteriorate the knowledge that was already learned. 
Not only is calcium the main regulator of synaptic plasticity, it can also activate 
the process of apoptosis.4 The increased amount of Ca2+ that is present in the cytoplasm 
promotes the mitochondria to take up as much calcium as possible in order to stabilize 
the levels. The large amount of calcium taken up by the mitochondria puts pressure on it 
causing the mitochondrial permeability transition pore (MTP) to open, collapsing the 
mitochondrial membrane potential, and releasing protein factors like cytochrome c to 
activate apoptosis.12 In the process, this also generates free-radical oxidation that leads to 
more neuronal damages and later further promotes cell death.7 Since accumulating Aβ 
significantly disrupts calcium levels, neurons that are located close to amyloid plaques 
have higher Ca2+ concentrations.12  
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Chapter 2: Cellular Effects of Alzheimer’s Disease 
Once the prominent characteristics of AD were determined and how they were 
created, one needed to know what effect does the amyloid plaques, the neurofibrillary 
tangles, and the calcium level disruption do to the brain. Why do they cause dementia in 
AD patients? What is the cellular effect that they cause in the brain and how does that 
translate into the traits that people observe in AD individuals? These are the questions 
that provide the purpose into researching the disease and through many studies 
researchers have determined the reason why and how AD is the way it is. 
In Alzheimer’s patients, the disease is first exhibited as mild cognitive impairment 
that gradually develops into more “severe amnesia accompanied by apathy and stupor,” 
thereby affecting the ability to perform daily living tasks. In the later stages, the patients 
become bedridden and must be “dependent on others for all basic living activities.”4,13 
Along with losing their cognitive abilities, their memories, and exhibiting personality 
changes, Alzheimer’s patients also experience psychiatric disturbances such as delusions, 
depression, agitation, hallucinations, sleep disturbance, and behavioral problems.5,13  
The disease involves the death of neurons that function to process and store 
information. The regions in the brain that are involved in memory and learning processes 
such as the frontal and temporal lobes are smaller in size in an AD brain compared to 
those same regions in a normal brain due to the deterioration of the synapses and massive 
cell death.5 Along with a smaller brain size, AD patients also have large decreases in 
cellular metabolism in the mitochondria throughout the brain.5,7  
Definitive diagnosis of AD involves postmortem examination of the brain and it 
must contain an abundant amount of senile plaques and neurofibrillary tangles in order to 
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be classified as AD.5 Amyloid plaques and neurofibrillary tangles are present mainly in 
areas of the brain that are associated with memory, learning, and emotional behaviors 
such as the hippocampus and the neocortex of the brain and their numbers increase as the 
disease progresses.4,5 What triggers cell death may include high production of Aβ leading 
to increased extracellular plaques, the disruption of the microtubules paving way to the 
formation of neurofibrillary tangles, large amounts of cellular damages including the 
DNA, elevated intracellular calcium levels, and increased oxidative stress.5 
2.1 Amyloid Plaques 
One of the noticeable traits of AD is the high formation of Aβ42 resulting in large 
accumulation of plaques. The Aβ peptides first form dimers, then oligomers, and 
protofibrils before they form plaques.12 Research has shown that Aβ are the most toxic 
when it is a soluble oligomer since they can diffuse into the synaptic clefts and interfere 
with synaptic functions, as well as being able to form the insoluble plaques that surround 
neurons.5,10  
The oligomers aid in memory impairment by inhibiting long-term potentiation 
because they can increase Ca2+ entry into cells by functioning as either a channel or by 
activating channels in the plasma membrane through receptor operated channels.5,12 
Along with memory decline, the increased formation of Aβ leads to the death of neurons 
because the protein is directly toxic to the cells and enhances their vulnerability to 
metabolic and oxidative stress as well as excitotoxicity, a constant stimulation of a 
neurotransmitter.5 Not only can Aβ oligomers diffuse into the synaptic cleft and form 
plaques this way, but also APP can move along the axon and accumulate at presynaptic 
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terminals in high levels as well. This results into an additional buildup of Aβ at the 
synapses.  
The presence of Aβ proteins injures the synapses and axons that are associated 
with the plaques.5 The damaged and dilated dendrites and axons near the amyloid plaques 
show signs of “altered intracellular transport and slowed nerve conduction that 
contributes to compromised information processing in the limbic and association 
cortices.”10 The synapses also contain many of the proteins that are involved in the 
commencement and implementation of apoptosis. Since many of the Aβ are located at the 
synapses and they can induce apoptosis, the site for initiation of neuronal death usually 
happens at the synaptic clefts.5 
Along with the ability to initiate apoptosis, the aggregated Aβ in the synaptic 
clefts can also accelerate chronic destructive inflammatory processes by activating 
microglia and astrocytes. This stimulates the glial cells production of cytokines, which 
leads to increased expression of APP and later destruction of the nerve cells due to high 
levels of microglia-activated free radicals produced and damages to the membrane.7 
There are more glial cells (astrocytes, oligodendrocytes and microglia) in the 
brain than neurons and they are subjected to the same conditions as neurons, experiencing 
the negative effects and abnormalities in the presence of Aβ plaques and neurofibrillary 
tangles. In astrocytes, the Aβ plaques disturb calcium regulation, impair glutamate 
transport, and promote the production of pro-inflammatory cytokines thereby influencing 
synaptic dysfunction and neuronal death. White matters that surround neurons act as an 
insulator and facilitate fast conduction of action potential and are composed of axons and 
oligodendrocytes. Oligodendrocytes are susceptible to damages and are often destroyed 
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by Aβ, leading to the deterioration of white matter, which is very prominent in AD 
individuals. Microglia cells participate in the immune system by engulfing debris and 
respond to infection and injury to the brain. In AD, they surround amyloid plaques and 
deteriorated neurons in order to remove them from the brain and in the process may 
produce inflammatory cytokines and toxins that aid in the neurodegenerative process.5 
2.2 Neurofibrillary Tangles 
The purpose of tau protein is to promote microtubule assembly, which is one of 
the key components of the cytoskeleton that functions to transport organelles, proteins, 
and maintain cell integrity.3 Therefore, the malfunctioning of tau affects axonal 
transport.5 The tangles that accumulate in the cells disrupt axonal and dendritic transport, 
alter neuronal metabolism, and cause structural changes in the cell bodies and the 
neurites.10 Neurons that contain neurofibrillary tangles have high levels of calcium, which 
also cause over activation of Ca2+-activated kinases and Ca2+-dependent proteases. This 
leads to large levels of activated apoptotic proteins.5 
2.3 Calcium Levels and Mitochondrial Dysfunction 
The malfunction and deterioration of synapses may also involve Aβ-induced 
oxidative stress caused by the impairment of membrane ion, glucose, and glutamate 
transporters as well as the interference with mitochondrial function by an oxidative stress 
mediated mechanism.5  
The presence of Aβ plaques promote the formation of free radicals in the 
mitochondria, increase the number of reactive oxygen species (ROS) in the cell, 
“[disrupt] the dendrite apparatus” and finally activate apoptosis and necrosis of the 
neurons.7 When apoptosis is activated, it promotes the production and activation of 
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proteins whose function is to increase the permeability of the ER and the mitochondria. 
This causes calcium to be released from the ER and cytochrome c and apoptosis-inducing 
factors to be released from the mitochondria. The release of calcium activates caspases 
and along with endonucleases they cleave many different proteins like ion channels, 
cytoskeleton, and DNA resulting in cell death.5  
Oxidative stress is especially prominent in neurons that are surrounded by senile 
plaques and neurofibrillary tangles, exhibiting oxidatively modified lipids, proteins, and 
DNA. The source of oxidative stress comes from the redo-active metals like Cu+ and Fe2+ 
and Aβ plaque generation. When Aβ oligomers interact with Cu+ or Fe2+, it generates 
H2O2.5 
Free radicals such as hydrogen peroxide (H2O2), hydroxide (OH-), and oxide ions 
(O2-) are normally produced in the cell as a result of oxidative phosphorylation. Cells 
have several ways to detoxify and convert the free radicals to harmless products using 
many different enzymes. If the cell can no longer detoxify, the free radicals wreak havoc 
within the cell, altering many different classes of macromolecules and DNA. Because 
mitochondrial DNA does not have histones or a DNA repair system, the oxidative stress 
is especially damaging.14 
When the mitochondrial permeability transient pores (MPTPs) opens, it initiates 
apoptosis by collapsing the electrochemical gradient and activating caspases and 
apoptosis-inducing factors. Significant uptake of calcium by the mitochondria, excessive 
mitochondrial energy metabolism reduction, and the activity of ROSs can cause the 
opening of MPTP and initiate apoptosis in AD.7 
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The functions of key enzymes in energy metabolism like pyruvate dehydrogenase, 
α-ketoglutarate dehydrogenase, and cytochrome c oxidase are reduced in the 
mitochondria of neurons.5 Due to the collapsing of the electrochemical gradient and the 
deterioration of the mitochondria, many of the mitochondrial DNA and cytochrome c 
oxidase is found in the cytoplasm along with swollen and decreased numbers of 
mitochondria and lack of microtubules in the neurons.14  
The neurons with defective mitochondria (low levels of cytochrome c oxidase) 
would have impaired intracellular calcium buffering, further excessive production of free 
radicals, inhibited glucose metabolism, greater sensitivity to IP3-mediated calcium 
release, and high calcium concentrations in the cytosol.5,14 In the regions of the brain 
involved in cognition, the neurons lacking mitochondria would contain high levels of Aβ 
and have decreased hypoxia tolerance.5  
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Chapter 3: Genetics 
Genes may play a role in AD, specifically for familial Alzhiemer’s disease 
(FAD). Through the use of “linkage analysis of familial AD” four genes that are 
responsible for the disease were identified: three causative genes [β-amyloid precursor 
protein (APP), presenilin 1 (PS1), and presenilin 2 (PS2)] for FAD and one 
predisposition gene [apolipoprotein E ε4 (APOEε4)] that is more specific for sporadic 
AD. Mutations in these genes all cause an increase in the production of Aβ especially for 
the “highly amyloidogenic 42 amino acid variant (Aβ42)”, and/or an increased deposit of 
amyloid plaques.3,8  
Sporadic AD is much more common than familial AD, which indicates that gene 
mutations are not a common cause of AD.5,9 Familial AD happens mostly in young adults 
between 40 to 60 years old while sporadic AD happens mostly in older adult ages from 
65 years or older.7 Even though gene mutations are not a common cause of AD, the 
mutation still represents “an acceleration of the disease process that occurs gradually with 
advancing age.”10 For the mutations that do occur, Alzheimer’s requires mutations on 
multiple genes in order to be manifested in an individual and is therefore considered a 
“genetically heterogeneous disorder” and “not a single-gene disease.”3 
3.1 Amyloid Precursor Protein 
Mutations in APP involve “one or two amino acid changes within or immediately 
adjacent to the Aβ” region which increases its cleavage by β-secretase and γ-secretase.5 
Mutations in the APP gene on chromosome 21 have been identified near or at the 
cleavage sites of both β-secretase and γ-secretase, promoting the increased production for 
the long form of β-amyloid, Aβ42, which aggregates more readily than the shorter form 
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of β-amyloid, Aβ40.1,8 However, these particular mutations are rare in FAD.8 Mutations 
that occur in the middle of the Aβ region on APP “enhances the oligomerization and 
fibril formation” of the Aβ peptides.10 
3.2 Presenilin 1 and Presenilin 2 
The majority of the mutations that are connected with FAD are located in the 
“two PS genes, particularly in the PS1 gene.”8 Presenilin is an intramembrane aspartyl 
protease that is present on the membranes of multiple organelles including the ER, Golgi 
apparatus, and endosomes.10,12 Presenilin is involved in multiple functions including 
calcium regulations, unfolded protein response, APP processing as well as Notch 
signaling, which is a key process in cellular differentiation and releasing intracellular 
domains to signal in the nucleus.10 Normally when presenilin is in the ER, it controls the 
passive leak of Ca2+ but when it is processed and located in the Golgi and the endosomes 
they interact with γ-secretase to form the γ-secretase complex.12 
Presenilin binds to the catalytic site on γ-secretase and forms a presenilin-γ-
secretase complex that participates in the cleavage of APP.  Therefore, presenilin 
mutations affect the proteins’ function, preventing the proteolytic processing of Notch 
and “the normal γ-secretase processing of APP to release Aβ.” Mutations in PS1 or PS2 
change the cleavage specificity of γ-secretase creating more of the minor cleavage at the 
Aβ42 residue and less of the major cleavage at the Aβ40 residue.10 Cells with mutations 
in PS1 or PS2 lead to a 1.5 to 5-fold increase of Aβ42 compared to cells that had no 
mutations in PS1 or PS2.9 If the PS1 gene was deleted, then it would cause a reduction of 
γ-secretase cleavage, which would results in a decreased amounts of Aβ formed.8  
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Genetic analysis has also shown that the age of onset is related to the position and 
type of amino acid substitutions in the PS1 mutations. The study involved taking blood 
samples from 70 FAD subjects and their DNA analyzed to detect where the amino acid 
substitutions were at and compare that to the subjects’ age of onset.9 
Presenilin that are located on the ER control the passive leak of calcium and 
therefore calcium homeostasis.12 Sarcoplasmic ER Ca+2-ATPase (SERCA) pumps are 
located on the ER and function to pump cytosolic calcium into the ER to maintain a low 
level in the cytosol. Presenilin functions to regulate SERCA pumps in order for them to 
work normally and the regulation of SERCA affect Aβ formation. In cells without 
presenilin, there is an elevated level of calcium in the cytosol and weak ER calcium 
stores. 
When wild-type presenilin is overexpressed or when the genes are mutated, it 
causes an overfilling of the ER calcium stores caused by the upregulation of the SERCA 
pumps. This overfilling enhances the InsP3-mediated calcium release by increasing the 
sensitivity of the InsP3 receptors to presenilin and this only gets worse when the 
presenilin genes are mutated.15 This dual and conflicting effect may be a way for the cell 
to try to respond to the overfilling of the ER by releasing calcium and at in the same time 
try to respond to the high intracellular concentration of calcium by storing the excess in 
the ER. This back and forth movement of calcium to try to fix the excess concentration in 
the cell results in a neuron that cannot solve any of the underlying issues. In the end the 
“increase release of intracellular calcium from the ryanodine or inositol 1,4,5-
trisphosphate (InsP3) channels on the ER” is what overpowers the overloading of the ER 
and is the most harmful to the cell and the brain by leading to memory deterioration and 
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activation of apoptosis.4,7 Therefore, presenilin is directly involved in filling the ER stores 
and indirectly involved in emptying it of calcium, which explains why a mutation in the 
gene can cause both an increase in the ER stores and an altered calcium homeostasis that 
resulted from “an increase amount of Ca2+ being released from the ER”.12,15  
Another important proteolytic function of PS involves two signaling molecules 
(IRE1 and ATF6) that are part of the unfolded protein response (UPR), which is a 
signaling pathway that initiates the proper folding of misfolded or unfolded proteins. 
Both IRE1 and ATF6 are ER transmembrane proteins that undergo proteolytic cleavage 
to allow themselves to enter the nucleus upon initiation of UPR. When PS1 is mutated, it 
impairs the UPR by reducing the expression of chaperone molecules, which are proteins 
that properly fold misfolded proteins, in the ER, causing the accumulation of unfolded 
proteins such as APP and Aβ.9 
3.3 Apolipoprotein E 
An important gene that plays a role in sporadic AD is the apolipoprotein E gene 
(APOE), which is “firmly established as the major risk factor other than age for the 
development of AD.”1 The apolipoprotein E gene is the susceptibility genes, which 
means that if an individual has this gene he has a higher chance of developing AD, 
thereby making him susceptible to the disease. The gene has 3 allelic forms (ε2, ε3, and 
ε4) and the lipoprotein that is produced is involved in synaptic repair in response to tissue 
injury as well as maintenance of neuron structures and cholinergic functions.1,5  
An individual that has the ε4 isoform has a higher chance of getting AD.5 The 
chance of developing the disease sharply increases when APOEε4 and one or two of the 
alleles are inherited and enhances the levels of amyloid plaques in the brain. The 
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mechanism is not involved in increased Aβ production but instead stabilizes and 
decreases the clearance of the fibrillar Aβ deposits.10 Along with diminishing removal of 
Aβ, the ε4 allelic form is involved in raising oxidative stress, promoting Aβ aggregation 
and amyloidgenic processing of APP, and interfering with neuronal plasticity.5  
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Chapter 4: Possible Risk Factors of Alzheimer’s Disease 
Through numerous amounts of studies and research being done on Alzheimer’s, a 
great deal of progress has been made in understanding this disease. Yet there is still so 
much that is unknown. The mechanism as to how the disease works is slowly being 
deciphered, however the reason as to why the disease happens, or even what factors may 
trigger it are still not fully understood. Although there is so much information and data 
that needs to be understood, there is a general idea as to what are the risk factors for 
Alzheimer’s. Some of the factors may be indirect causes of Alzheimer’s, a result of the 
disease, or just a symptom that happened to be present but has no relationship to the 
disease. Nevertheless, there are still risk factors that need to be looked at and understood. 
The table below gives a general overview to the risk factors presented.  
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Table 1: Possible Risk Factors for Alzheimer’s Disease 
Possible Risk Factors Reasoning 
Down’s Syndrome Extra copy of chromosome 21 results in an 
increase production or mutation of APP 
leading to a higher concentration of Aβ16 
Type	  II	  Diabetes	  Mellitus	   Insulin	  resistance	  promotes	  increase	  secretion	  of	  Aβ	  and	  hyperphosphorylation	  of	  tau	  proteins	  as	  well	  as	  inhibiting	  Aβ	  degrade17	  
Stroke	   Lack	  of	  blood	  flow	  damages	  the	  brain18,25	  
History	  of	  Head	  Trauma	   Damages	  the	  brain	  with	  it	  being	  more	  serious	  when	  loss	  of	  consciousness	  accompanies	  the	  head	  injury20	  
Depression	   Causes	  neuronal	  death	  in	  regions	  of	  the	  brain	  like	  the	  hippocampus13	  	  
High	  Blood	  Pressure	   Decrease	  blood	  flow	  to	  the	  brain	  resulting	  in	  hypoxia	  injuries	  and	  later	  cognitive	  decline23,24,25	  	  
Dietary	  (high	  consumption	  of	  calories,	  
cholesterol,	  saturated	  fats,	  and	  red	  
meat	  as	  well	  as	  low	  consumption	  of	  
fruits	  and	  vegetables)	  
High	  levels	  of	  cholesterol,	  calories,	  and	  saturated	  fats	  contributes	  to	  heart	  disease	  like	  high	  blood	  pressure,2	  promotes	  the	  production	  of	  Aβ42,5	  aid	  in	  insulin	  resistance,2	  and	  neuronal	  degeneration;5	  high	  levels	  of	  red	  meat	  increases	  the	  level	  of	  iron;26	  low	  levels	  of	  fruits	  and	  vegetables	  provide	  low	  levels	  of	  antioxidants2	  
Vitamins	  (low	  levels	  of	  vitamin	  B,	  A,	  C,	  
and	  E)	  
Low	  levels	  of	  vitamin	  B	  increases	  the	  level	  of	  homocysteine;2,5	  low	  levels	  of	  vitamin	  A,	  C	  and	  E	  gives	  low	  levels	  of	  antioxidants2	  	  
Metals	  (high	  levels	  of	  iron,	  copper,	  and	  
zinc)	  
High	  levels	  of	  iron,	  copper,	  and	  zinc	  leads	  to	  high	  oxidative	  stress,	  increase	  production	  of	  Aβ	  and	  neurofibrillary	  tangles,	  and	  later	  neuronal	  death26,27	  
Sedentary	  Lifestyles	  	   Decreases	  neurogenesis,	  hippocampal	  synaptic	  plasticity,	  and	  long-­‐term	  potentiation28,29	  
Chronic	  Stress	   Increases	  the	  production	  of	  APP	  and	  apoptotic	  enzymes	  along	  with	  enhancing	  senile	  plaques	  accumulation	  and	  tau	  phosphorylation28	  
High	  Alcohol	  Consumption	   Promotes	  oxidative	  damage	  in	  the	  brain	  leading	  to	  brain	  atrophy	  and	  causes	  mitochondrial	  dysfunction	  and	  deterioration2	  
Low	  Education	  Levels	   	   Less	  network	  of	  synapses	  and	  inefficient	  use	  of	  neural	  networks	  as	  well	  as	  a	  less	  ability	  to	  recruit	  networks30	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4.1 Down’s Syndrome 
Down’s syndrome is a chromosomal disorder where an individual is born with an 
extra copy of chromosome 21, resulting in a total of 3 copies, which is why it is also 
called Trisomy 21. The disease starts from birth and causes malformation and mental 
retardation throughout the life of the individual. What correlates AD with Down’s 
syndrome is that not only do both diseases cause brain dysfunction but people with 
Down’s syndrome also exhibit abnormal buildup of Aβ in the brain. The reason for this is 
because the gene for APP is located on chromosome 21. With an extra copy of 
chromosome 21, Down’s patients have a higher chance of having mutations on the APP 
gene, thereby increasing their chance of producing malfunctioning APP that can later 
result in misfolded and highly amyloidogenic Aβ. Even if there was no mutations in the 
APP gene, the extra copy of the chromosome would still contribute to an overexpression 
of APP and later Aβ, giving rise to an increased amount of amyloid plaques in the 
brain.16 As with high productions of anything, the increase concentration of the protein 
would allow for a higher chance for something to go wrong. 
4.2 Type II Diabetes Mellitus 
Diabetes mellitus, or simply diabetes, is a disorder where the body produces little 
to no insulin, a hormone that functions to control the level of sugar in the blood. 
Therefore an individual with diabetes has high levels of glucose in the blood or 
hyperglycemia. There are two types of diabetes: type I and type II. Individuals with type I 
diabetes are considered insulin dependent since their body cannot produce any insulin 
while individuals with type II diabetes are considered non-insulin dependent since their 
body is still able to produce insulin just in inadequate amounts. Sometimes in type II 
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diabetes, even though the body is still making insulin, the cells are not using it efficiently 
and have lowered responses to the hormone, resulting in what is called insulin resistance. 
Therefore, the insulin is not being used by the cell and is left circulating and 
accumulating in the blood along with high blood sugar. 
What connects diabetes with AD is that insulin resistance is “associated with β-
Amyloid-accumulation and hyperphosphorylation of tau-protein,” the two characteristics 
of AD.63 Studies have shown that insulin increases the amount of Aβ by inhibiting its 
degrade by insulin-degrading enzymes and can stimulate the secretion of Aβ “by the 
enhancement of its trafficking from the ER and trans-Golgi network, the main site for Aβ 
generation, to the plasma membrane.”17 It has also been noted that AD patients have large 
decreases in glucose metabolism throughout the brain that is attributed to disruption in 
the insulin signal transduction.7,17 This impairment in the insulin signal transduction 
cascade, which is also observed in type II diabetes, prevents glucose from being 
transported from the blood into the cells, thereby providing the cells, including neurons, 
with inadequate energy to perform properly, eventually leading to apoptosis.17  
4.3 Stroke 
 Stroke happens when the brain suddenly cannot receive nutrients and oxygen due 
to the loss of blood or inadequate blood supply. The lack of blood flow to the region of 
the brain causes damages that can lead to neuronal death. Studies indicate that stroke 
increases the risk of getting dementia, whether or not the stroke was symptomatic, and 
the risk only increases with each successive stroke.  Not only does the number of strokes 
experienced contribute to the risk but also the location of where it happens, such as the 
hippocampus, as well as the intensity of the stroke can play a role.18,19 It has been shown 
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that the risk of developing AD in relation to stroke increases if the individual also 
exhibits vascular problems such as high blood pressure, heart disease, and diabetes.19 
4.4 Head Trauma 
While any damage to the brain is unfavorable, there has been no conclusive 
evidence that indicates head trauma causes Alzheimer’s disease in individuals. Some 
studies show that there is a correlation between head trauma and AD while other studies 
show that there are no correlations between the two. However, there is evidence 
indicating that men with head injuries have a higher chance of getting AD than women 
with head injuries. What can cause this discrepancy may be due to female hormones, 
particularly progesterone and estrogen. In an animal model, the female rats would have 
considerably smaller contusions in the brain than in male rats, which may suggest that the 
hormones play a neuroregenerative and neuroprotective role in the brain.20 As with any 
injury, the more serious the head trauma, such as ones that causes unconsciousness, the 
more damage it can create to the brain.  
4.5 Depression 
Depression is very common in Alzheimer’s patients as well as being one of the 
first symptoms expressed. However it is difficult to show whether depression is a result 
of having AD or is a cause of AD.21 Some studies indicate that depression is a risk factor, 
while others show that AD causes depression, and still others say there is no association 
between the two.22 Depression does negatively influences the brain by being directly 
involved in hippocampal atrophy, thereby interfering with information recall and memory 
performance, one of the key signs of AD. Therefore, it has a toxic effect on the brain that 
decreases cognition.13 
46	  	  
4.6 High Blood Pressure 
There is increased evidence that indicates good heart health and good brain health 
are intertwined. An individual with high blood pressure has a higher chance of getting a 
heart attack, stroke, and an aneurysm, a swelling of the artery walls. While high blood 
pressure does not cause Alzheimer’s disease, it can make the brain more vulnerable to 
dementia.23 Hypertension decreases the blood flow to the brain causing cerebral infracts, 
which are localized cell deaths, and medial temporal lobe atrophy.24 The microinfarctions 
of the cerebral white matter result in demyelination, the loss of the myelin covering on 
neurons, and the elevated blood pressure promotes increased plaque and neurofibrillary 
tangle formation in the hippocampus and the neocortex. All of the resulting injuries 
caused by the hypoxia, which is the deficiency of oxygen, later stimulates cognitive 
decline in the individual.25   
4.7 Dietary 
 High consumption of saturated fats, cholesterols, and calories contribute to 
cardiovascular diseases such as high blood pressure, which that can affect the brain since 
the systems in the body are highly connected. High levels of saturated fats can aid in 
insulin resistance and further promote the development of diabetes.2 Cholesterol, on the 
other hand, has been indicated to play a more direct role in the brain by stimulating 
amyloidogenic processing of APP. In both cultured cells and APP mutant transgenic 
mice, the high levels of cholesterol increased the production of Aβ.  The cholesterol 
levels can also disturb signal transduction and membrane fluidity in the neurons, thereby 
promoting neuronal degeneration. With high levels of cholesterol, it is highly 
incorporated into lipid rafts on the plasma membrane, which are known to contribute to 
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the APP processing, synaptic signal transduction, and the activation of apoptosis. When 
increased amounts of cholesterols are incorporated into the lipid rafts, this also indicates 
that there is an increased level of oxidative stress present.5  
High consumption of red meat increases the level of iron in the body and that can 
lead to increase production of reactive oxygen species.26 Low intake of fruits and 
vegetables provide lack of antioxidants such as carotenes that can combat oxidative stress 
like the formation of peroxide. There are many evidences that support the fact that high 
consumption of dietary antioxidants can also lower the risk of stroke and cerebrovascular 
diseases.2 In animal models that had dietary restrictions, the animals showed prolonged 
lifespan and greater resistance to neuronal deterioration. Even though there has been 
accumulating evidences that suggest dietary factors may impact the development of AD, 
there is no causal or direct relationship between the two. However, there might be an 
indirect relationship between dietary factors and AD.5  
4.8 Vitamins  
 A low level of vitamin B results in a high level of homocysteine, a precursor in 
making methionine and cysteine, in the brain.2,5 The homocysteine is active in the brain 
and can act as a neurotoxin in high concentrations by impairing DNA repair in the 
neurons located in the hippocampus and making them more vulnerable to Aβ toxicity. 
High consumption of vitamin B lowers the risk of heart disease as well as stroke thereby 
lowering the risk of getting AD.2 Vitamins A, C, and E, on the other hand, are 
antioxidants that help suppress the inflammation signaling cascade and oxidative stress as 
well as hinder the formation of nitrosamines, a carcinogen that helps forms cancerous 
cells. Along with these benefits, antioxidants are also known to lower the risk of stroke 
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and cerebrovascular diseases. Therefore a high intake of vitamins is beneficial to the 
body with dietary antioxidants being more beneficial than supplemental antioxidants. 
Although there are numerous studies illustrating the positive effect of antioxidants, there 
is no consistent data showing that vitamins help with lowering cognitive decline and 
AD.2 
4.9 Metals 
 Both iron and copper are necessary for proper growth and development. Iron is 
essential for oxygen transport in hemoglobin and both metals are components of other 
proteins and enzymes. However in high amount they can catalyze the production of toxic 
hydroxyl radicals and reactive oxygen species that can lead to neurodegeneration. 
Moreover, copper is also involved in amyloidogenic formation since both APP and β-
secretase have a binding site for the metal. β-secretase needs to bind to copper in order to 
be activated to cleave APP and form Aβ. Therefore high concentrations of copper can 
result in increased β-secretase activity in the brain. Tau also associates with copper by 
binding to it to form the neurofibrillary tangles.26 Along with copper, zinc can also bind 
to Aβ and promote its aggregation as well as produce reactive oxygen species.27 Although 
copper may play many essential roles in AD, there are conflicting studies as to whether 
its increased amount may contribute to AD pathology.26 Nonetheless iron, copper, and 
zinc do promote the formation of reactive oxygen species that increase oxidative 
stress.26,27 
4.10 Sedentary Lifestyles 
 In many animal studies involving transgenic mice, exercise has improved their 
learning and memory abilities as well as decreased Aβ plaques and increased 
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hippocampal synaptic plasticity, volume, and neurogenesis. Exercise stimulates gene 
expression such as increasing the production of brain-derived neurotrophic factors 
(BDNF) in the hippocampus. Brain-derived neurotrophic factors are involved in many 
intracellular signaling pathways that initiate neurogenesis and neuronal survival. The 
neurotropic factors also stimulate synaptic plasticity and long-term potentiation (LTP), 
both of which play a role in memory and learning.28 Exercise also decreases tau 
phosphorylation, APP cleavage, the number of plaques through the production of 
plasmin, and apoptotic signaling in the brain.28,29 Besides promoting neuronal survival 
and improving cognitive functioning, exercise increases the cerebral blood flow and 
promotes the development of capillaries in the brain, allowing for improved circulation of 
nutrients, glucose, and oxygen.29 Therefore a sedentary lifestyle does not provide any of 
the benefits that accompany an active lifestyle. 
4.11 Chronic Stress 
 Increased amount of recurring stress can lead to cognitive decline caused by 
promoting cortical and hippocampal apoptosis and decreasing neurogenesis. Along with 
that are defects in dendritic branching and long-term potentiation, reduced BDNF levels 
as well as impaired memory and learning. In relation to AD pathology, stress can enhance 
senile plaques accumulation, tau phosphorylation, APP production, and apoptotic 
enzymes. Essentially stress produces the opposite effect of increased physical activity. 
Even though there are a few studies that illustrate stress is involved in dementia, there is 
no causal relationship suggesting that stress causes AD.28  
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4.12 High Alcohol Consumption 
 Alcohol is a neurotoxin and a high concentration of it can lead to oxidative 
damage to the brain. Studies show that rats with recurrent exposure to intoxicating levels 
of alcohol had developed neuronal mitochondrial dysfunction and deterioration. In 
humans, a moderate alcohol consumption results in brain atrophy, less white matter, and 
a lower brain weight. However, it also contributes to less infarcts, strokes, better 
endothelial function, increased concentration of high-density lipoprotein (HDL), and 
decreased platelet adhesiveness. This dual effect illustrates that alcohol acts as both a 
neurotoxin and helps lower cerebrovascular disease regardless of what type of alcohol it 
may be. However, there have been increased studies indicating that wine is much more 
beneficial than all the other alcoholic beverages simply because it contains antioxidants 
that can help combat oxidative stress. Even though alcohol may exhibit this dual effect of 
negatively affecting the brain while also lowering cerebrovascular disease, a high intake 
of alcohol does cause it to be more of a neurotoxin that far outweighs the benefits and is 
therefore considered to contribute to a higher risk of dementia including AD.2 
4.13 Low Education 
Many studies involving education indicate that increased schooling can protect 
individuals from developing Alzheimer’s disease. Patients that were diagnosed with AD 
showed decreased dementia when they had additional education.  The additional 
education did not reduce the AD pathology, but instead aided in increasing the patients’ 
ability to resist decline in cognitive function, illustrating that the same number of amyloid 
plaques would have less effect on cognition with increased education. The brain may use 
pre-existing neural networks and cognitive processing attained through past experiences 
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and challenging tasks like education more efficiently and improve the ability to recruit 
networks as a way of compensating and coping with the pathological damage, thereby 
postponing clinical manifestations.  
There are many studies demonstrating that increased education as being protective 
against AD but there is no indication that a low level of education is a risk factor for 
AD.30 However, it can be assumed that an individual with a low education will have 
fewer benefits attained than an individual with a high education, like dense network of 
synapses, efficient use of neural networks, and the ability to recruit networks. Therefore 
an individual with a low level of education would have a higher risk of experiencing AD. 
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Chapter 5: Biochemical Markers 
Research has shown that the pathology of AD starts to become active even before 
showing signs of neurodegeneration. Therefore, the most effective way to treat AD would 
be to detect and diagnose AD at its earliest possible stage. Currently, the diagnosis for 
possible AD is a neuropsychological exam that tests for memory and other cognitive 
functions. There are numerous types of neuropsychological tests that are relatively 
sensitive and specific for diagnosing AD and distinguishing AD from other neurological 
disorders. These evaluations can also track and document the progression of AD and 
describe the psychiatric symptoms associated with the disease. However, these tests are 
mostly used in assessing the efficacy of prospective AD clinical drugs. Furthermore, 
other neuropsychological tests are less well developed. Therefore, they continue to 
remain an area of controversy on their reliability and validity. Other methods for 
diagnosing AD are magnetic resonance imaging (MRI) or single photon emission 
computed tomography (SPECT), one of the numerous imaging methods that can detect 
vascular dementia. Genetic analyses demonstrate mutations in the amyloid precursor 
genes are for familial AD, and the presence of the APOEε4 allele is proven to be 
associated only with sporadic AD. In addition, these factors are only found in a small 
number of AD cases and thus cannot be used as a diagnostic test. Nonetheless, AD can 
only be confirmed after a post-mortem examination of the brain. The post-mortem 
examination checks for the presence of large numbers of plaques and tangles. However, 
the presence of plaques and tangles is also seen in healthy, elderly people but to a lesser 
extent. Therefore, a better strategy to confirm AD would be to use a biomarker that 
would detect and diagnose AD at it earliest state. 
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A biomarker is any detectable biological feature that provides information about 
its source.  A biomarker can be any or all of the detection modalities from imaging to 
chemical. Characteristics of an ideal diagnostic or prognostic biomarker include detecting 
a fundamental feature in the pathology of AD that is different from other dementias, 
being reliable and valid in confirmed AD cases, as well as being inexpensive and 
minimally invasive. The guideline for a biomarker to reflect the neuropathologic 
characteristic of AD should have a sensitivity of at least 85% and, to differentiate AD 
patients from controls of the same age and patients with other forms of dementia, a 
specificity of at least 75%.31The ideal biomarker would be an easy and inexpensive blood 
test that would reflect AD in proteins, nutrients, and DNA. However, there is no 
biomarker that can differentiate whether a patient has AD or another form of dementia 
because not a single biologic marker has specificity towards AD.  
Since AD occurs due to various pathophysiological causes and mechanisms, it 
may be that the different mechanisms that cause AD are different in each patient, and 
thus each biomarker can only be found in subpopulations of patients and not in all AD 
patients.32 In addition, different tests might be effective at different AD stages, which 
range from early to late stages. There might be some fallbacks to each test such as the 
patient’s mood, side effects of treatments, or the presence of another illness.31 The results 
of the test might also be detected late and may be dismissed mistakenly.31 Therefore, 
there is an urgent need for biomarkers to provide insight into the physiology, severity, 
and stage of AD. Currently, there are 3 main categories of biomarkers being investigated: 
genetic biomarkers, biochemical biomarkers, and neuroimaging biomarkers. 
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Genetic AD biomarkers do not seem to take on a major role as a diagnostic 
marker because they only account for 2-5% of all AD cases, which are typically 
associated with the rarest form of AD: familial AD.31 Therefore, the following section 
delves into the current biologic markers in serum (also known as plasma) and 
cerebrospinal fluid (CSF) that test for molecules prominent in AD pathology oxidative 
stress, inflammation reactions, cholesterol homeostasis (maintenance and regulation of 
cholesterol), plaque formation and vitamin levels in AD patients.  
5.1 Alzheimer’s Disease Pathological Alteration Markers 
Because neurofibrillary tangles and Aβ plaques are characteristics in the 
pathology of Alzheimer’s disease, it is elementary that the proteins associated with them 
can be potential biomarkers for AD. These proteins are amyloid-β (Aβ), tau protein, glial 
fibrillary acidic protein (GFAP), and amyloid precursor proteins (APP). 
5.1.1 Amyloid β-Protein 
Aβ protein is a prominent feature in the pathology of AD. Because Aβ can be 
detected in both CSF and plasma, it serves as the most convincing candidate biomarker 
for AD. Aβ occurs in two main forms, Aβ40 and Aβ42 amino acids, depending on the C 
terminus.33 Several studies demonstrate Aβ-protein is decreased in CSF in AD patients 
compared to other types of dementia (Table 2), which remains unclear.  However, 
decreased CSF Aβ concentrations are observed at moderate severity of the disease, 
suggesting a possible use as marker in early diagnosis. However, its use in differential 
diagnosis is limited and it can only be differentiated by 60% from other types of 
dementia.32  
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Investigations of Aβ42 in CSF then came about with the discovery that Aβ 
peptide forms the main component of AD plaques, which is composed primarily with a 
length of 42 amino acids (Aβ42) and is secreted by cells.34 Several experiments show a 
reduction of Aβ42 by approximately 50% in AD patients compared to normal controls of 
the same age (Table 2).31 The diagnostic sensitivity and specificity levels ranged between 
80% and 90%, although it is not clear why Aβ42 is reduced in AD patients. Compared 
with other types of dementia, the specificity level was only approximately 60%. An 
autopsy study demonstrates an inverse correlation between Aβ42 levels in the CSF and 
the number of plaques. It was also recently shown that subjects with a positive signal in 
amyloid positron emission tomography (PET) studies with Pittsburgh Compound B 
(PIB), a molecular imaging agent, had the lowest Aβ42 values in the CSF.31 
Nevertheless, future research need to take into account the considerable daily fluctuations 
in Aβ levels in the CSF. 
In several experiments, the concentration of Aβ, including Aβ42 and Aβ40 
(another variant form of Aβ peptide), in plasma are not consistent with each other, giving 
contradictory results (Table 2).32 The broad overlap in both types of plasma Aβ 
concentrations between AD and control subjects suggests that plasma Aβ cannot 
accurately distinguish sporadic AD from control cases, and even more so between AD 
and mild cognitive impairment (MCI) subjects, which is the transitional region between 
normal aging and AD. Furthermore, several studies have shown plasma Aβ levels do not 
correlate with the severity of the disease. Thus, plasma Aβ measures are not sensitive or 
specific enough to be considered candidate biomarkers for AD. 
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CSF analyses show that Aβ42 levels are decreased in AD patients, but have 
fluctuating levels in plasma in AD and MCI subjects. Earlier research shows that in AD 
patients there are no correlations found between Aβ concentration in CSF and in plasma. 
Yet one analysis observes a clear correlation between CSF and plasma level for both 
Aβ40 and Aβ42 in healthy individuals and found no such correlation in AD and MCI 
individuals. The findings suggest that the normal equilibrium between Aβ concentrations 
in CSF and in plasma is disrupted with the start of amyloid deposition in the brain.35 
5.1.2 Tau protein 
Tau protein is the main component involved in the intraneuronal changes in AD, 
as neurofibrillary tangles are formed when tau protein is dissociated from its binding sites 
on the microtubules. Total tau protein (t-tau) shows an increase in concentration in AD 
by 300% in several reports (Table 2). The specificity and sensitivity levels are between 
80% and 90%.32 Levels of CSF tau protein are elevated in AD patients and could be 
distinguished from vascular dementia, frontotemporal dementia (FTD), alcoholic 
dementia, or depression of Parkinson’s disease, indicating its use as a marker for early 
diagnosis.  
The combination of Aβ42 and total tau could differentiate AD from healthy 
controls with a sensitivity of 85% and a specificity of 86% (Table 2).32 However, this 
combination could not differentiate AD from other degenerative dementias. Yet, several 
studies demonstrate that the ratio of Aβ (Aβ42/Aβ40) combined with the increased tau 
concentration give an increased specificity and sensitivity, and could distinguish between 
AD patients and other neurological patients and controls. This leads to the conclusion that 
this specific combination is a good marker for early diagnosis. However, tau protein 
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measurement in CSF should have some standardization on genetic and geographic 
differences, and “the use of CSF limits the possibility to develop the assay for routine 
diagnostic purposes or as a population screening method.”32 
In AD patients, tau protein is present in a pathologic, hyperphosphorylated form.32 
Research suggests hyperphosphorylated tau (p-tau) is promising in distinguishing AD 
from FTD, with sensitivity and specificity rates of 85% to 90% (Table 2).32 Although a 
combination of various p-tau subtypes did not provide improved results in distinguishing 
between groups, reports show that high p-tau concentration correlates with a decline in 
cognitive performance and conversion to AD. They also correlate with disease 
progression as measured structurally by the rate of hippocampal atrophy.32 In addition, a 
report on CSF p-tau in MCI subjects proved to be a powerful candidate of AD even for a 
short observation period of 1 to 2 years. Nonetheless, it is promising for the clinical use 
of p-tau by general practitioners as consultants to inform patients as soon as possible.  
A combination of all 3 markers (t-tau, Aβ42, and p-tau) proved to be useful in 
optimizing prediction in a varied MCI population during a longer observation period. The 
assay used is Luminex XMAP technology that is based on flow cytometry that counts and 
examines molecules in order to determine different biomarkers simultaneously with only 
a small volume of CSF.  
5.1.3 Glial Fibrillary Acidic Protein 
Glial fibrillary acidic protein (GFAP) is the “major intermediate filament 
cytoskeletal protein expressed mainly by astrocytes” and it is found in increased tissue 
concentrations in several neurodegenerative diseases.32 Various diseases have shown an 
increase of GFAP in CSF and in serum (Table 2). However, it should be noted that during 
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normal aging, levels of GFAP expression increase in the brain and in CSF. Nonetheless, 
GFAP autoantibodies could be detected in serum and in CSF of patients with several 
types of dementias. Thus, GFAP autoantibodies may be markers with high specificity for 
brain damage or other types of dementia.32 However, no anti-GFAP autoantibodies are 
observed in presenile dementia, suggesting limited applicability as an early diagnostic 
marker.32 
5.1.4 Platelet Amyloid Precursor Protein Isoforms 
The amyloid precursor protein (APP) is involved in the proteolytic process of Aβ 
protein in order to yield Aβ42 and Aβ40. Investigations report reduced isoform ratios of 
APP in platelets, which are irregularly shaped cell fragments, in AD patients (Table 2).33 
The diagnostic sensitivity and specificity levels range between 85% and 90%. These 
reports find that the reduction in the APP isoform ratio correlate with the severity and 
progression of the disease, but not with age.33 One particularly promising approach in 
CSF studies is the detection and quantification of BACE, one of the key enzymes 
responsible for the pathology of amyloid cleavage of APP. Therefore, a significant 
increase in BACE concentration in the CSF of AD patients compared to healthy controls 
would help in diagnosis of AD. 
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Table 2: Summary of Concentration of Pathological Alterations Markers in Serum and 
CSF of AD Patients 
 Marker AD vs. Normal 
CSF Aβ -­‐ (9) 
Aβ autoantibodies = (2) 
Tau + (14) 
Hyperphosphorylated tau + (1) 
Combination tau + (5) 
Combination tau with Aβ42/Aβ40 
ratio 
-­‐ (1) 
β-secretase (BACE1) + (1) 
GFAP protein + (4) 
GFAP autoantibodies + (2) 
Serum/plasma Aβ + (3) 
= (2) 
Aβ40 + (with age and initial stages)(2) 
Aβ42 + (with age and initial stages)(1) 
- (1) 
GFAP autoantibodies + (4) 
Aβ autoantibodies = (2) 
Platelet APP isoforms - (2)  
+: Increased levels observed in AD patients compared to controls 
=: No difference observed in levels of AD patients compared to controls 
-: Decreased levels observed in AD patients compared to controls 
#: Number of studies conducted 
 
5.2 Cholesterol Homeostasis Markers 
The maintenance and regulation of cholesterol is essential in the brain. Excess 
cholesterol, particularly extracerebral cholesterol, in the brain needs to be removed 
because it does not contribute to the brain cholesterol content.32 The transport mechanism 
of cholesterol is not entirely clear, but it is speculated that APOE and 24S-
hydroxycholesterol, an oxidized product, facilitates in its removal. 
5.2.1 Cholesterol 
Cholesterol in plasma yield inconclusive results due to conflicting outcomes 
conducted by several studies. Increased cholesterol levels were associated with an 
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increased risk of AD in several investigations, although no association was found in one 
study, and established AD cases had lower cholesterol levels in other studies (Table 3). 
5.2.2 24S-Hydroxycholesterol 
24S-hydroxycholesterol is produced through enzymatic oxidation for the removal 
of cholesterol from the brain. Several analyses observe increased CSF levels of this 
oxysterol during early stages of AD and decreased levels in the more advanced stages 
(Table 3). These results suggest that 24S-hydroxycholesterol could possibly be a stage 
marker of neurodegenerative diseases. Because it is “present almost exclusively in the 
brain,” it might be of use as a biological marker with “high specificity for alteration in 
brain cholesterol constituency.”32 However, its use as a single marker might be limited in 
individual patients because there are large overlaps between patients and controls. 24S-
hydroxycholesterol in plasma represents a balance between production in the brain and 
metabolism in the liver.33 However, plasma levels show a weak correlation with CSF 
levels in that 24S-hydroxycholesterol levels in AD plasma are inconsistently increased 
compared to that of in AD CSF (Table 3).33  
5.2.3 Apolipoprotein E 
APOE plays a major role in lipid transport and cholesterol homeostasis.32 It 
mediates cholesterol transport to repair and remove excess cholesterol from dying cells.32 
Experiments indicate increased APOE CSF expression in astrocytes in the frontal and 
temporal cortex of AD patients (Table 3).32 However, no clear differences or correlations 
have been found in CSF and plasma concentrations. Although the mechanism for APOE 
is not entirely clear, the APOEε4 allele is one of the main risk factors currently known for 
increased risk of AD, getting AD at an early age, increased amyloid plaque load, and 
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elevated levels of Aβ40 levels in the AD brain.33 Research shows that a defect in or close 
to the APOE gene could be responsible for the increased susceptibility to AD.33 
Subjects with the APOEε4 risk allele were found to have the highest 
concentrations of APOE in CSF (Table 3). There was no consistent association of plasma 
APOE protein levels with diagnosis. Plasma experiments documented elevated APOE 
levels in AD, no difference, or reduced levels relative to controls (Table 3).33 These 
conflicting results of APOE concentrations in CSF and in serum may be only limited to 
large groups, and therefore have limited value for diagnosis of individual patients.33 
Nevertheless, researchers postulate that there may be a correlation between APOE 
concentration or the number of ε4 alleles and tau protein concentration.32 
5.2.4 Lipoprotein Lp(a) 
Lipoprotein Lp(a) is a low-density lipoprotein-like particle containing the 
plasminogen-like APOE.33 Because APOE was detected in primate brain,  Lp(a) particles 
(which can also carry APOE) was suggested to be involved in cerebral lipoprotein 
metabolism.33 Serum Lp(a) levels were not associated with cognitive decline over 3 years 
within an elderly population, although AD patients had higher levels of Lp(a) in a cross-
sectional study, which is a descriptive study that observes and provides data on an entire 
population that consists of different subgroups (Table 3).33 
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Table 3: Summary of Concentrations of Cholesterol Homeostasis Markers in Serum and 
CSF of AD Patients 
 Marker AD vs. Normal 
CSF Apolipoprotein ε4 + (1) 
= (1) 
-­‐ (1) 
24S-hydroxycholesterol + (2) 
Serum/plasma Apolipoprotein ε4 = (3) 
-­‐ (2) 
24S-hydroxycholesterol + (1) 
-­‐ (2) 
Cholesterol + (4) 
= (1) 
- (2) 
Lp(a) + (1) 
= (1) 
Homocysteine + (6) 
= (1) 
+: Increased levels observed in AD patients compared to controls 
=: No difference observed in levels of AD patients compared to controls 
-: Decreased levels observed in AD patients compared to controls 
#: Number of studies conducted 
 
5.3 Oxidative Stress Markers 
Literature research has shown that oxidative stress plays a significant role in the 
process of AD. The brain has high oxygen consumption and is rich in polyunsaturated 
fatty acids that are easily oxidized.32 Yet, decreased cerebral perfusion in AD patients 
leads to a decrease in oxygen and in glucose delivery to the brain, resulting in energy 
deprivation.32 This then causes oxidative stress in the brain. Therefore, oxidative stress in 
AD can be detected by an increase in protein carbonyl content and lipid, protein, and 
DNA oxidation products. 
Isoprostanes are likely candidates as oxidative stress (OS) markers, specifically 
markers of lipid peroxidation, which are particular for a neurodegenerative disease. They 
are derived from the free radical mediated peroxidation of polyunsaturated fatty acids.32 
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Isoprostanes, specifically F2-isoprostanes, are found to increase in the CSF of MCI and 
AD brains of subjects over time (Table 4). Other isoprostane-like compounds include F-4 
isoprostanes that are shown to be elevated in the “temporal and occipital [lobes of the 
brain], but not in the parietal lobes of AD patients.”32 Another variant of isoprostanes, 
8,12-isoprostane-F2α-VI shows an increase in CSF as well in blood and urine of AD 
patients (Table 4). 8-hydroxy-2’-deoxyguanosine is a DNA oxidation product that is 
shown to increase in concentration in the CSF of AD patients compared to controls 
(Table 4). No overlaps were observed between the two groups, suggesting an interesting 
CSF marker that can distinguish AD patients from controls.32 Another oxidative stress is 
3-nitrotyrosine because it is seen in various neurodegenerative diseases. Analyses have 
shown increased levels of 3-nitrotyrosine in CSF, but cannot be detected in serum due to 
breakdown of nitrated protein and different phases (Table 4).32 CSF isoprostane markers 
perform better than memory tests because of their diagnostic precision. CSF isoprostane 
markers even improve the results obtained with hippocampal volumetric analysis to 
distinguish AD from the other dementia types.  
F-2-isoprostanes are increased in plasma also; however this was contradictory to 
another group (Table 4). This might reflect the differences in measurement techniques. 
8,12-isoprostane-F2α-VI was observed to have no change in concentration in the plasma 
of AD patients (Table 3), conflicting with the increased concentration in CSF. Another 
product of lipid peroxidation, 4-hydroxynonenal, is also elevated in AD plasma (Table 4). 
One difficulty in detecting isoprostanes in plasma is that they can be oxidizes easily. 
Overall, the limit to the use of isoprostanes as biomarkers is the very demanding analysis 
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method that is required to detect it. Therefore, isoprostranes should still be regarded as a 
merely scientific approach.32 
Table 4: Summary of Concentrations of Oxidative Stress Markers in Serum and CSF of 
AD Patients 
+:	  Increased	  levels	  observed	  in	  AD	  patients	  compared	  to	  controls	  =:	  No	  difference	  observed	  in	  levels	  of	  AD	  patients	  compared	  to	  controls	  -­‐:	  Decreased	  levels	  observed	  in	  AD	  patients	  compared	  to	  controls	  #:	  Number	  of	  studies	  conducted	  
 
5.4 Vitamins 
Vitamins are known to be modulators of cognitive performance. Vitamins A, B6, 
B12, C, and E are important antioxidants that are possibly related to cognitive 
deterioration. Vitamin E is known to break major chains in biological membranes, which 
are high in lipid content and polyunsaturated fatty acids of the brain.32 Homocysteine, a 
sulfur containing amino acid, and folic acid are also known to be associated with 
cognitive impairment, but their mechanisms are not clearly understood. 
A CSF study observes the levels of vitamin E to be significantly low, while 
another one finds no change (Table 5). The same results of no difference in the levels is 
observed in vitamin A and C. Overall, a low vitamin level might indicate the 
susceptibility of a patient to oxidative damage (Table 5). Several studies observe reduced 
serum or plasma levels of vitamins A, C, and E in AD and vascular dementia patients, 
even when controlled for nutritional status (Table 5). Other clinical researches observe no 
 Marker AD vs. Normal 
CSF 8-hydroxy-2’-deoxguanosine + (1) 
F2-isoprostanes + (6) 
F4-isoprostanes + (1) 
3-nitrotyrosine + (3) 
8,12-isoprostane-F2α-VI + (1) 
Serum/plasma 
 
8,12-isoprostane-F2α-VI + (1) 
F2-isoprostanes = (3) 
4-hydroxynonenal = (1) 
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difference in the levels of vitamin C and E in plasma (Table 5). “Increased levels of 
homocysteine in serum in combination with decreased levels of vitamin B12, B6, or folic 
acid are deemed a possible risk factor in AD”32 as epidemiologic reports indicate a 
relation among them in the aspect of cognitive performance. More insight is needed for 
this relation. Also, it must be considered that vitamin B12 and folic acid deficiencies are 
common among the elderly. Biasing factors such as age, education, and gender should 
also be taken into account. After adjustment of those biasing factors in one CSF report, it 
was observed that the levels of the vitamins A, C, and E did not change in both AD and 
normal patients (Table 5). Yet, another research group still observed a decreased level of 
vitamin E in dementia patients. Thus, the intake of vitamins or dietary habits can affect 
the levels of vitamin markers. 
Table 5: Summary of Concentrations of Vitamins in Serum and CSF of AD Patients 
+: Increased levels observed in AD patients compared to controls 
=: No difference observed in levels of AD patients compared to controls 
-: Decreased levels observed in AD patients compared to controls 
#: Number of studies conducted 
 
 
 Marker AD vs. Normal 
CSF Vitamin A = (1) 
Vitamin C = (1) 
Vitamin E - (1) 
= (1) 
Serum/plasma 
 
Vitamin B6 -­‐ (1) 
Vitamin B12 -­‐ (1) 
= (1) 
Folic acid -­‐ (2) 
Homocysteine -­‐ (1) 
Vitamin A -­‐ (3) 
Vitamin C -­‐ (4) 
= (1) 
Vitamin E -­‐ (6) 
= (1) 
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5.5 Inflammatory Markers 
 Reports indicate that proteins such as interleukin-1(IL-1β), interleukin-6 (IL-6) 
and tumor necrosis factor (TNF-α), usually associated with inflammatory processes, are 
found in senile plaques. IL-1β, IL-6, and TNF-α are cytokines that participate in 
inflammatory reactions Normally, microglia and astroglia (which are both glial cells in 
the brain) and even neurons produce interleukins at low levels.32 However, if the brain is 
under oxidative stress, then microglia are activated and produce high amounts of IL-1β 
and TNF-α. Furthermore, the concentrations of inflammatory-related proteins change in 
AD patients. 
 CSF and plasma studies of inflammation markers produce conflicting results 
(Table 6). One analysis shows that there is an increase in several interleukins in CSF, 
another shows decreased levels, and yet another shows no change at all in the levels. 
Inflammatory molecules variably increased in CSF and plasma AD include interleukin 
(IL)-1, tumor necrosis factor-α, IL-6, IL-6 receptor complex, α 1-antichymotrypsin, and 
transforming growth factor-β; these were unchanged in other reports, as were other 
cytokines including IL-12, interferon-α, and interferon-γ (Table 6). Problems can arise 
due to low levels of interleukins and low sensitivity of the ELISA assays (biochemistry 
assay that detects the presence of a substance) and due to using control groups with other 
neurological diseases. Another problem is that studies focus on different stages of the 
disease. One group focused on severely affected patients, while another on early-onset 
AD patients. Also, investigations were done in smaller groups, thus contributing to the 
differences when comparing to larger groups.  
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α-antichymotrypsin (α-ACT), a glycoprotein that inhibits the activity of certain 
enzymes, showed higher concentrations in more severely affected patients. Thus, α-ACT 
may prove to be a marker in monitoring the progression of the severity of AD symptoms. 
Haptoglobin (Hp), an iron transporting protein involved in the process of oxidative stress 
and an acute-phase protein, show an increase in some of the lower weight isoforms in AD 
patients, indicating a promising discriminative role between AD and controls.32 Acute-
phase proteins are proteins that increase or decrease their concentrations in plasma in 
response to inflammation. There is still a large overlap of Hp concentrations between AD 
and controls. In addition, the method 2D gel electrophoresis is used to separate the 
proteins by charge or size, but it is laborious as a diagnostic practice. In order to have 
better analyses and consistent results, it is suggested to use sensitive assays and large 
patient groups with the similar stages of AD.32 Other markers related to inflammation 
have been investigated: lithostathine, glycoprotein 130, and cleavage products of 
kininogen in CSF; mannan-binding lectin and proteinase kallikrein in both serum and 
CSF; histamine, anti-GFAP, anti-NGF, anti-histone, and anti double-stranded DNA 
antibodies in serum.32 
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Table 6: Summary of Inflammatory Proteins in Serum and CSF of AD Patients 
 Marker AD vs. Normal 
CSF IL-6 + (2) 
= (8) 
-­‐ (1) 
IL-6 receptor = (1) 
-­‐ (2) 
Glycoprotein 130 = (1) 
-­‐ (1) 
IL-1β + (2) 
= (6) 
IL-1β receptor II + (1) 
TNF-α + (1) 
= (3) 
TNF-α receptors = (3) 
α-ACT + (3) 
= (2) 
Haptoglobin = (1) 
Haptoglobin fragments + (2) 
Lithostathine + (1) 
Proteinase kallikrein + (1) 
Mannan-binding lectin -­‐ (1) 
Cleavage products of kininogen -  (1) 
Serum/plasma IL-6 + (5) 
= (4) 
IL-6 receptor -­‐ (1) 
IL-1β + (1) 
= (5) 
TNF-α + (3) 
= (4) 
-­‐ (1) 
α-ACT + (5) 
= (2) 
Haptoglobin = (2) 
Haptoglobin 2-1 + (1) 
= (4) 
Proteinase kallikrein + (1) 
Histamine + (1) 
Anti-glial fibrillary acidic protein + (1) 
Anti-nerve growth factor + (1) 
Anti-histone + (1) 
Anti-double stranded DNA + (1) 
Mannan-binding lectin = (1) 
+: Increased levels observed in AD patients compared to controls 
=: No difference observed in levels of AD patients compared to controls 
-: Decreased levels observed in AD patients compared to controls 
#: Number of studies conducted 
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5.6 Novel Markers 
Other proteins worth mentioning are L-glutamine, L-aspartate, glutamic oxaloacetate 
transaminase (GOT), and glutamic pyruvate transaminase (GPT). L-glutamine and L-
aspartate are one of the most abundant amino acids in CSF.36 L-glutamine occurs at 
higher levels in AD CSF than in normal CSF. L-glutamic acid is derived from L-
glutamate and thus occurs at higher levels as well. L-aspartate occurs at significantly 
lower levels in AD CSF than in normal CSF. GOT and GPT are two transaminases that 
removes the amino group from the amino acid leaving behind an α-keto acid and 
converting it into an amino acid. In AD, frontal, parietal, and occipital cortices, GOT is 
present at “higher levels (about 1.5 times higher) than in normal brain cortices.”36 No 
significant difference for GPT activity between AD and normal. Because CSF receives 
amino acids from brain tissues and because GOT catalyzes the conversion of L-aspartate 
to L-glutamine, the high concentration of L-glutamine and the low concentration of L-
aspartate found in AD CSF might be a consequence of the higher activity of GOT that 
occurs in the AD brain.36 
Another research group has discovered a different path of detecting AD. They 
identified Aβ40 and Aβ42 in lenses from people with and without Alzheimer’s at 
concentrations that are the same in the brain and Aβ40 in the primary aqueous humor at 
concentrations that are the same in CSF. Yet, Aβ accumulate in lenses specifically in the 
cataracts of AD subjects and not in controls. The mechanism by which AB accumulates 
in this compartment is unclear.35 
They find that Aβ binds to αβ-crystallin, an abundant cytosolic lens protein, and 
promotes lens protein aggregation, extracerebral amyloid formation, and supranuclear 
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cataracts, which are located just above the center of the nucleus of the lens. This was 
observed from doing a double immunogold electron microscopic examination of lenses 
from people with AD showing Aβ and αβ-crystallin immunoreactivity within single 
cytosolic aggregates. They examination also shows high-affinity binding and 
coaggregation of Aβ and αβ-crystallin.35 This could be measured non-invasively and 
tracked optically. Two technologies that apply this noninvasive quantitative measurement 
are quasi-elastic light scattering (QLS) and fluorescent ligand scanning (FLS). The 
company Neuroptix is commercializing these technologies and combining them into a 
screening system that can be used in a doctor’s office.  
QLS emits an IR laser beam in certain sections of the eye and collects the light 
scattered at various angles by using a device called a photon-counting detector and 
correlator assembly. It yields an estimate of the molecular size of the scattering elements 
by measuring the intensity of the scattered light as a function of time. In AD, protein 
aggregates have a high molecular weight that is large enough to scatter light. Therefore, 
by monitoring the light scattering, you can monitor the process of protein aggregation, its 
size and shape. 
FLS is a complement method that validates if these suspect proteins are indeed 
Aβ proteins. Topical applications of Aβ-specific molecules are applied to the patient’s 
eye. These molecules then bind to the amyloid aggregates and emit light at a certain 
wavelength.  Namely, the molecules are methoxy-X04 and methoxy-X34 due to their 
strong binding to amyloid and their high fluorescence. These emissions are measured 
quantitatively in specific locations to confirm the presence of amyloid. If the binding 
increases over time, then there is more fluorescence, proving to be a positive diagnosis of 
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AD. Clinicians can then monitor the progression of the disease by measuring the levels of 
fluorescence. QLS is only dimly visible to the human eye, which means it is well-
tolerated and safe to patients. Both technologies are currently being combined to be used 
in clinical settings. 
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Chapter 6: Neuroimaging Biomarkers - Structural and Functional Imaging 
As mentioned earlier, a biomarker can be any detectable biological feature that 
provides insight about its source. This is not exclusive only to molecules that can provide 
information on concentration levels in AD patients but also neuroimaging of these 
molecular and volumetric changes in the brain. Therefore, a neuroimaging biomarker 
detects a biological feature in the brain through the use of imaging modalities. 
Neuroimaging AD biomarkers are divided into 2 categories. One is structural imaging – 
which includes computed tomography (CT) and magnetic resonance imaging (MRI) – 
and the other is functional imaging – which includes single photon emission tomography 
(SPECT) and positron-emission tomography (PET). These neuroimaging techniques are 
used nowadays to detect different types of brain changes associated with AD, and thus 
have potential as markers of disease progression, monitors of therapeutic effects, and 
predictors of future dementia prior to symptoms. Each imaging marker offers positive 
and negative predictive values with the appropriate sensitivity and specificity, suggesting 
each one as a promising AD biomarker. 
6.1 Computed Tomography 
Computed tomography (CT) is a medical imaging method that uses tomography 
to image sections created by computer processing. Because atrophy (partial or complete 
wasting away) in the medial temporal lobe is an early sign of AD, CT can volumetrically 
measure this medial temporal lobe atrophy (MTA). One study on simple CT linear 
measurements of the brain documented  atrophy factors, specifically ratios of particular 
areas of the brain, that contribute most significantly to AD diagnoses.37 In combination 
with other clinical factors such as apolipoprotein ε4 genotype, AD classification was 
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achieved with 90.2% accuracy. As a result of the inexpensiveness, availability, and 
simplicity of linear measurements, CT linear measurements can be valuable in the 
assessment of AD patients.37 
6.2 Magnetic Resonance Imaging 
Although CT has observed atrophy of medial temporal regions, magnetic 
resonance imaging (MRI) is superior to CT in AD studies due to its greater accuracy, 
manipulability, and precision.38 MRI measures in vivo brain morphometry, or brain shape 
and size, by capturing gray and white matter atrophy as well as cerebrospinal fluid 
spaces. Gray matter is a component of the central nervous system (CNS) that consists of 
neurons, dendrites, unmyelinated axons, and glial cells. White matter is also part of the 
CNS that consists mostly of glial cells and myelinated axons. Measurements of MRI 
atrophy have accuracies between 70% and 90% in AD depending on the type of MRI 
method used.  
6.2.1 Methods 
There are several commonly used methods to extract information from MRI 
images. These are volumetry, quantitative voxel-based techniques, boundary shift integral 
(BSI), T1ρ, and other less common methods discussed in the following section. Visual 
assessment is a method worth mentioning because it is fast and efficient in analyzing 
MRI scans. However, the drawback to it is that it does not capture the fine incremental 
grades of atrophy.39 On the other hand, volumetry is a more powerful strategy and it is 
the most common cross-sectional quantitative measurement used in AD when “changes 
in different individuals are measured cross-sectionally.”39  
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6.2.1a Volumetry 
MRI traces and quantifies the volume of medial temporal lobe structures such as 
the hippocampus or entorhinal cortex. Hippocampal volumetry and entorhinal cortex 
volumetry are beneficial because both “measure a known anatomic structure that is 
closely related to the pathological manifestation of the disease and is also functionally 
related to one of the paramount early clinical symptoms, memory impairment.”39 
Hippocampal volumetry is the leading method in determining the hippocampal volume. 
Yet, it is time-consuming and involves a great deal of manual work. The large amount of 
manual work in using hippocampal volumetry is compensated through automation 
protocols, which uses control systems and information technology to reduce human work 
in the measurements of volumetry. However, these automation protocols still need to be 
comprehensively automated. However, it is the best-established structural biomarker for 
AD to date. A recent analysis proves that hippocampal volume can detect approximately 
73% of the conversion from MCI to AD.  
Volumetry of the entorhinal cortex, which lies adjacent to the hippocampus, at the 
MCI stage can improve prognostic efficacy by a few percentages as compared to 
hippocampal volumetry. However, it is more laborious than hippocampal volumetry as 
no automated procedures are available yet and no sufficient data were obtained to assess 
whether it adds on another benefit such as distinguishing AD from other forms of 
dementia.  
In addition, several experiments using both cross-sectional methods (visual 
assessment and hippocampal volumetry) demonstrate that atrophy observed using MRI 
can predict the likely progression to AD with good accuracy. Though it is not known if 
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the accuracy of using both hippocampal volumetry and visual assessment is acceptable 
for use as a potential biomarker, it provides an example to find other possible 
combinations of MRI methods that can predict the conversion to AD with higher 
accuracy.39 As a result of detecting pathological changes that occur before the onset of 
clinical symptoms, these imaging MRI methods can serve as biomarkers that aid in the 
prediction of conversion from MCI and normal to AD.39 
6.2.1b Quantitative Voxel-Based Techniques 
Quantitative voxel-based methods are other strategies that assess atrophy over the 
entire 3D MRI scan. These are advantageous over visual assessment and volumetric 
methods because using all of the spatial information in a 3D MRI provides a more 
accurate disease measurement compared to using only using a single region of interest.38 
Quantitative voxel-based methods include voxel-based morphometry (VBM), 
deformation-based morphometry (DBM), boundary shift integral (BSI), and tensor-based 
morphometry (TBM). The term voxel is a volumetric pixel representing a value in 3D 
space. Morphometry is the volume of an object measured by drawing regions of interests 
on the image of the object and calculating the volume of the object from those regions of 
interests.  
VBM and DBM utilize the concept of morphometry which is measured in voxels 
to visualize the pattern of neurodegeneration. Methods for VBM additionally provide 
statistical analyses to test for group-wise comparisons between cross-sectional MRI scans 
of AD and those of normal controls.38 VBM demonstrates reduction in the cortical gray 
matter in the region of mediotemporal, laterotemporal, and parietal associative areas in 
AD patients. However, it is difficult to determine this reduction in each AD individual 
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because it is always based on group statistics. On the other hand, DBM transforms brain 
volume to a standard template brain to eliminate the large difference in the brain anatomy 
of AD patients. These differences in reduction, which form deformation fields, provide 
statistical information to distinguish between AD patients and healthy controls by 80%. 
Thus, DBM might be used for individual risk prediction and VBM might be used for 
group-wise differences between AD and normal subjects.  
6.2.1c Boundary Shift Integral 
In addition to assessing atrophy in regions of or the entire brain at one point in 
time, BSI tracks structural changes in the brain over time in order to monitor the 
progression of the disease. BSI quantifies the “global percentage change in brain volume 
between two MRI scans and determines the total volume through which the surface of the 
brain has moved between scans acquired at two time points.”39 This is especially helpful 
in tracking the disease in MCI patients and normal controls because atrophy rates can 
predict the conversion to AD in both groups. The measurements commonly used for 
evaluating or tracking disease progression are increased in ventricular volume and 
decrease in brain volume over time.39 These measurements are more sensitive in 
capturing changes over time compared to cross-sectional measurements because all scans 
of the same subject are registered together in order to reduce inter-scan variability.39  
6.2.1c T1ρ 
T-1-rho (T1ρ) is an alternate “contrast [MRI] mechanism that visualizes the early 
pathological changes using the spin lattice relaxation time constant in the rotating 
frame.”40 MRI is so dynamic and flexible that variable image contrast can be achieved by 
using different pulse sequences and by changing the imaging parameters. Because senile 
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plaques and neurofibrillary tangles are seen in early AD, these are expected to alter bulk 
water T1ρ relaxation times. Results from this experiment show that T1ρ MRI increased 
by 6% in AD patients compared to controls. Follow-up reports and longer evaluation 
periods need to be conducted in order to examine whether normal and MCI patients with 
high values will progress to AD or not. However, T1ρ experiments have the potential to 
provide information on low frequency motions in biological systems. For this reason, it is 
possible for T1ρ MRI to probe protein content in an indirect manner in tissues such as 
cartilage, brain, and blood.40 Thus, measuring and comparing T1ρ values with changes in 
brain volume demonstrate T1ρ’s potential value as an important AD biomarker. 
6.2.1d Other Methods 
While BSI monitors only spatial shift in the brain surfaces, TBM further provides 
a 3D profile of voxel-level brain degeneration. TBM uses 3D voxel-based methods to 
observe how the disease progresses in the brain as a result of the underlying pathological 
changes. Another method worth mentioning is analysis of cortical thickness. For this 
method, the cortical thickness of the neocortical and entorhinal cortex is 90% 
distinguishable between AD and normal subjects. Further investigations need to be 
conducted because: 1)this method has not yet been evaluated in independent groups and 
2)the accuracy of predicting conversion to AD in MCI subjects has yet to be studied. 
Another method would be imaging structural changes of the cholinergic nuclei in the 
basal forebrain that occur in early AD. MRI-based method showed a signal reduction in 
the region of lateral and medial nuclei of basal nucleus. 
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6.2.2 Other Applications 
In addition to using MRI methods to differentiate AD from normal patients, other 
applications of using MRI methods include measuring the efficacy of therapeutics, 
screening in clinical trials, differentiating from other dementia subtypes, and 
extrapolating mechanisms into the disease process of AD. MRI measurements can allow 
clinical research to be conducted in smaller sample sizes than is usually possible using 
traditional clinical instruments such CT measurements or neuropsychological exams. 
Currently, AD biomarkers have not yet been “validated as surrogate endpoints for 
regulatory purposes and therefore cannot be used as the primary indicators of efficacy.” 39 
However, in a few clinical trials these have been found to be potentially useful in 
capturing the pharmacodynamic effects.39 In addition to evaluating therapeutic efficacy, 
atrophy on MRI can be used to selectively choose at-risk MCI subjects for clinical 
trials.39 MRI is also routinely used at two stages in clinical trials and used for safety 
screening during the investigation.39 
Because the pathology of AD does not always match the clinical expression of the 
disease and has considerable clinical heterogeneity, MRI markers can aid in the 
differentiating AD diagnosis from other dementia types. “The absence of significant 
medial temporal lobe atrophy in dementia with Lewy bodies [abnormal aggregates of 
protein that develop inside nerve cells] and vascular dementia, significant frontal lobe 
atrophy in behavioral variant frontotemporal dementia, or pronounced asymmetrical 
temporal lobe atrophy in semantic dementia can be used to separate these non-AD 
dementias from AD.”39 The differential diagnosis of dementias using MRI will be 
particularly helpful when therapeutics become readily available.39 In addition, using MRI 
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as an independent biomarker of neurodegeneration helps in understanding relationships 
between cognition and neurodegeneration in AD.39 This has led to insights into disease 
mechanisms in AD. The conclusion that neurodegeneration is more associated with 
cognitive decline was derived from several MRI analyses.39 Thus, structural MRI is a 
powerful biomarker in the stage and intensity of the neurodegenerative aspect of AD 
pathology. 
6.3 Functional Magnetic Resonance Imaging 
Functional magnetic resonance imaging (fMRI) allows measurement of brain 
activity during cognitive tasks at high resolution without any radiation exposure.35 It 
investigates changes in the functional connectivity between regions of an activated 
network. By examining changes across the network supporting cognitive function, fMRI 
shows promise as a biomarker of AD. Several fMRI investigations observe altered 
activation in AD as well as in MCI.38 Several research groups have also tested and 
quantified the diagnostic value of various fMRI paradigms 
(activation/deactivation/resting state) in AD.42 Research focusing on resting state fMRI 
report diagnostic values with sensitivity and specificity well above 70% (Table 7).42 Only 
values from AD patients and healthy controls (HC) are included in the table because they 
were reported across all studies.42  
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Table 7: Overview of Studies that assessed the Diagnostic Value of Resting State fMRI 
(rs-fMRI) Candidate Biomarkers42 
Study fMRI candidate biomarker Patients and subjects Diagnostic 
value 
Li et al. 
(2002) 
rs-fMRI (COSLOF-Index) AD (N = 14) vs. 
HC (N = 13) 
Sensitivity: 
80% 
Specificity: 
90% 
Greicius 
et al. 
(2004) 
rs-fMRI- 
ICA components of the DMN 
AD (N = 13) vs. 
HC (N = 13) 
Sensitivity: 
85% 
Specificity: 
77% 
Koch et 
al. 
(2010b) 
rs-fMRI- 
Combined functional connectivity 
(ROI based) and coactivation 
magnitude (ICA-based) 
AD (N = 15) vs. 
HC (N = 21) 
Sensitivity: 
100% 
Specificity: 
95% 
Chen et 
al. 
(2011) 
rs-fMRI- 
ROI-based pairwise product 
moment coefficients 
AD (N = 20) vs. 
Non-AD group 
(=pooled aMCI and 
HC (N = 35)) 
Sensitivity: 
85% 
Specificity: 
80% 
Supekar 
et al. 
(2008) 
rs-fMRI- 
Small world network properties 
(clustering coefficient) 
AD (N = 21) vs. 
HC (N = 18) 
Sensitivity: 
72% 
Specificity: 
78% 
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In differentiating AD from other dementia types, one report finds an almost 
inverted picture in frontotemporal dementia (FTD) compared with AD patients when 
assessing intrinsic brain activity during resting state using fMRI.43 It was found that in 
the FTD group, the connectivity in certain brain regions increased, and in other areas it 
decreased. The opposite picture was observed in AD patients, with decreased 
connectivity in areas that had increased connectivity in the FTD group, and increased 
connectivity in areas that decreased connectivity in the FTD group. These results are 
highly promising and should encourage further fMRI-based comparisons of AD with 
other neurodegenerative diseases.  
Overall, functional activation and connectivity in the brain constitute a new group 
of potential dynamic candidate biomarkers and surrogate biomarkers in AD. Nonetheless, 
fMRI needs further stepwise validation. Incorporation of CSF and plasma markers as 
well as integration of physiological signals (e.g. respiration) should be routinely 
implemented in fMRI analyses in order to add value to the diagnostic case.42 In general, 
confirmation of its potential value as a biomarker can be attained through longitudinal 
studies (studies that can be repeated over long periods of time with the same variables) 
and long-term population based observations. 
6.4 Positron Emission Tomography and Single Photon Emission Computed 
Tomography 
Positron emission tomography (PET) is used to study the metabolic activity in 
cortical regions of the brain. It is one of the leading methods for in vivo diagnosis of early 
AD. The disadvantages of PET are that it is not widely available and it is very costly. It is 
less validated for differential diagnosis, but has an established automated analysis. In 
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PET, there are 2 markers used to detect the cortical metabolism. 18F-2-deoxy-2-fluoro-D-
glucose (FDG) is used as a marker to examine regional cerebral metabolism.38 Observed 
changes using FDG-PET show reduced pattern of cortical uptake in several regions of the 
brain such as temporoparietal, entorhinal, posterior cingulate, hippocampal complex, 
medial thalamic regions, and mammillary bodies. Decreased cortical uptake “reflects 
metabolic deficits due to synaptic dysfunction and probably tau-mediated neuronal 
injury.”39 H215O is another marker used in PET studies to measure regional cerebral blood 
perfusion, and in turn cerebral activation. Analyses have demonstrated that AD and MCI 
brains have patterns of activation that differ significantly from normal controls when 
performing the same task.38  
Single photon emission computed tomography (SPECT) is similar to PET, also 
measuring cortical metabolism. Most SPECT studies show a decreased regional cerebral 
perfusion in AD compared to controls.38 Furthermore, one study that examined the 
accuracy of SPECT in differentiating AD from FTD found that the diagnostic 
differentiation of FTD from AD using SPECT alone was less accurate than clinical 
diagnosis. It was found that the sensitivity is only 65% and specificity is only 72%.44 
Record studies show that a combination of using SPECT and clinical diagnosis is more 
accurate than either diagnostic tool alone, with an increase of sensitivity to 84% and an 
increase in specificity to 84%.44 
Both PET and SPECT are imaging methods that are also used for in vivo 
evaluation of brain function in health and in disease.45 By “binding radioactive molecules 
to water, neurotransmitters, or products of intermediary metabolism and imaging the 
distribution of radioactivity within the brain, PET and SPECT images can provide 
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information on neural or synaptic function, the status of neurotransmitter systems, or 
specific metabolic processes within the brain under controlled conditions.”45 Therefore, 
the use of several markers that bind to specific AD pathology enables PET and SPECT to 
visualize these characteristics. 
6.5 Molecular Markers Used in Neuroimaging Methods 
A promising approach is imaging receptor-binding of specific transmitters. Recent 
research focuses on developing compounds for the in vivo imaging of brain amyloid, 
neurofibrillary tangles, and activated microglia. Because AD pathology precedes the 
onset of AD symptoms by many years, “molecular” imaging agents would allow for early 
diagnosis and for the monitoring of disease progression and treatment efficacy.38 Five 
amyloid PET ligands and two microglial PET ligands have been tested in AD patients 
and have yielded promising results. 
Amyloid imaging agents are [18F]FDDNP, Pittsburgh compound B (PIB), 18F-
BAY94-9172, 11C-SB-13, and 11C-BF-227. The microglial imaging agents are 
[11C](R)PK11195, [123I]iodo-PK11195, and [18F]FE-DAA1106. FDDNP-PET 
experiments demonstrate increased retention of [18F]FDDNP in the brains of AD patients. 
FDDNP has been proven to bind to neurofibrillary tangles in vivo and prion plaques ex 
vivo as well.38 PIB-PET, the most successful of the imaging amyloid agents, observes 
increased retention of PIB in the brains of AD patients as well as, specifically in the 
frontal, parietal, temporal, and occipital cortices and striatum. Additionally, PIB studies 
report Aβ plaques in a subset of cognitively normal controls and detect cerebral amyloid 
angiopathy, which is a form of angiopathy in which amyloid deposits form in the walls of 
blood vessels of the CNS. The other three PET amyloid imaging agents also demonstrate 
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an increased retention in AD patients. Similarly, PET markers of microglial activation 
also demonstrate an increased retention in AD patients. Although microglial activation is 
not specific to AD, activated microglia is closely associated with neurotic plaques, 
providing a marker for inflammatory processes. Therefore, due to the fact that activated 
microglia are associated in inflammatory mechanisms in neurodegenerative diseases, the 
unique pattern of ligand binding within AD brains along with the use of other more 
specific markers of AD may prove to be useful for the diagnosis of AD.38 
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Chapter 7: Combinations and Comparisons of AD Biomarkers 
The major AD biomarkers that are typically considered for clinical trials are CSF 
Aβ42, CSF t-tau, FDG-PET, PIB-PET, and MRI. A few comparisons among major AD 
biomarkers by summarizing the results from several studies provide insight into the 
usefulness of combining specific markers to accurately diagnose AD. 
7.1 Combinations of MRI Methods 
One study tested if there was a correlation between “different methods of 
measuring rates of brain atrophy from serial MRI with corresponding clinical change in 
normal elderly subjects, with mild cognitive impairment (MCI), and probable AD.”41 The 
results of this study indicate that normal subjects who converted to MCI or AD had 
higher atrophy rates than those who remained stable. Specifically, MCI participants who 
converted to AD had higher rates than those who remained stable, and fast AD 
progressors had higher rates than their slow counterparts. It was found that “atrophy on 
MRI was detected more consistently than decline on cognitive tests/rating scales” 
because the tests were frequently unreliable.41 Some MCI and AD subjects saw 
improvement in cognitive performance. Therefore, it is probable that using the rate of 
change from MRI analyses coupled with standard clinical/psychometric measures may be 
used as a marker of disease progression in AD in order to produce more meaningful 
measures than using either measure alone. 
7.2 MRI vs. CSF 
Several CSF and MRI reports compare the diagnostic and prognostic accuracy of 
both and attempt to characterize the associations between the two biomarkers in the same 
set of subjects (Table 8 – please refer to Appendix M on page 165). The earlier reports 
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concentrate mainly on the associations between CSF and MRI biomarkers, whereas the 
more recent ones investigate the association between these biomarkers and cognition. For 
example, one study suggests CSF Aβ signifies a specific molecular pathway whereas 
CSF tau, p-tau, and MRI may reflect the disease stage or intensity of AD.39 As mentioned 
before, BSI tracks structural changes in the brain over time and is therefore able to 
monitor the progression of the disease However, MRI appears to be a more stable 
indicator of neuronal loss in comparison with the CSF measures because the brain 
volume quantification with MRI is not similar to the daily turnover of a soluble protein 
measured using CSF. Nevertheless, the majority of the analyses conclude that although 
MRI and CSF provide independent diagnostic information, the combination provides 
better discrimination of AD than either one does alone. Research also demonstrates that 
both biomarkers are good predictors of MCI progression to AD. However, the 
associations between both of the biomarkers are inconsistent across studies. This could be 
due to measuring the biomarkers at different stages of the disease, thereby providing 
different results. Another source of inconsistency comes from the large variability in the 
methodologies used such as the assays performed and different MRI methods. 
7.3 MRI vs. FDG-PET 
MRI atrophy is observed in the medial temporal lobes, whereas decreases of 
FDG-PET uptake are observed in the posterior cingulate and parietal lobes. Studies 
investigate FDG-PET and MRI in the same group of subjects and compare both markers 
on the basis of diagnostic and prognostic accuracy (Table 9 – please refer to Appendix N 
on page 166). FDG-PET is found have better discrimination accuracy than MRI. Still, a 
couple of recent ADNI investigations found that both FDG-PET and MRI have similar 
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performance and have largely overlapping value for discrimination.39 This overlapping 
information between FDG-PET and MRI remains to be investigated in large study 
populations. 
7.4 MRI vs. PIB-PET 
Studies investigate both PIB-PET and MRI in the same group of subjects and the 
effect of Aβ plaques as measured by both on cognition (Table 10). The majority of 
reports have found a correlation between baseline MRI and PIB-PET measures. PIB-PET 
and MRI analyses have found that “longitudinal changes are much more pronounced on 
MRI and that longitudinal change in PIB-PET is minimal.”39 These analyses have shed 
light on the understanding that Aβ accumulation increases, as detected using PIB-PET, in 
the brain and  is therefore an upstream process in AD, whereas, neurofibrillary tangles 
and neurodegeneration are considered to be downstream pathological processes that 
progressively worsen in the presence of Aβ plaques and which then directly lead to 
cognitive decline.39 
Table 10: Summary of Combined MRI and PIB Studies in AD39 
Study Subjects Associations 
Archer et al., 
2006 
9 AD Positive correlation between rates of whole-brain atrophy and 
regional PIB uptake 
Jack et al., 
2008 
20 CN, 17 MCI, 8 AD aProportional odds to separate all groups: PIB: 0.75; MRI: 0.84; 
MRI + PIB: 0.86. Global PIB and MRI were correlated with each 
other as well as with clinical measures. 
Jack et al., 
2009 
21 CN, 32 MCI, 8 AD Longitudinal annual change was observed only in MRI and not in 
PIB. Change in MRI was associated with change in cognitive 
measures. 
Mormino et 
al., 2009 
37 CN, 39 PIB + MCI PIB and MRI were correlated with each other as well as with 
episodic memory. 
Scheinin et al., 
2009 
13 CN, 14 AD During 2 years, only longitudinal MRI change was observed but 
not in PIB. 
Strorandt et 
al., 2009 
135 CN PIB was associated with cross-sectional brain atrophy and 
longitudinal cognitive decline. 
Bourgeat et al., 
2010 
92 CN, 32 MCI, 35 AD In CN, PIB retention in the inferior temporal region and 
hippocampal volume were strongly correlated. 
Chetalat et al., 
2010 
94 CN (49 subjective 
cognitive impairment), 34 
MCI, 35 AD 
Global atrophy and regional atrophy were strongly related to PIB 
load in CN subjects with subjective cognitive impairment but not 
MCI and AD. 
Driscoll et al., 
2010 
57 CN In CN, current PIB load was not related to longitudinal MRI 
changes in the preceding years. 
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7.5 FDG-PET vs. SPECT vs. MRI 
One report evaluated and compared FDG-PET, SPECT, and MRI to predict 
conversion to AD in patients with MCI (Table 11).46 Results showed that FDG-PET 
performed statistically better than the other two methods.  
Table 11: Weighted Summary of Sensitivity and Specificity for Each Modality46 
Modality Sensitivity Specificity 
FDG-PET 88.8% 84.9% 
SPECT 83.8% 70.4% 
MRI 72.8% 81.0% 
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Chapter 8: Current and Potential Treatments for Alzheimer’s Disease 
 The battle against Alzheimer's is one that has been fought for a long time, and has 
so much information and documentation that it is extremely difficult to process and 
condense it all. However, in the presented chapters, a good overview on where the field 
of research is in regards to current and possible treatments for Alzheimer's is provided. 
Although it is not common knowledge, there are indeed drugs currently on the market to 
treat AD patients. These therapies are sold commercially and are used in clinical 
treatments for those suffering from AD. However, these treatments are not perfect; they 
do not slow neurodegeneration, nor can they eradicate the disease fully and restore 
cognitive function permanently. Thus, the current treatments for AD are simply 
temporary reliefs from the disease. 
 The current "gold standard" for treatment in AD is a group of drugs that treats the 
symptoms of AD and neurodegeneration, but not the disease-causing aspects of the 
condition. There is ongoing research into drugs and other potential treatments in which 
people are working to develop a disease-preventing or disease-modifying treatment for 
AD. The ideal goal would be to develop these types of therapies, but unfortunately these 
potential treatments are incredibly difficult to go through later phases of clinical testing. 
Although many treatments show great promise in initial testing periods on mouse models, 
the human biology is very different and successes become much rarer. Many drugs 
simply do not reach a point where they are reliable enough for market release. 
Unfortunately, this is not a very big surprise considering the complicated nature of AD. 
Its neurodegenerative effects, and the fact that our understanding of AD is still quite 
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limited as to what the "true cause" of the disease may be, has slowed the progress of 
therapeutic developments. 
 The following section of the paper will be devoted to research on the potential 
treatments of AD, as well as a discussion on the current standards of treatment for AD 
patients and where the field of therapy research is currently moving. In order to 
understand where the field of research will go in the future, it must be understood where 
the world is currently with respect to understanding and treating the disease.  
8.1 Acetylcholinesterase Inhibitors  
 There are a number of treatments currently on the market for AD. The "gold 
standard" of treatment is a group of drugs known as acetylcholinesterase (AChE) 
inhibitors. As mentioned above, these drugs are not disease-modifying, but they do 
improve cognitive function and temporarily guard against the neurodegenerative 
symptoms of AD. However, to presume that these treatments are not effective for those 
suffering from AD would be incorrect. These treatments are still critically important for 
those who suffer from AD. Although disease-modifying strategies will be discussed in-
depth later on, it is worth mentioning them now to highlight the differences between their 
approach and the current "gold standard" for treatment, which are AChE inhibitors. 
 Many disease-modifying strategies would potentially treat typical pathological 
hallmarks of AD. They typically focus on Aβ peptides and the pathologies associated 
with them, as were discussed earlier. Some of these strategies focus on amyloid plaques 
and neurofibrillary tangles. The negative effects of these are well-documented, but it 
should be noted that "cognitive impairment and behavioral abnormalities are not directly 
caused by [these] pathological hallmarks."47 Therefore treating amyloid plaques and 
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neurofibrillary tangles, which would modify the disease, would still not treat the loss of 
synaptic connections and damage caused by Aβ. However, AChE inhibitors are still 
extremely therapeutic for AD patients, though disease-modifying treatments would still 
be incredibly worthwhile to research. 
  AChE inhibitors are useful treatments for AD patients because of how they work 
with respect to Alzheimer’s therapy. The cholinergic system is a system of nerve cells 
that uses the neurotransmitter acetylcholine to transmit signals. This system is heavily 
involved in the regulation of memory and learning in the brain, and is heavily 
degenerated in those that suffer from AD. Studies showed that "Aβ peptides are able to 
reduce choline uptake, inhibit acetylcholine releases", which alters the efficiency of the 
cholinergic system and results in cognitive harm for the AD patient.47 Therefore, many 
treatments designed to counteract AD seek to enhance cholinergic function, usually 
through inhibitors of AChE. The function of these treatments is to inhibit the 
acetylcholinesterase enzyme from breaking down acetylcholine, which therefore 
increases the duration in which acetylcholine can act as a neurotransmitter.  
 Unfortunately, AChE inhibitors can be extremely harmful. There can be severe 
neurodegenerative side effects associated with using these types of drugs to treat any 
condition, let alone Alzheimer's. Some AChE inhibitors, when in high quantities, can 
trigger acetylcholine to continue to act for long periods of time, which causes permanent 
contraction of certain bodily muscles. AChE inhibitors are, in fact, used as incredibly 
dangerous chemical weapons in some cases, including the infamous nerve agents used in 
WWII. But the current FDA approved AChE inhibitor drugs used to treat Alzheimer's are 
all reversible inhibitors and can be regulated in the system. In other words, the method of 
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action for AChE inhibitors can be reversed and will not have permanent negative effects 
on the body of a patient who is using it for therapy. 
  There are currently four AChE approved drugs that have been developed and 
marketed to treat AD. They are known as Tacrine, Donepezil, Rivastigmine, and 
Galantamine, and were developed in that order (i.e. Tacrine is the "oldest" approved 
treatment). Again, these drugs do not prevent or reverse the progression of AD but they 
do provide temporary improvement in cognitive function, have been a commercial 
success, and are currently considered a "gold standard" for AD therapy.48 Recent studies 
showed that AChE inhibitors could be "effective in protecting cortical neurons from 
glutamate-induced neuronal death."49 The fact that AChE inhibitors could act on 
glutamate allows for transition into a much newer development, which is the fifth and 
final FDA approved treatment for AD. This treatment is known as the NMDA-receptor 
modulator Memantine. 
8.2 Glutamate Receptors, NMDA, and Memantine 
 Glutamic acid is an incredibly important amino acid in the body, as it is the basis 
for an extremely prominent neurotransmitter. The carboxylate anions and salts of 
glutamic acid are known as glutamates. Glutamate is an extremely important 
neurotransmitter in the body; it is known as the "principal excitatory neurotransmitter in 
the brain."50 Glutamate, like acetylcholine, is a central molecule in aiding in memory and 
learning. However, in many AD patients, research showed that glutamate can cause 
severe problems within the nervous system. "Glutamic overstimulation may result in 
neuronal damage, a phenomenon that has been termed excitotoxicity. Such excitotoxicity 
ultimately leads to neuronal calcium overload and has been implicated in 
93	  	  
neurodegenerative disorders" including AD.50 According to research, "Almost all neurons 
in the CNS carry the N-methyl-D-aspartate (NMDA) subtype of ionotropic L-glutamate 
receptors, which can mediate post-synaptic Ca2+ influx."51 In addition, "excessive 
activation of NMDA receptors may enhance vulnerability of neurons in a manner 
consistent with AD neuropathology" due to the excitotoxicity and imbalance of neuronal 
and synaptic Ca2+ that results.51 Thus, the NMDA receptor has been implicated in 
Alzheimer's pathogenesis, particularly dementia and memory degeneration, and is the 
target of the drug therapy Memantine.51 
 Memantine is known as an "NMDA modulator", or an "NMDA receptor 
antagonist.” It is an uncompetitive NMDA receptor antagonist, meaning it binds within 
the ion channel to "block" it, and was studied and tested as a possible therapy for the 
neurodegenerative systems linked to dementia including AD. When it binds to the 
NMDA receptor, it is able to inhibit the receptor and thus slow the influx of Ca2+ ions, 
which protects against neuronal excitotoxicity. Memantine is a fairly recent treatment that 
has been developed and there are still ongoing tests about its potency, but it has been 
FDA approved and released as a therapy treatment for AD patients as it improves their 
cognitive function. Despite the method of action for therapy using this "NMDA 
modulator" approach is distinctive from the cholinomimetic mechanism addressed above, 
the end result is similar with improvements in cognitive function. In addition, one can see 
that there appears to be a link between the action of such AChE inhibitors and the 
functions of Memantine as stated above, indicating that the actions of the therapy 
treatments all perform on a linked system. This linkage between AChE inhibitors and 
Memantine could help us better understand the true nature of AD pathology. 
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 Despite the effectiveness of Memantine in terms of providing therapy to AD 
patients, it also suffers from the same downfalls as AChE inhibitor therapies.  Though it 
provides relief and a temporary counter to neurodegeneration and the loss of cognitive 
function that AD patients suffer, it is simply not viable as a permanent solution. 
Memantine, like the AChE inhibitors, is not a disease-modifying drug; therefore, it does 
not prevent or treat the underlying causes of AD, nor does it reverse any existing 
neurodegeneration. While these current standards of treatment are important for 
improving cognitive function and thus helping the quality of life for AD patients, they 
simply cannot be considered as a long-term solution to the problem of Alzheimer's 
disease. Thus, research is moving to look into other possible treatments that are actually 
disease-modifying with respect to AD therapy. 
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Chapter 9: Research and Possible Future Treatments for Alzheimer’s Disease 
  The fact that the current "gold standard" of treatment for AD does not actually 
work in a disease-modifying manner has caused the current field of AD therapy research 
to branch out in several different ways. The research is mainly looking into possible 
treatments that do indeed modify the disease and attempt to inhibit AD progression. The 
role of Aβ in the progression of AD pathogenesis is well documented, and the focus of 
current inquiries has largely been on the toxic Aβ peptide. Current strategies aim to target 
the production and clearance of these peptides in order to prevent their aggregation in the 
brain. In addition, some research has focused on the treatment of neurofibrillary tangles 
containing p-tau protein, which is another significant marker of Alzheimer's pathology, 
though these explorations have not been developed and studied as much as research 
focusing on Aβ. Both of these features of AD have been discussed at length in previous 
chapters, and since they are two of the largest and well-documented aspects of 
Alzheimer's disease, it is extremely important to examine them in terms of developing a 
possible treatment and therapy. 
 There are other less known directions that research has been going towards 
recently that also deserve to be mentioned in regards to possible future therapies for AD. 
One such area of investigation is the use of anti-inflammatory drugs in order to help treat 
AD, though this is a very nebulous area and not much is known about it. Anti-
inflammatory drugs are typically used in studies that are focused on modification of Aβ. 
Additionally, approaches to AD therapy focused on APOE are discussed. Yet ultimately 
there is not much research devoted to these potential treatments in comparison to the 
96	  	  
major areas of study noted above. Ultimately, the wide majority of research is focused on 
modulating Aβ in some way, and that is where the bulk of the focus will be.  
9.1 Aβ Modulation  
 Aβ, specifically Aβ42, has an immense role in the pathology of AD, and produces 
an incredible number of negative effects in the brain. Therefore, with the shift in 
Alzheimer's research aimed at possible disease-modifying approaches, it is only natural 
that Aβ would become the focus of a large portion of research. However, study on 
treatments of Aβ is further divided into a number of potential areas of investigation. One 
significant area of inquiry is devoted to the modulation of Aβ production, where enzymes 
such as β and γ secretases are targeted in an attempt to slow or halt Aβ production in 
order to prevent negative developments including neurotoxicity that goes along with Aβ 
production. In addition to preventing Aβ production, there are also other areas of study 
that are devoted to preventing  Aβ aggregation into harmful plaques and possible 
clearance of Aβ from the system, though this area of research is still very new and no real 
effective drugs have been developed.  
 Both of these are challenging aspects of research to conquer due to the blood 
brain barrier resisting movement of drugs in the brain. Additionally, the activation of 
enzymes can be a difficult task. Yet, they are still attractive areas of inquiry. One area of 
research worth mentioning is the role of trace metals in AD pathology, and how potential 
treatments revolving around Aβ aggregation could relate to them. Another one focuses on 
immunotherapeutic approaches for treating AD through vaccination of Aβ42. Finally, 
there are also a few less known treatments, revolving around the tau protein and the 
APOE gene. These treatments are not very well known, but they are worth discussing, 
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since the field of research for Alzheimer's treatment is extremely broad and any leads on 
potential treatments are worth looking into. 
9.1.1 Aβ Production Research  
Research devoted to modulation of Aβ production is a wide field and there are 
many camps within this field investigating different aspects to altering Aβ production as 
means of countering AD by modulating and interfering with Aβ production. There are 
two major fields of study within this line of thinking, and they both focus on the enzymes 
related to Aβ. One area of investigation is devoted to inhibiting γ-secretase specifically, 
focusing on the role of anti-inflammatory drugs with relation to γ-secretase inhibition and 
modulation. The second distinct area of examination in this area of inquiry revolves 
around modulation and alteration of β-secretase, which also plays a major role in AD 
pathology. Though these areas of exploration are all extremely attractive with respect to 
AD therapy, there are unfortunately a number of problems associated with developing 
them as well. 
9.1.1a γ-Secretase Inhibition 
 γ-secretase is an enzyme that was noted very early in Alzheimer's inquiries as a 
potential therapy target, but it is a very difficult enzyme to try to inhibit. 52 Since it plays 
an immense role in Notch cleavage in the brain, which is a function that is absolutely 
necessary for development. Thus, simply deleting the PS1 gene responsible for faulty γ-
secretase cleavage in AD patients would lead to extremely hazardous complications. The 
link between γ-secretase and Notch cleavage did slow this field of research for a time, 
because scientists were not sure how to inhibit action of γ-secretase but keep Notch 
cleavage functioning correctly. Recent explorations have gone into an interesting 
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direction, where non-steroidal anti-inflammatory drugs (NSAIDs) have been studied as a 
potential treatment for γ-secretase. 
 There have been many inquiries in the last decade focused on the role of NSAIDs 
with respect to γ-secretase and Alzheimer's disease. This area of investigation was built 
off of observations that chronic users of NSAIDs had a reduced prevalence of AD.53 This 
area of research attempts to treat AD by reducing the inflammatory response in the brain, 
which results from of neurotoxicity. In addition, Aβ42 reduction can, in theory, be 
mediated by direct interactions between these compounds and γ-secretase or its 
substrates.52 One risky aspect of NSAID research is that although these compounds can 
generally avoid interfering with γ-secretase's Notch cleavage mechanism, they are 
generally used to inhibit cyclooxygenase (COX), which is an important biological 
enzyme, as it is responsible for the formation of important biological mediators. NSAIDs 
typically inhibit COX to relieve pain and inflammation, but therapies do not wish to 
overly inhibit this important enzyme. Luckily, research has shown that a subset of 
NSAIDs, including common ibuprofen, can lower toxic Aβ42 production independently 
of COX inhibition.53 This is a very significant development, but scientists still speculate 
whether or not COX is upregulated in AD patients.54 More research will have to be 
devoted to that possible link, but as of now, these scientists are working under the 
assumption that COX inhibition and Aβ42-lowering activities operate under separate 
pharmacological pathways.54 Particularly, there have been NSAID derivatives that can 
"potently lower Aβ42 levels but lack COX inhibitory activity."54  
 Although this is an exciting field of research, and there has been a large area of 
study devoted to the action of NSAIDs on γ-secretase, the understanding of all the 
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mechanisms involved is not complete. Furthermore, γ-secretase inhibiting drugs can be 
developed, but without a full understanding of the inhibition mechanism, it can be 
difficult to move these drugs through clinical trials. Many of them do not even reach 
clinical trials, as they are found to result in suppression of the Notch signaling.  
There are some current drugs which, although they are very potent against Aβ42 
production and do not inhibit other functions of γ-secretase, are not easy to clinically test. 
This is due to their low brain permeability and COX inhibition, which could potentially 
harm elderly AD patients.54 γ-secretase inhibition is a very exciting, yet complicated 
field, one that is still not fully understood. 
9.1.1b β-Secretase Inhibition 
 A second area of research by which scientists seek to inhibit the production of 
Aβ42 is through the modulation of β-secretase. β-secretase modulation and inhibition can 
potentially be a great candidate for AD examination since, like γ-secretase, it plays a very 
early part in AD pathology through its role in Aβ42 production. However, its natural 
biological function is not entirely clear, and in research where BACE1 gene has been 
knocked out in mice, they appeared to suffer no noticeable negative effects.52 This is 
another reason why β-secretase is a promising area of study, as it does not carry the 
weight of something akin to the Notch risk of γ-secretase. In fact, even transgenic mice 
engineered to overexpress APP did not develop any amyloid deposits when BACE1 was 
knocked out.55 Although there could be underlying behavioral effects due to the knockout 
of the BACE1 gene in mice that were observed, this successful knockout without any 
severe harmful implications gives many researchers the hope that this could be a pathway 
to a successful AD treatment if BACE1 could be easily inhibited. 
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 Despite all of this research, there is a major problem with attempting to inhibit 
BACE1 in vivo and it has been documented that developing such a drug has been 
incredibly challenging.55 One of the reasons being that the size of a possible inhibition 
drug. This inhibition drug must be small enough to cross the blood brain barrier. Very 
few drugs, which are both small enough to pass through and yet effective enough to 
achieve inhibition, have been produced. In addition, the specificity needed to produce a 
desirable result is not fully understood. There are questions as to whether or not scientists 
must exclusively work with BACE1, or if they can cross-inhibit with the similar, but far 
less dangerous BACE2 protease. In conclusion, although this field is very promising, it is 
extremely complex and even less understood than the field of γ-secretase inhibition. 
More research must be undertaken before any real conclusions about this method versus 
other methods of AD therapy can be made. 
9.1.2 Preventing Aβ Aggregation 
 As it has been documented, one of the main aspects of Alzheimer's pathology is 
the aggregation of Aβ, particularly Aβ42, into oligomeric plaques. While in the past, 
many scientific groups believed that only the large aggregates, known as the "mature 
plaques," could induce toxicity, current research have been looking into  the early, small 
aggregates of Aβ as also playing a role in neurotoxicity. Studies have demonstrated that 
these small oligomeric assemblies can induce some synaptic dysfunction.52 Even though 
this is a field of study that is very much unknown, it is still an attractive one to explore. 
However, there are issues with attempting to find solutions using this method. 
 One serious problem with attempting to develop methods to prevent Aβ comes 
from the fact that no consensus regarding the mechanism of oligomer assembly has 
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emerged.52 Without a full understanding of how the aggregates assemble, it is a challenge 
to attempt to produce something that interferes with the unknown mechanism. In 
addition, "the exact nature of the pathogenic oligomeric species remains unclear."52 If 
these mechanisms become understood, developing a drug that will interfere with Aβ 
peptide would be an extremely promising area of study for AD research. Currently 
though, there are very few drugs that have made it to clinical testing, and much 
discussion on the topic is limited to speculation. 
9.1.2a Trace Metals and Aβ 
 An interesting field of study to mention is the apparent influence of trace metals 
may influence Aβ pathology and current attempts to interfere with toxic Aβ species The 
idea is that impaired metal ion homeostasis can cause synaptic dysfunction and influence 
AD.56 Indeed, there is "considerable evidence that free zinc in the extracellular fluid 
induces amyloid deposition."57 AD is also "characterized by elevated brain iron levels 
and accumulation of copper and zinc in cerebral Aβ deposits (e.g. senile plaques)."58 In 
particular, copper can yield toxicity, either through direct toxicity when binding with Aβ 
or through an oxidative process, which may make the Aβ easy to precipitate with zinc.57 
Moreover, "Copper (and iron) can also promote the neurotoxic redox activity of Aβ and 
induce oxidative cross-linking of the peptide into stable oligomers."58 Thus it can be seen 
that "both ionic zinc and copper are able to accelerate the aggregation of Aβ, the principle 
component of [Aβ] deposits" and stabilize the structure.58 In addition, copper oxidation of 
Aβ can result in the "generation of hydrogen peroxide by soluble but oxidized forms of 
Aβ."57 Thus, trace metals play an extremely important role in the aggregation of toxic Aβ 
in the brain. The role of metal imbalance in the brain has been studied intensively in 
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recent history, and has become a great area of interest with respect to Alzheimer's 
disease.  
 Using the "Metal Hypothesis of Alzheimer's Disease," which emphasizes the 
incredibly important role of metals in AD, researchers have begun developing therapies  
to inhibit the action of trace metals in Aβ oligomer production. It is noted that zinc 
chelators can inhibit Aβ plaque deposition and when combined with copper chelators, can 
"reverse Zn/Cu-induced aggregation of synthetic Aβ in vitro, [and] inhibit Aβ-mediated 
hydrogen peroxide formation."57 Research and testing on some chelator drugs are 
underway, including a compound known as clioquinol that can cross the blood-brain 
barrier and bind to zinc. This has resulted in a dramatic reduction of the number of 
amyloid plaques in transgenic mice.57 The potential treatments seem to be lesser known 
among Alzheimer's studies, but they are very worth looking into and companies such as 
Prana have been working to take advantage of this hypothesis. In addition, a compound 
known as PBT2 is in clinical trials and it has been shown to decrease Aβ levels by 
sequestering zinc, which otherwise could be "protease resistant Aβ:Zn aggregates."56 The 
New York Times conducted an interview with Dr. Rudolph Tanzi, a leading researcher in 
the field of Alzheimer’s therapy. Dr. Tanzi explains this particular treatment as 
something that "sucks metals out of the amyloid deposits."59 He clarifies that "If you suck 
copper and zinc out the [sic] amyloids, they fall apart."59 Thus, these chelators also work 
by attempting to prevent Aβ aggregation by sequestering trace metals, and by helping to 
degrade the already present amyloids by removing these trace metals from Aβ. 
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9.1.3 Aβ Degradation and Its Challenges 
 Traditional thinking is that many forms of Aβ are completely insoluble. However, 
recently, there has been an increase in research attempting to determine ways to degrade 
and clear Aβ through a number of proteases and enzymes.52 Cleaving and degrading Aβ 
could be an interesting way to attack Aβ toxicity. However, like many other potential AD 
treatments, there are struggles in attempting to develop a reliable method of Aβ 
degradation. Once again, the blood brain barrier remains a significant blockade to 
potential therapy treatments as it is difficult for many treatment drugs to cross this barrier 
safely. In addition, being able to activate an enzyme is much more difficult than 
inhibiting an enzyme. Potential treatments using this method will have to either move 
enzymes to the periphery where they could be acted upon, or use a cascade path in which 
the potential degradation enzyme is no longer inhibited by a currently active inhibitor 
enzyme.52 This is an extremely exciting field of research for AD, but one that has many 
barriers to progress. 
9.2 Immunotherapy Possibilities  
 The field of immunotherapy is vast and nearly overwhelming one with respect to 
worldly diseases. This field has been extended towards the realm of AD therapy in the 
last decade. It is an area of study that has absolutely exploded within the last decade, 
which makes it even more difficult to know exactly where to start looking for possible 
treatments that focus on immunization as a primary means of treating AD pathology. The 
paper that is often credited as being the first paper to really discuss the possibility of 
vaccinating for Aβ42 is one by Schenk et al in 1999, and the industry has moved forward 
using this paper as a baseline.52,60 Dr. Rudolph Tanzi describes it as a similar treatment to 
104	  	  
a vaccination "where you actually inject the amyloid so that you have an immune 
response to it, and that promotes clearance of the amyloid."58 Interestingly, the 
immunization worked very well, yet the mechanisms of this action are not fully 
understood, which has stalled this area of research for a short time. Despite that, 
hypotheses have been developed to explain how AD immunotherapy could work and this 
has grown into a very important field for AD therapy research. 
 The major hypothesis for AD immunotherapy, which could provide insight as to 
the processes involved, revolves around a "mechanism based on microglial activation and 
phagocytosis,"52 in which a small proportion of antibody reaches the CNS. This antibody, 
distributed peripherally, would bind to amyloid deposits and trigger phagocytosis of the 
amyloid.52 Although that is the hypothesis that is most well-known, there have been other 
hypotheses proposed for the action of immunotherapy with regards to AD treatment. In 
addition to the phagocytic hypothesis, one report indicates that, "antibodies can resolve in 
vitro aggregated Aβ fibrils."52 Specifically, studies have shown that "monoclonal 
antibodies (mAbs) specific for N-terminal epitopes of the Aβ peptide disaggregated 
preformed Aβ fibrils and neutralized their neurotoxic effects."60 While there have been 
promising results for this hypothesis in initial testing, it is not truly understood "how 
small amounts of antibody would dissolve existing insoluble fibrils in the brain."52 
Another proposed action of immunotherapy is a method of Aβ clearance performed by 
"Aβ mid-region monoclonal antibody 266," which have been found to reduce amyloid 
levels.52 This antibody works not by binding to insoluble plaques, but rather through 
"passive administration."52 It is believed that it captures soluble Aβ and "produces a net 
flux of Aβ from the CNS to the periphery."52 This occurs in "concentrations sufficient to 
105	  	  
produce detectable cerebrospinal fluid levels", and it is believed that this mechanism can 
"lead to decreased … amyloid load."52 Even though it is not fully understood, this 
proposed clearance mechanism has been modeled and shows promising results during in 
vivo testing in some transgenic models. Studies have shown that in transgenic mouse 
models immunotherapy with regards to toxic Aβ has provided beneficial effects on 
cognitive performance and that "an immune response against Aβ reduced the amyloid 
plaques and associated dystrophic neuritis."60  
 Nonetheless, there are ongoing debates on which hypothesis and antibody should 
be researched further, and that these are primarily based around the epitope conformation 
of antibodies used for treatments. Despite the small molecular size of Aβ, it is possible to 
"raise antibodies to distinct [among] aminoterminal, mid-region, carboxy-terminal and 
possibly conformational epitopes." This results in a number of different antibodies being 
used for testing, each with a unique effect. All three proposed hypotheses discussed 
revolve around antibodies which each recognize different epitopes of Aβ, and none of the 
antibodies perform in the same way. It is hypothesized that the specific choice of epitope 
"affects the predominate mechanism of action and determines which Aβ isoforms are 
cleared."52 One reason for the debate over which epitope and hypothesis should be tested 
more is because certain epitope choices can determine a number of possible liabilities and 
complications that could arise from treatment. Specifically, many Aβ-specific antibodies 
result in intracerebral hemorrhage when administrated. Yet this hemorrhaging only 
appears to occur in specific plaque-binding antibodies; antibodies which act in a different 
manner. For example, the 266 antibody do not show this effect. Researchers must thus 
take possible side effects into consideration when discussing possible immunotherapeutic 
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treatments. The risk of side effects arising when using certain antibodies serves to 
highlight one concern in a long list of setbacks with attempting to move forward in an 
immunotherapeutic manner for AD therapy. 
 Many immunotherapy tests that are done clinically perform fairly well in their 
early trials. Therapy approaches generally do well in early clinical trials, with 
improvement being shown in a large number of transgenic models. Unfortunately, they 
have almost universally run into problems during Phase II and III testing. "Although 
several Aβ immunotherapeutic are currently in clinical development, there are no 
definitive data on the efficacy of any immunotherapeutic approach, and no Phase III trial 
has been completed yet.”52 This indicates that, even if Phase III trials have been 
performed for immunotherapeutic treatments, there has been no Phase III success for any 
of the proposed treatments. It is likely that this is due to a number of problems with 
attempting to apply in vivo models of action in transgenic mice to the immune system of 
humans. There are a number of problems that arise with immunotherapy procedures, 
including possible autoimmune responses and the presence of the blood-brain barrier, 
which works to prevent the introduction of many drugs into the brain.60 The blood-brain 
barrier is a layer of endothelial cells which works to prevent the leakage of blood from 
circulatory vessels into the brain. This layer of cells also prevents against diffusion of 
small and large molecules into the brain tissue and fluid. Thus, a drug which is able to 
bypass this barrier is extremely rare and difficult to develop. There is also a concern over 
whether or not immunotherapies truly do aid in Alzheimer's. However, this is primarily 
due to conflicting results when analyzing post-mortem trial patients, who either have 
continued to progress to end-stage AD or have had significantly reduced functional 
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decline. Research will have to continue in order to give a better estimation of whether or 
not immunotherapeutic truly aid in treatment for those suffering from AD. Despite the 
drawbacks of this area of study, it is still a hopeful one, and could provide an answer for 
the treatment and prevention of AD if the mechanisms involved were truly understood. 
9.3 Tau Pathology Approaches 
 The involvement of tau in Alzheimer's pathology, particularly its role in creating 
neurofibrillary tangles when it is hyperphosphorylated, is well documented. Tau is a 
soluble microtubule-binding protein that plays a major role in stabilizing microtubules in 
axons.52 These tubules are used for both cell growth and axonal transport, which serves 
critical function in the brain. However, problems can arise when tau becomes 
hyperphosphorylated, aggregates in the brain, and becomes insoluble. These aggregates 
greatly contribute to neurotoxicity by being unable to support axonal transport. The 
presence of tau tangles and the presence of tangle load have a distinct correlation with 
cognitive dysfunction in not only AD, but other cognitive disorders as well. Thus, it 
provides an interesting angle for those wishing to treat AD, with two strategies primarily 
being approached: inhibition of tau aggregation and blockade of tau 
hyperphosphorylation. 
 Inhibition of tau aggregation is a desirable strategy since tau aggregates are 
incredibly detrimental to brain cells and tissues and it is seen as a possible preventative 
treatment, to inhibit tau aggregation before toxicity spreads. However, there are issues 
with attempting to follow up with this therapy, and "anti-aggregation approaches pose a 
lot of challenges."52 Specifically, the blood-brain barrier provides a large and difficult 
blockade for therapy molecules. In addition, attempting to "[find] molecules with drug-
108	  	  
like properties that specifically disrupt protein-protein interactions over large interaction 
surfaces" is incredibly difficult.52 Despite this, the research continues and efforts have 
been initiated to attempt to find possible therapies using this strategy. 
 The second primary strategy used to provide AD therapy with respect to tau is a 
strategy focused on reducing tau hyperphosphorylation. These areas of study are more 
widely pursued and yet it also contain problems that scientists must struggle to overcome. 
There are questions on whether or not hyperphosphorylation is truly critical to tau 
pathology or if there is another possible cause.52 In addition, there is no broad consensus 
on what key pathogenic kinase should be inhibited in order to prevent this 
hyperphosphorylation, or even if such a single kinase "culprit" exists.52 Additionally, 
generation of a small-molecule inhibitor of such an enzyme would be incredibly 
challenging as there could be severe side effects with chronic inhibition of tau. Finally, 
the blood-brain barrier once again provides a challenge for drugs to attempt to pass 
through into the brain. 
 Although there are major issues with exploring tau-focused therapies for AD, 
there are some clinically advanced trials being conducted in this area of study. "At 
present, the clinically most advanced tau-directed therapy is methylionium chloride … 
which has been reported to dissolve tau filaments from AD brains in vitro and to prevent 
tau aggregation in cell-based models."52 These findings have allowed the company 
TauRx Therapeutics to initiate a Phase II clinical trial for mild and moderate AD patients. 
Though these tests are ongoing, researchers believe that proper treatment could possibly 
arrest AD disease progression. This would be an immense step forward for AD research 
as a whole as preventing progression entirely would be a disease-modifying strategy and 
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would provide a basis for further therapy. Despite the fact that there are many problems 
with using a tau-based approach to AD therapy, this is an extremely promising field of 
study. 
9.4 APOE-Related Therapies 
 Therapies focusing on the role of APOE in the brain have been researched as 
well. As discussed earlier in chapter 3, APOE plays a role in the development of AD in 
many patients. The gene that encodes APOE has been identified as a large genetic risk 
factor for late-onset AD, and specifically, it is the ε 4 allele that carries the highest 
increase in risk with respect to other alleles of the APOE gene.52,61,62,63 In fact, 
examination has shown that the "risk for AD increased from 20% to 90% and mean age 
at onset decreased from 84 to 68 years with increasing number of APOEε4 alleles."62 
This is incredibly significant and studies such as the one conducted by EH Corder et al62 
have led researchers to conclude that the APOEε4 gene is "a major risk factor for late 
onset AD and, in these families, homozygosity for APOEε4 was virtually sufficient to 
cause AD by age 80."62 With APOEε4 being such a large risk factor, in principle it could 
be a huge target for potential therapeutic treatments attempting to alter or correct the 
action of this gene in order to prevent or treat AD in many patients. While this approach 
makes sense, in theory, research on an APOE-centric treatment has moved very slowly. 
 Unfortunately, research relating to APOE-related treatments to help prevent or 
treat Alzheimer's disease has moved rather slowly, despite the fact that APOEε4 has been 
identified clearly as a risk factor.52 This is due to a number of reasons, primarily because 
the biological effects of APOE and its isoforms are very complex, and that APOEε4 is a 
specific risk factor for a number of other conditions. While it is known that APOEε4 
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disrupts cholesterol and brain lipid metabolism, regulates synaptic functions, and 
"contributes to AD pathogenesis,"65 it is not known if there is a specific pathway of 
molecular action relating to AD.52 There are two lines of research related to APOEε4 
research relevant to AD. Although different, the two research directions focus on 
APOEε4 modulation. 
 One area of exploration is focused on the notion that APOEε4 could have gained 
some toxic properties relative to APOEε3.52 Those who believe this stance to be true 
study APOEε4 in an attempt to mitigate its toxic effects. An approach that is used is to 
inhibit a neuronal protease that generates a toxic APOEε4 fragment.52,64 Another 
approach would be to use molecules known as "'structure correctors' to convert 
[APOEε4] to an ['APOEε3-like'] molecule."52,65 This method of action binds a specific 
molecule to APOEε4 in order to "block the intramolecular domain interaction that is 
characteristic of this isoform,"52 which would convert the structure to one akin to 
APOEε3, which is much less likely to take on a pathogenic state. There are other areas of 
examination that believe that the problem with APOEε4 is that it has lost a beneficial 
function of APOEε3 with respect to the amyloid pathway, and is proven with results 
suggesting that enhancing APOE could benefit those who carry alleles for APOEε3.52. 
Although this is a growing field of research, there are no reported progressions of APOE-
related treatments into clinical trials.52 
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Chapter 10: Discussion of Treatments and Early Detection 
 It has been established that the current standards of care and treatment for those 
that suffer from Alzheimer's disease are not entirely sufficient. While the current 
treatments do relieve some symptoms of cognitive dysfunction, and are thus very 
important for those suffering from the disease, they are not sufficient to prevent the 
progression of AD permanently. Because the current standards of treatment only help 
with the symptoms and do not change the underlying causes of the disease, they are not 
considered preventative or disease-modifying. Currently, there are many possible 
answers to this solution, but the search continues for a disease-modifying approach to AD 
therapy. 
 It is important to note that, granted, this area of study appears to have many faults, 
it is still growing extremely rapidly. Over the past decade, the understanding of 
Alzheimer's has expanded to a far greater degree. The many possible treatment options 
outlined in the previous chapter are a result of this explosion of study into AD. As 
understanding of the mechanisms of AD grows, so too does research areas focused on 
treating the underlying causes of AD. To understand the biological mechanisms that go 
into the disease provides a base for the development of possible treatments and cures. 
Nevertheless, AD is an extremely complex disorder with many parts involved.  However, 
the mechanisms of the disease are much more fully understood now than they used to be. 
This expansion of knowledge has thus provided an avenue for those seeking to use 
disease-modifying approaches in order to treat AD. Treatments such as those focused on 
modifying or preventing Aβ aggregation, modification of tau, alteration of APOE, and 
immunotherapy of Aβ, all have their roots in understanding the biology of the disease. 
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 The field of research for Alzheimer's treatment does have a number of struggles. 
Particularly, the blood brain barrier serves as a formidable obstacle to many researchers 
attempting to provide therapy through drugs that would work in the brain. In addition, the 
mechanisms of actions for some potential therapies are not fully understood, and this 
provides a blockade to some potential treatments, which require this understanding in 
order to move forward. Questions about some mechanisms of AD also have slowed 
development of some therapies because although the understanding of AD has grown 
exponentially in the recent decade, there are still some mysteries. Still, this large, all-
encompassing area of disease-modifying treatments is extremely promising, and will 
prove to be at the forefront of Alzheimer's research for a long time. Particularly, this will 
happen if steps are taken in order to develop means of detecting AD early in those who 
may be at risk. 
 The notion of a disease-modifying approach to AD goes hand in hand with the 
idea of detecting Alzheimer's early. As discussed in Chapters 8-9, the current standards of 
care are not sufficient even without reliable early detection techniques. For those 
determined to be significantly at risk for Alzheimer's or those in the early stages of AD, 
the current symptomatic treatments would still not be enough to prevent these patients 
from proceeding into the later stages of AD. Thus, developing disease-modifying 
techniques for Alzheimer's treatment is just as critical as developing a reliable means of 
detecting the disease early in patients. If a disease-modifying treatment was tested and 
found to be a great means of slowing or even stopping the progression of AD altogether, 
and combine it with early detection techniques available, then it would be possible to use 
these treatments in order to greatly slow or possibly prevent the disease in those who may 
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develop it thereby curing them of AD. This would be an outstanding breakthrough in 
Alzheimer's research. There are many different areas of study revolving around potential 
detection techniques as well as potential treatments, but as these two areas of research 
continue to move forward, the world moves closer to developing a reliable way to 
prevent and even cure Alzheimer's disease. 
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Chapter 11: Correlation with Other Diseases 
 Neurodegenerative disorders have crippled the society since the evolution of man. 
Alzheimer’s disease, as explained in the aforementioned chapters, has been a major 
culprit, especially causing dementia in older patients. As with all of the major disorders, 
Alzheimer’s disease (AD) has been related to several epidemic-like diseases around the 
world. Whether or not there is a perfect correlation between AD and these other disorders 
is uncertain; however research has developed models which may be able to explain the 
complicated yet severe relationship.  
 In the presented chapter, the relationship of AD with two main diseases is 
discussed: Type II Diabetes and Down’s syndrome. This includes briefly examining the 
origins, explaining the different types of similarities and differences, and finally 
providing possible evidence for detection and diagnoses. There are several other 
disorders related to AD, which will be mentioned briefly; however the main focus will 
remain on the two major diseases mentioned above.  
11.1 Type II Diabetes Mellitus 
 One of the diseases that is medically interrelated to AD is type II diabetes mellitus 
(T2DM). Mainly, caused by insulin resistance due to hypercortisolaemia, type II diabetes 
has been around for ages. High dietary saturated fat and high cholesterol levels cause 
T2DM. Furthermore, it can also be genetic or be induced by low levels of physical and 
social activities. However, it has been determined that the above factors can also induce 
AD as well. It has been shown that exercise and physical activity not only are associated 
with cholesterol levels, but are also associated with cognitive impairment and function.66 
Both of the diseases are rapidly becoming an epidemic and have created several problems 
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for society. Usually occurring in adults, these diseases are very well known to the 
common public and extensive research has been done to try to find a cure for them.  
  There are several perspectives that can relate T2DM to AD, one of them being 
from an evolutionary standpoint. Natural selection states that the genes from the most 
favorable species will be transferred to their offspring. Therefore, the genetic contribution 
of the population would also include genes from T2DM and AD patients. Since both of 
the diseases are known to be partly genetic, they can be reproduced due to the post-
reproductive ideal, which disregards natural selection. Furthermore, technological 
advancements have greatly reduced the need for physical activity for humans and 
therefore have affected the prevalence of T2DM and AD in older patients.66 Due to the 
lack of physical activity; this has greatly affected cognitive function.  
  Moreover, it can also be concluded that since society is based on a fragile 
physical state, T2DM has been more prevalent in the recent years. There also stands a 
direct correlation between the physical systems and the mental and neural systems of the 
body. Therefore, because of the repressed neural function, AD has become a major 
negative factor in the lives of millions of adults. The neuropathological aspects of AD 
have been discovered in patients with T2DM, and these aspects display a disruption in 
insulin production and consequently results in chronic intermittent hyperglycemia.66 
Conclusively, these two diseases have been connected through generations due to the fact 
that there exists an evolutionary relationship between the insulin levels in the brain and 
the skeletal and muscular systems. However, the evolutionary evidence simply scratches 
the surface of the relationship because AD and T2DM are indeed connected on a genetic 
and physical level as well. As a result, the parallel evolution of the two diseases can 
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further be explained. 
  Although at first glance it may not seem that there is much correlation between 
AD and T2DM, physical commonalities and genetic mechanisms disprove the thought. 
AD and T2DM have similar risk factors that allow them to be categorized. Some of the 
factors are outlined in Table 12 below.  
Table 12: Table Outlining Several Risk Factors for AD and T2DM17 
 
  As it can be noted, several of the risk factors are similar in both AD and T2DM. 
For example, both of the disorders have familial hereditary risk factors and are caused by 
high dietary saturated fat and high cholesterol. Additionally, lack of physical activity and 
negative mental factors such as depression and dementia can contribute to the two 
diseases. Depression is a major risk factor since T2DM patients have anxiety, which in 
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turn increases the body mass index. As noted, depression occurs in 20-40% of AD 
patients, which is a very high ratio in the patients.17 Since depression paves a pathway to 
T2DM, it can also be deduced that diabetes is very prevalent in AD patients as well. The 
table above clearly describes the similarities very efficiently as major factors of each of 
the categories are covered. 
  T2DM has several complications, which are affected by neurodegenerative 
symptoms that in turn worsen the degeneration in AD. The hypothalamus controls the 
glucose and the insulin levels in the brain. If there is neuron damage in the brain, the 
levels fluctuate, causing diabetic symptoms.17 Thus, diabetic symptoms occur as a result 
of damage in the brain and it becomes almost a cycle to which the patient adheres.  
  There are several commonalities, which have also been found in T2DM and AD 
patients. One of the similarities is the mechanisms of degradation and allowance of Aβ 
and amylin. These fibrils are degraded by insulin-degrading enzyme (IDE) and amylin is 
a substrate of the enzyme.67 Therefore, the degradation of Aβ causes AD and mutations in 
IDE lead to T2DM. Also, the production level of amylin also increases leading to 
apoptotic cell death. This in turn leads to AD since the cells in the brain have been 
destroyed. Conclusively, since the two metabolic factors are related to both AD and 
T2DM, mutations can lead to one or both disease in severe cases.  
  Besides the enzymatic mutations, there are other factors which can be comparable 
to AD and T2DM. As mentioned above, hypertension and obesity are risky factors for 
dementia. Recent studies show that genetically the relationship between AD and 
abnormal insulin metabolism can be greatly affected by APOE genotype.67 If the patient 
has the APOE allele, diabetes increases the risk of AD in the patient. The reason being is 
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that insulin resistance causes an increase in the risk of AD due to it being triggered by a 
low level of glucose breakdown in the brain. Consequently, it results in T2DM and 
causes sporadic AD.67  
  While AD and T2DM are widespread throughout the world, there have been 
several treatment strategies proposed which halt the occurrence or treat the disease. These 
strategies are common to both diseases and predominantly consist of insulin 
manipulation. Since human evaluation cannot be replicated in a laboratory settings, these 
studies are conducted on mice with AD and T2DM. This is done because the genome of 
the mouse is closely related to the human genome. Most recently, it was shown that 
intrahippocampal injection of insulin has a minor dose-dependent effect on the memory 
and cognitive function of rodents.17 The dose-dependent effect proves that insulin may 
play a role in AD patients and may be a major breakthrough in the treatment. The 
drawback of using insulin, as a treatment is that insulin, when administered into blood 
may cause hyperglycemia. One possible way to overcome this problem is to somewhat 
bypass the blood-brain barrier and the circulatory system altogether. For instance, 
intranasal injection of insulin goes directly into the brain and the patient has a much 
lower risk of high levels of insulin in the blood.17 This treatment may also be faster and 
more reliable in terms of safety; however further testing may be necessary in order to 
ensure no life-threatening complications can occur. Another way is treatment with 
insulin-sensitizing drugs such as thiazolidinedione (TZDs). 
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Figure 6: Pathway to show TZD Mechanism68 
 
  Figure 6 demonstrates how TZDs work in the human body. TZDs function as a 
specific “agnostics of the peroxisome proliferator-activated receptor (PPAR).”17 PPAR 
are transcription factors and their diagnostics may prevent neurodegenerative disorders. 
In the above figure, TZD allows for direct activation of the PPAR in the liver and the 
muscle, which improves the insulin sensitivity. If there was a higher sensitivity in the 
body to insulin, the levels may be regulated more efficiently and thus preventing AD and 
T2DM. Since insulin is a major factor in the treatment of such disorders, biomarkers 
allow for regulations within the body in order to prevent the diseases from occurring in 
the first place.  
  For future treatments, attempting to improve metabolic regulation may be the best 
option. Additionally, identifying deregulated genes and proteins can provide a pathway to 
prevent AD and T2DM from occurring. In order to reach a conclusive treatment strategy, 
it may be beneficial to consider the different physical, mental, environmental, and 
metabolic risk factors. By preventing people from partaking in debilitating activities that 
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are harmful to their physical being, it may be possible to slow down AD and T2DM. 
However, since the identification and the complete prevention from the risk factors is 
very tedious, AD and T2DM continue to be very dangerous, epidemic-like diseases. It 
seems that the two diseases have continued to elude treatment and perfect detection.  
11.2 Down’s Syndrome 
  For a long time T2DM seemed irrelevant to AD in terms of medicinal diagnostics, 
another neurodegenerative disorder that correlates to AD is Trisomy 21, commonly 
known as Down’s syndrome (DS).  
     
 
Figure 7: Trisomy 21 or Down’s Syndrome69 
 
  Down’s syndrome is the most prevalent disorder related to mental retardation in 
the United States. Figure 7 displays the extra chromosome at number 21, which causes 
dementia and mental retardation. Both of the diseases amplify with aging in the human 
population and are caused by familial and genetic malfunctions in the brain. For the most 
part, genetic diseases are caused by chromosomal abnormalities or aneuploidies. These 
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genetic deficiencies are unable to exactly determine the location of the gene, and AD and 
Down’s syndrome show parallelism to each other.  
  Chromosome 21 is the major cause of DS; and studies have shown AD causing 
genes on it as well. Therefore, there are similar characteristics between each of the 
disorders, the main one being neurodegeneration. Studies have recently been able to 
determine the similarities between the two diseases. The similarities arise from genetic, 
pathological, and chromosomal aneuploidy tendencies of AD and DS.  
  In terms of genetic similarities, the main component related to the senile plaques 
is β-amyloid.16 The accumulation of the protein causes the faulty programming of the 
brain. Similarities in brain autopsies of DS patients to AD patients imply that the two 
diseases are pathologically related. Statistical evidence comparing a control group and a 
DS group shows that DS is more prevalent among AD patients.16 Furthermore, it can also 
be deduced that mothers with DS have a higher chance of passing AD to their offspring 
which suggests that AD and DS are genetically passed together from the mother to 
offspring. The risk increases with age as the severity of DS increases in older patients. 
The risk is similar to that of AD, which only occurs in older patients. Another clinical 
study has shown that fingerprints of AD and DS patients are very similar in terms of 
creases and loops on the fingertips. This suggests that even something small as 
dermatoglyphic similarity can provide information towards the relationship between AD 
and DS.16 
  Chromosomal aneuploidy is another aspect in which AD and DS can be found to 
coexist. Studies showed that DS patients who have survived beyond 40 years of age have 
brain pathology almost the same as AD patients.70 The brain cells are more prone to 
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apoptosis, which causes neurodegeneration. One clinical study shows that if a mother 
with DS has a higher chance of passing AD to her offspring then mothers with DS can 
give birth to children that are at a higher risk of AD. This suggests that AD degeneration 
causes the offspring to have DS since the genes are related and due to an extra 
chromosome. The aneuploidy is also caused by defects in meiosis in AD patients that 
leads to DS. This leads to the trisomy mosaicism model that explains that the genes are 
randomly distributed due to mutations. 
 
 
Figure 8: Trisomy 21 Mosaicism Model71 
 
  The above figure is a clear representation of the model where random X-
chromosome inactivation is passed to all of the cells, which ultimately results in a 
mosaic-like shape. These defects lead to a lack of chromosome segregation and 
consequently to trisomy 21 and cell apoptosis in AD patients. The trisomy 21 causes DS 
and occurs as a result of the defect in AD patients as well. The most evident example of 
the defects in AD has been observed in the metaphase where the chromosome pattern is 
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similar to spontaneous centromere division that makes cells more susceptible to cell 
mosaicism.70 The above mentioned structure is able to disrupt the proper formation of 
genetic code in AD patients, resulting in the patient having DS, which is in turn passed on 
to the offspring. AD and DS seem to be interrelated and can have a cause-effect 
relationship with each other. 
  Besides aneuploidy, another major factor which supports the similarities between 
AD and DS is the oxidative stress (OS) in the pathogenesis. As evidence supports, DS 
patients with dementia have AD present in 75% of the cases with age above 60 years.72 
This statistic shows that there may be a common pathway between the two diseases. One 
hypothesis that explains the phenomena is the “two-hit” hypothesis, which states that 
either OS or disruptions in mitosis can initiate AD-like symptoms but both are needed for 
the prevalence of AD.70 Although AD can be caused by several other factors, OS and 
mitosis failure increases the risk of both AD and DS. This relates to DS as it causes 
neurodegeneration and as previously noted they have similar pathological characteristics. 
OS is known as the misbalance between the generation and expulsion of OS that can lead 
to lack of free radicals in the brain, ultimately causing AD and DS. The genetic and the 
OS pathway have become the major cornerstones in determining the relationship between 
AD and DS due to their mutations and lack of mechanisms which allow for proper 
function of the brain. 
  There are proposed solutions to ameliorate the risk factors and the mutations and 
these treatments have become a major factor in the control of AD and DS. In terms of 
early detection and diagnostics, since AD and DS have similar properties and 
characteristics, it may be easier to diagnose AD or DS with the aid of certain tests.70 The 
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diagnostic tests can also contain chromosomal analysis to determine the severity of 
trisomy 21 in a patient and then use the same results in determining either of the diseases. 
In terms of finding a cure of AD and DS, drugs which are able to prevent disruptions or 
problems in mitosis could stop the defect. Furthermore, it may be possible to stop the 
mosaic-like chromosomal segregation by eliminating the environmental toxins. Since 
these toxins cause cell apoptosis, drugs could be developed to prevent the toxins from 
causing damage. A more implausible approach might be to remove the extra chromosome 
21 from the body with the use of gene regulation.70 Although the idea for these 
techniques are far from being introduced to the general public, they are still possible. 
Perhaps in the future, it may pave way to a cure for Alzheimer’s disease, Down’s 
syndrome, and other neurodegenerative disorders.  
  In summary, it may seem that several diseases are unrelated to each other; 
however, genetic and pathological similarities may prove otherwise. While only T2DS 
and DS were discussed, there are several other types of diseases related to Alzheimer’s 
such as dementia, Parkinson’s disease, and other metabolic disorders. Each of the 
diseases is specifically related to AD whether in terms of genetic pathways or 
regeneration failures. T2DM and DS are very prevalent in AD patients and because they 
share similar characteristics, it also allows for a possible future cure for all of the 
disorders. By having parallel pathways, the disorders can be detected with the use of 
many more techniques and one cure might be the answer to all. Finally, 
neurodegeneration and physical degeneration have survived due to genetic misregulation, 
and the above-mentioned disorders will continue to elude medicine and society until a 
cure is discovered. 
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Chapter 12: Socioeconomic Impact of Alzheimer’s Disease 
  Society has been crippled by neurodegenerative disorders such as Alzheimer’s 
disease for ages. Whether it is socially or economically, AD has been a major part of the 
lives of millions of people around the world causing damaging results in everyday life. 
Several of the factors not only affect the patient, but also the family and the people 
around the patient. There have been advancements, which allow them to become more 
social and improve their cognitive function. The improvement in the cognitive function 
also enhances the economic impact and the cost-effectiveness of early detection 
increases. Many economic factors also weigh into the lives of AD patients and there must 
be several steps that need to be considered in order to prevent the patients from living a 
life of solitude and disappointment.  
12.1 Social Impacts 
  Several of the impacts that AD patients suffer through also prevent them from 
associating with the society. One of the major aspects of the disease is the caretakers and 
the family members of the patients. Since AD is a neurological disorder, it prevents the 
patients from being able to perform daily tasks needed for survival such as eating and 
getting dressed. Furthermore, they are also unable to recall everything and need a 
caretaker by their side at all times. Many of the patients are forced to live in community 
homes and face the problem of effective housing and care by volunteers or caretakers. 
Studies have shown that group homes are able to provide better care and quality of life 
for patients than special care units assembled by medical authorities. Many times the 
families are “unable to provide the necessary care” 73 and are compelled to place the 
patients under professional care. The reason for the inability of care could be economical, 
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emotional, or social. 
  Aging also plays a factor in neurodegenerative disorders since adults are more 
difficult to take care of as compared to taking care of children and are thus placed under 
special care. The quality of life of the patients is also decreased due to “insufficient staff, 
lack of money and financing, disabilities, lack of communication skills and accessibility 
issues.” 73 This prevents them from living what everyone would consider the “normal” 
life. Furthermore, the issues are also very serious since Alzheimer’s requires a great sum 
of money for care and detection. 
Table 13: Demographic Distribution of Caregivers for AD Patients74 
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  There are also statistical studies done which provide an idea of the demographics 
of the caregivers. As it is noted, most of the caregivers are women and are part of the 
family. Psychologically, according the studies, women are more caring and are able to 
provide better care therefore being easier for the patient to live with the caregiver. 
Additionally, the caregivers are usually 60 years old and are retired. It is reasonable to 
conclude that they devote their entire time to the care of the AD patients.  The 
aforementioned study deduced that most of the caregivers are able to aid in the 
improvement of the quality of life of the patient due to their relationship and background 
in relation to the patient.  
  In terms of patients, most of them are in their late 70s and are female. AD also is 
more prevalent in people of Caucasian race than any other races around the world.  
 
 
Figure 9: Risk of AD in Males vs. Females75 
 
  Figure 9 explains the prevalence of AD in males versus females and it proves that 
females are at a higher risk of getting AD than males. Therefore, female caretakers are 
able to relate well to patients and communicate better because they are the same gender.  
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  Socially, the staffs of the homes are hired to devote all of their time and effort in 
order to provide the best quality of life for AD patients, or any other dementia patient for 
that matter. Moreover, the patients also need to live away from their own families and 
connect with the patients on a deeper level in order to prevent them from feeling as if 
they were living in “solitary confinement.”  
  On a personal level, the patients are unable to communicate with anyone 
including the family members. This ultimately has a devastating effect on the morale of 
both parties. Due to their disorders and symptoms, AD patients are also unable to 
participate in everyday activities, which forces them to deviate from the norm of the 
society and become an outcast. As harsh as that may be, it is the reality and unless a cure 
is found, the patients will continue to live a life that cannot be replicated under normal 
conditions.  
  Any form of dementia, especially AD, is a life altering condition and early 
detection can aid in the eventual restoration of the lives of the patients. Even though there 
may not be any short-term benefits for the early detection and diagnosis, there are several 
positive long-term benefits.76 As the patient and the family are informed of the early 
diagnosis, they are shocked and overcome with grief. However, overtime they are able to 
cope with the condition and accept their respective roles in the treatment and the care for 
the patient.  
  The disease progresses severely with age and there are several factors, which 
contribute to early detection, especially the techniques used, which were discussed in the 
previous chapters.
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Figure 10: Timeline of the Progression of AD76 
 
  The above figure taken from the World Alzheimer’s Report from 2011 outlines 
the timeline of the progress of AD from the onset to ‘late-stage’ diagnosis. As it is noted, 
the earliest possible diagnosis can only occur when a reliable biomarker is developed and 
it can be determined only after the primary onset of AD. Furthermore, the technology that 
is available presently is only able to detect AD after cognitive decline and the patient 
slowly starts to lose function.  
  Early detection holds a high importance in the lives of AD patients. Preparing for 
early detection can be attained through educational programs in primary care and the 
introduction of care services into the society.76 Diagnosing the condition earlier can allow 
the patient to receive proper and better care and treatment. Additionally, the family and 
friends are able to cope with it much easily and allow their loved ones to live the best 
quality of life possible for them.  Early diagnosis also benefits people with AD and their 
caregivers in terms of symptomatic decline and quality of life.76 Through early detection 
the patient goes through slower cognitive decline and has a better quality of life and 
improved social abilities. As a result, the caregivers also have a better quality of life and 
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have reduced strain on their physical and mental state. This ultimately leads to reduced 
economic and social impact on healthcare and society. With the knowledge of the 
diagnosis, the family and the healthcare industry are able to better arm themselves with 
the tools necessary for a more effective and beneficial future. The patient and the family 
are also able to “think about safety and security issues, including living arrangements, 
driving, cooking, and managing medication” .76 The basic needs can be more easily taken 
care of and the patient is able to better manage his/her life with the help of the family. 
  There are other social impacts of AD as well, including the media. In the pop 
culture media, there have been several movies about future AD cures and treating the 
disorder such as Rise of the Planet of the Apes. The movie sought to find a cure for AD 
and improve cognitive function exponentially and has been affected by the idea and 
principles of the disease. The pop culture media alters the mindset of the society and still 
is able to accurately display that there is not a certain cure for Alzheimer’s presently.  
  Overall, Alzheimer’s has a major impact on the social life of the patient and the 
family. The disruption of daily life and withdrawal from social activities compels the 
patient to live a life of confinement within his/her own life. In addition, there are several 
economic impacts of AD, which have been detrimental to the society as well. 
12.2 Economic Impacts 
  Besides having social impacts, AD also causes severe economic impacts. There 
are several costs associated with AD patients including care costs, treatment costs, and 
cost of research. AD has become one of the most expensive and deadliest disorders to 
deal with in the world. Furthermore, as AD becomes increasingly prevalent throughout 
the world, the price associated with it increases. Most of the cost is associated with the 
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treatment and the research; however, care and living expenses also cost a fortune and 
compel the patient to live a life of misery. 
  AD has caused a great economic imbalance in the society due to the high-
maintenance care and lack of answers to problems relating to the disease. Most of the 
time, the patients’ health and condition do not allow them to live at home with their 
families, and they are compelled to live in costly care centers, nursing homes, and 
assisted living homes. For example, the average cost of services at an assisted living 
facility is approximately $53,220 per year. The cost is even higher at a nursing home, 
being about $75,920 per year.75 It can be concluded that the cost is even higher than the 
average person’s salary within the United States, which becomes very problematic for the 
patient as most of the time they are unable to afford such expensive care and are forced to 
live in subpar conditions. Additionally, the cost becomes a great burden very quickly as 
the lack of cure causes a dent in the economic conditions of the society.  
  There are several direct and indirect costs for AD as well. Direct costs are the 
resources used by the patient and the indirect costs are the care and the research abilities. 
The following figure illustrates the division of the costs of AD in 2004: 
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Figure 11: Cost Comparison of the Direct and Indirect Care of AD74 
 
  As noted, most of the cost is associated with providing care for the patients and 
the salaries of the caregivers. Additionally, the other majority of the cost goes towards the 
hospitalization of the patient. This becomes very important as the lack of resources in the 
hospitals increase the cost of hospital care. Since most of the patients are put into care 
homes afterwards, they have to incur those costs as well. The money for the care mostly 
comes from the family of the patient. However, Medicare and health insurance and other 
governmental allocations also aid them in the process. It is shown that AD uses up about 
$3 billion in costs every year for the US, including care and research.75 This number is 
higher than any other major cause of death in the US including cancer, coronary heart 
disease, and diabetes. It proves that dementia has become an enormous problem for the 
US in terms of costs and research and action needs to be taken as soon as possible.  
  Even though AD has a generalized cost, there are certain factors that fluctuate the 
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cost of AD. One such factor is early detection in terms of the time period when the 
patient is diagnosed with a neurodegenerative condition such as AD.  
 
 
Figure 12: Cost vs. AD Severity in Early Detection74 
 
  The above graph depicts the cost-effectiveness of AD in response to the time 
period of the diagnosis. In the very early stages, the symptoms are just arising and the 
cost is about $27,500. This is lower than the higher pervasiveness of the symptoms in the 
later stages of the diagnosis, which is about $35,000. Similarly, the daily activities and 
the physical functioning also have a similar trend. In such aspects, when the patient is 
diagnosed early, the cost is about $20,000 as opposed to when the patient is diagnosed 
very late in the disease, which is about $ 36,000 on average. Therefore, it can be 
concluded that early detection of Alzheimer’s becomes very beneficial financially for the 
patient, as there is almost a $10,000 difference within early and late diagnoses. 
Furthermore, the high cost of late detection also provides an incentive for providing 
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future techniques that can detect the disorder in its earliest stages so as to provide the 
patient with enough time and financial support to be able to live life to the fullest.   
  Alzheimer’s disease has plagued the world in societal and economical aspects. As 
the disease progresses in a certain patient, the cost of treatment and accommodations also 
increases. Social and economic reasons have always been intertwined with each other 
since each of the factors affects the other greatly. For example, familial and local support 
is necessary in order to cover the expenses of diagnosing and properly treating the 
condition. Early detection techniques in the present have aided several patients into 
achieving somewhat of a promising future socially and financially. This not only applies 
to patients and their families a micro scale but also to the government and the nation on a 
macro scale. The disorder requires a certain percentage of the whole economy of a nation 
and that is very demanding. As a result, the future of early treatment needs to succeed in 
creating detection techniques that will be able to diagnose the disorder as early as 
possible, which would relieve social detriments and isolation and mitigating financial 
distresses.  
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Chapter 13: Future Prevention 
  AD is one of the most prevalent dementias in the world today. As is the case with 
every disease and disorder, medicine and science have been trying to find a cure to either 
prevent the onset or detect it early enough to stop it from occurring in a patient. There are 
several initiatives, which are being taken to develop a pathway for accelerated AD 
treatment using the best combinations. Several of the techniques have already been 
mentioned before using specific genetic relationships, and in the past there have been 
early basic remedies as well. Furthermore, presently there are also several techniques to 
early detection and prevention of AD that have been described. However, the future 
needs to be promising since there is no cure or a foolproof prevention technique that has 
been developed to prevent AD. There are environmental factors and ideas that may 
prevent AD to an extent, but medically there is not enough evidence to support a certain 
cure. Two of the several organizations are also examining the AD symptoms and trying 
to determine the most promising treatments in order to control AD. These are 
Alzheimer’s Disease Neuroimaging Initiative (ADNI) following the Alzheimer’s 
Prevention Initiative (API). Lastly, research needs to be done in order to improve certain 
techniques and to increase the success rate of detecting and treating AD onset. Currently, 
there are measurements being taken; however, AD has become somewhat of an epidemic 
for which medicinal science needs to find better detection and ultimately, prevention 
techniques.  
13.1 Therapeutic Techniques and Biomarkers 
 There have been several approaches taken by hospitals in order to properly diagnose 
and figure out therapeutic methods by using biomarkers, to attempt in finding diagnostic 
136	  	  
criteria, and to care for AD patients. As proposed, AD is a major cause of dementia in 
people of ages over 60 and is more expensive in terms of care than cancer or any other 
cardiovascular disease. 77 Therefore it is imperative to find a way to control and detect 
AD in patients to avoid further delays. Presently, most of the research has focused on 
biomarkers and their effect on AD during the early onset. The biomarkers should be able 
to aid in the diagnosis and treatment of AD and allow the patient to be monitored.77 Even 
though this may seem effective; there are complications such as Aβ positive patients, 
which may provide faulty results. Therefore, further research needs to be performed on 
biochemical pathways and AD pathology, which will aid and amplify the effect of 
detection techniques in AD. Additionally, more research towards the environmental 
factors and neuroimaging could aid in the detection and prevention process as well. As a 
result, more patients will be able to adapt to a certain plan that can aid them with AD 
within the next 10 years.  
  There are other techniques that could be amplified or altered to attain better 
results in prevention of AD. One of the current therapies is the use of cholinesterase 
inhibitors. The bodies of AD patients are found to be lacking acetylcholine (Ach) due to 
reduced choline intake. Additionally, by increasing the cholinergic balance due to the 
inhibition of Ach breakdown would slow the progression of AD and ameliorate the 
symptoms.78 The cholinesterase inhibitor drug was used in AD therapy, however there 
was a very short follow up period. For that reason, patients were unable to attain long-
term effects for the drug even though the drug did alleviate AD symptoms. Another type 
of therapy is the anti-amyloid therapy, which states that AD can be prevented by 
decreasing the production of Aβ and preventing Aβ from forming into amyloid plaques.78 
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Aβ is the major cause of AD in patients and if there are techniques that are able to halt 
the overproduction of Aβ, AD can be prevented. Additionally, decreasing Aβ generation 
can aid in the understanding of the disease but that has yet to be achieved. In conclusion, 
there is research being conducted, however, there must be a “disease-modifying 
intervention [to] reduce AD.” 78 Specifically, in order to attain such a result, there must be 
a complete understanding of the disease and finally testing of new drugs to prevent the 
disease from prevailing.  
13.2 Organizations for Cure 
 Besides the research being performed, there are several organizations that are aiming at 
curing AD, specifically, Alzheimer’s Disease Neuroimaging Initiative (ADNI) following 
the Alzheimer’s Prevention Initiative (API). The API examines the most promising pre-
symptomatic AD treatments and drugs and aids in the production of a mechanism for 
their use into the public market. On the other hand, ADNI is a study “aiming to elucidate 
biomarker trajectories in AD.”79 ADNI seeks to find a cure in terms of biomarkers and 
their effectiveness in curing AD. ADNI has been able to and is trying to improve the 
early detection techniques for the future including, “Structural MRI, FDG-PET, amyloid 
PET, LPs, genetic analysis, and blood studies.”79 The aforementioned techniques are the 
most common AD detection methods that in the future will be able to diagnose AD more 
accurately. As a result, if AD is detected very early, the drugs in the future may be able to 
prevent the onset altogether and successfully find a way to end the epidemic.  
  As a result, the future holds a hazy view of the cure for AD due to uncertainties in 
the detection techniques and the lack of firm understanding of the disease itself. As 
mentioned, the techniques and the drugs in process today are effective; however they 
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need to be improved in order to completely undermine the effectiveness of AD. Other 
organizations and laboratories besides ADNI are also working on better detection 
techniques so that maybe someday in the future AD can be diagnosed in the infant as 
opposed to in an adult. This would require genetic analysis and manipulation in order to 
diagnose the disease that early in life, if at all possible. Furthermore, the third-world 
countries need the most care due to lack of hospital and medicinal training, and since AD 
is found worldwide, it is taking a higher toll on those nations. In conclusion, the level of 
detection and prevention of AD needs to be raised in the future in order to successfully 
combat and possibly defeat Alzheimer’s disease and its unpleasant effect on the society. 
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Conclusion 
There are two types of AD, familial and sporadic, which differ depending on 
the onset of the disease and whether there is an involvement of gene mutations. Gene 
mutations are more involved in familial AD while the possible risk factors are more 
associated with sporadic AD. The characteristics as well as the pathological mechanisms 
of the disease occur in the same way in both types of AD. What happens in AD is that the 
increased expression and production of APP and Aβ42 results in high accumulation of 
senile plaques that can interfere with synapses, leading to destructive inflammatory 
processes and the activation of apoptosis. The deterioration of the microtubules leads to 
the production of free cytosolic tau proteins that aggregate together to form the 
neurofibrillary tangles. The presence of the tangles in the cytoplasm as well as the 
absence of microtubules prevents the trafficking and transportation of proteins and 
nutrients, which are necessary for the neurons to survive. 
Along with the presence of high concentration of amyloid plaques around the 
neurons and neurofibrillary tangles in the neurons, the cells also exhibit another newly 
characteristic of AD: disruption of the calcium homeostasis. The high concentration of 
intracellular calcium levels causes overfilling of the ER and the mitochondria resulting in 
the deterioration of the mitochondria. The content of the mitochondria such as caspases, 
cytochrome c oxidase, and apoptosis-inducing factors are released into the cytoplasm 
where they cleave many of the proteins in the cell, leading to apoptosis of the neuron. 
The entire process along with plaque and tangle formation and disruption of calcium 
homeostasis causes an increase in production of ROSs, which results in higher oxidative 
stress and further promotion of neurodegeneration. The region of the brain that is most 
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affected by the neurodegeneration and ultimately by AD are the regions that functions in 
learning and memory formation particularly the hippocampus, frontal and temporal lobes. 
However, in order to effectively gain an understanding of AD, researchers have 
developed biomarkers to learn about the neurodegeneration. 
Several neurochemical and MRI-based markers are currently being analyzed in 
order to determine their sensitivity and specificity. Moreover, these biomarkers are being 
studied in order to elevate our understanding of the pathology of Alzheimer’s disease. 
The combination of CSF tau and amyloid beta proteins would be an accurate diagnostic 
tool. In CSF, haptoglobin has been reported to show a consistent increase as well. 
Furthermore, oxidative stress markers 3-nitrotyrosine, DNA oxidation product 8-
hydroxyl-2’-deoxyguanosine, and isoprostanes have increased concentrations in CSF. In 
serum, 24S-hydroxycholesterol and GFAP antibody concentrations are the most 
promising markers to date in screening a large group as 24S-hydroxycholesterol has been 
shown to be an early marker and GFAP autoantibodies as late markers. The α-ACT 
concentration in serum is currently the most convincing inflammation marker, whereas 
haptoglobin and IL-6 need to be further investigated. In addition, oxidative stress markers 
such as vitamin A, C, and E need further investigation because dietary supplementation is 
a variable factor. Homocysteine must be combined with other sets of markers because 
although it is not specific to brain-related processes, it has high levels of concentration in 
both AD and normal cognitive aging patients. 
As for neuroimaging markers, hippocampal volumetry is the best established 
structural biomarker for AD. However, since it is laborious, it is only used for clinical 
studies and as an end point for treatment effects. VBM, DBM, and measurement of 
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cortical thickness are currently being investigated as well. PET is the gold standard in in 
vivo diagnosis and gives a better distinction between controls and AD. Furthermore, a 
combination of FDG-PET and PIB-PET shows improvement in the diagnostic 
discrimination between MCI and AD and between MCI and control. Other markers such 
as SPECT, entorhinal cortex volumes, and functional magnetic resonance imaging need 
to be further developed for accuracy in the early diagnosis of AD. Even though there are 
techniques present for detecting the symptoms, they are not enough to prevent the onset 
completely. 
Although the state of current Alzheimer’s medicine is important in treating 
some cognitive function, it is not sufficient for those patients suffering from AD. These 
current treatments, acetylcholinesterase inhibitors and memantine, do not actually modify 
the disease, so they cannot prevent or completely stop the process of AD onset in the 
patients. Research is now focused towards finding a disease-modifying treatment, and 
there is much hope in this field of study. Much of the press and priority has been given to 
Aβ modulating and alteration as a means of therapy, both of which prevent Aβ formation 
and aggregation. However, lesser-known research that is emerging is just as important to 
learn about and understand Alzheimer’s therapy. 
Newer areas of research are interesting, important, and hopeful. As researchers 
learn more about the nature of AD and Aβ aggregation, they can begin to develop more 
reliable treatments and therapies for AD patients. Treatments to inhibit the action of trace 
metals are growing, and this field of study is extremely promising. Therapies devoted to 
immunotherapy are being explored as well, where vaccines are used to defend against 
toxic Aβ. There are even more fields of investigations devoted to searching for an AD 
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therapy on other known aspects of the disease, such as APOE and tau. However, there are 
still some issues with these newer fields of research. Many of the mechanisms involved 
with these parts of the disease are not fully understood, and although many upcoming 
treatments in development can be labeled as “hopeful” it is very rare that any of them 
advance deep into clinical trials. This is due to issues with treatment in humans, such as 
the blood brain barrier. With such a broad field of research and with so many possible 
treatments that could be explored, this is an area of study that can be very overwhelming. 
Yet it is a very important topic to look into and try to paint a broad picture of, as many of 
these treatments have great potential for the future of AD therapy. One of the major 
factors in determining treatments for AD is the relationship of the disease to other 
disorders.  
As the paper displays, there are several factors associated with Alzheimer’s 
disease. The relationship between Alzheimer’s and other diseases provides a more urgent 
need for a solution. The similarities may make it easier to detect the disease, which 
provides a basis for future prevention techniques. Using genetic modifications and 
evolutionary explanations, early detection techniques can be developed to cure not only 
AD, but also other types of dementia and type II diabetes. There are several 
socioeconomic impacts of such a disorder, relating to the society and the economic health 
of the patient and their family. There are very harsh impacts on the patient due to the 
inability to socialize with the world, and the families are forced to live away from the 
affected patient and pay for their care. The large scale impact of the disease is that it has 
affected the economy in several ways, thereby becoming one of the most researched 
diseases on the planet. However, all of the money and the society’s efforts may go to 
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waste if there are no earlier prevention and diagnosis techniques developed. There are 
several ways to achieve this as mentioned earlier, both socially and medicinally. 
Nevertheless, the future research needs to be more extensive if the world is to find a cure 
someday. One may never know, the monetary and the societal efforts may provide a 
solution to curing the disorder. In the end, the harsh truth about Alzheimer’s is that it may 
erase the memory of a person, but it will not erase the true façade of the society; and the 
future of medicine will determine whether Alzheimer’s is or isn’t. 
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Glossary 
24S-hydroxycholesterol - oxysterol that is produced through enzymatic oxidation for the 
removal of cholesterol from the brain 
α-antichymotrypsin - glycoprotein that inhibits the activity of certain enzymes 
α-secretase - cleaving enzyme that cleaves the middle section of Aβ 
Amyloid Beta (Aβ) - a protein that aggregates together to form senile plaques which are 
considered to be one of the main causes of AD 
Acetylcholine - neurotransmitter in central nervous system (CNS) and peripheral nervous 
system (PNS) 
Acetylcholinesterase (AChE) - an enzyme which specifically breaks down acetylcholine 
Acute-phase protein - protein that increases or decreases its concentration in plasma in 
response to inflammation 
Amyloidogenic - ability of a protein to aggregate together  
Amyloid precursor protein (APP) -  transmembrane glycoprotein that extends the lipid 
bilayer of a cell and contains an Aβ section within the membrane 
APP intracellular doman (AICD) - transcription factor that regulates the production of 
ryanodine receptors and Ca2+ buffer calbindin; peptide that is located inside the cell 
when APP is cleaved by γ-secretase 
Apolipoprotein E (APOE) - susceptibility genes involved in synaptic repair in response 
to tissue injury as well as maintenance of neuron structutres and cholinergic function 
Aneuploidy - having a chromosome number that is not an exact multiple of the haploid 
counterpart 
Aneurysm - swelling of the artery walls 
Apoptotic - a cell that is genetically regulated to process for death 
Atrophy - decrease in size 
Automation protocol - uses control systems and information technology to reduce 
human work in the measurements of MRI methods 
Autouimmune - referring to a failure in the immune system whereupon the the immune 
system no longer recognizes the body’s own cells, and the body produces an immune 
response against one’s own cells or tissues 
β-site APP cleaving enzyme or β-secretase (BACE1) - cleaves the Aβ section that is 
located outside the cell; one of the key enzymes responsible for the pathology of amyloid 
cleavage of the amyloid precursor protein (APP) 
Biomarker - any detectable biological feature that provides information about its source 
Blood-brain barrier - a layer of endothelial cells which separate the circulating blood 
from the brain’s extracellular fluid. This barrier restricts diffusion of both small and large 
molecules into the cerebral spinal fluid 
Boundary shift integral (BSI) - tracks stuctural changes in the brain over time in order 
to monitor the progression of the disease 
C terminus - one end of a protein that contains the free carboxylic acid (-COOH) group  
Caspase - a type of protease that facilitaes apoptosis 
Central nervous system (CNS) -  the part of the nervous system that consists of the 
brain, the spinal cord, and the meninges 
Cerebral amyloid angiopathy - form of angiopathy in which amyloid deposits form in 
the walls of blood vessels of the CNS 
Cerebral infract - localized cell death 
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Chelator - a chemical compound which removes a heavy metal from the bloodstream or 
cells by combining with the metal compound to form a ring. Chelation is used medically 
to treat heavy metal poisoning by this process 
Cholinergic System - a system of nerve cells that uses the neurotransmitter acetylcholine 
to transmit signals 
Computed tomography (CT) - medical imaging method that uses tomography created 
by computer processing 
Cortex - the outer layer of the brain 
Cross-sectional study - a descriptive study that observes and provides data on an entire 
population that consists of different subgroups 
Dementia - an illness that affects an individual’s brain resulting in memory and 
behavioral issues 
ELISA assay - biochemistry assay that detects the presence of a substance 
Endoplasmic reticulum (ER) - a structure in the cell that functions to help control 
protein synthesis and cellular organization 
Epitope - the part of an antigen that is recognized by the immune system 
Excitotoxicity - a process by which nerve cells are damaged or destroyed by excessive 
stimulation by neurotransmitters; typically results due to overstimulated glutamate 
Flow cytometry - technique for counting and examining molecules 
Fluorescent ligand scanning (FLS) - noninvasive quantitative measurement 
Functional magnetic resonance imaging (fMRI) - measurement of brain activity during 
cognitive tasks at high resolution without radiation exposure 
γ-secretase - cleaving enzyme that cleaves the section of Aβ that is inside the plasma 
membrane 
Gel electrophoresis - method that seprates protein by charge or size 
Glial fibrillary acidic protein (GFAP) - intermediate filament cytoskeletal protein 
expressed mainly by astrocytes 
Glycoprotein - a protein that has a carbohydrate 
Glycosaminoglycan - complex sugar polymer that aggregates with Aβ42 to form senile 
plaques 
Golgi apparatus - a structure in the cell that functions to package cell products and 
coordinate their transport to the outside of the cell  
Gray matter - a component of the central nervous system that consists of neurons, 
dendrites, unmyelinated axons, and glial cells 
Haptoglobin (Hp) - iron transporting protein involved in the process of oxidative stress 
Hemorrhage - the loss of blood from the circulatory system, generally due to leaks from 
blood vessels in the body. Bleeding can occur internally or through orifaces 
Hippocampus - a region in the brain that functions in learning and memory storage 
Homocysteine - precursor in making methionine and cysteine 
Homozygocity - referring to identical alleles of a certain gene on both homologous 
chromosomes 
Hypercortisolemia - refers to a high amount of cortisol levels in the body. Cortisol is a 
steroid hormone secreted by the adrenal gland. 
Hypertension - elevation of diastolic blood pressure 
Hypothalamus - a region that lies between the thalamus and the midbrain and functions 
as the control center for the autonomous nervous system, also partakes in producing 
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hormones 
Intermittent hyperglycemia - a prediabetic condition in which an excess amount of 
blood sugar circulates in the body. 
Intrahippocampal  - within the hippocampus 
Kinase - an enzyme that activates other enzymes or proteins by attaching a phosphate 
group 
Lewy bodies - abnormal aggregates of protein that develop inside nerve cells 
Lipid bilayer - a layer that surrounds a cell that is composed of two layers of lipids, it is 
what the cell membrane is made of 
Longitudinal study - studies that can be repeated over long periods of time with the 
same variables 
Mild cognitive impairment (MCI) - transitional region between normal aging and 
Alzheimer’s disease 
Mitochondria - a structure in the cell that functions to produce energy 
Morphometry - volume of an object measured by drawing regions of interests on the 
image of the object and calculating the volume of the object from those regions of 
interests 
Neurodegenerative - relating to a progressive loss of neurological functions 
Neurons - the type of cells in the brain 
Neurotoxic - poisonous to neurons 
Nicotinic acetylcholine receptor (nAchr) - transmembrane protein that mediates rapid 
transduction to initiate memory development 
Nitrosamine - carcinogen that helps form cancerous cells 
N-metyl-D-aspartate (NMDA) - a subtype of a specific glutamate receptor in the brain 
which mediates influxes of synaptic calcium 
Notch-1 - cell receptor that gets cleaved by γ-secretase when activated by a ligand 
phosphorylate - to add phosphate groups to a molecule 
N terminus - one end of a protein that contains the free animo acid (-NH2) group  
Oxidative stress - a condition of increased oxidant production in animal cells 
characterized by the release of free radicals and resulting in cellular degeneration. 
Pathology - the study of the causes of diseases and how they affect people 
Peptides - polymers of linked amino acids joined together with peptide bonds, also 
known as a protein 
Peripheral nervous system (PNS) - the part of the nervous system that lyes outside of 
the brain, the spinal cord, and the meninges 
Plasma membrane - a membrane that surrounds a cell to allow for the movement of 
materials 
Platelet - irregularly shaped cell fragments 
Positron emission tomography (PET) - imaging method used to study cortical 
metabolism 
Post-mortem autopsy - a medical examination after death 
Presenilin - intramembran aspartly protease that is present on the membranes of multiple 
organelles including the endoplasmic reticulum, Golgi apparatus, and endosome; 
involved in multiple function including Notch signaling 
Presynaptic terminals - an area in between neurons where neurotransmitters are 
released 
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Protease - an enzyme that cleaves peptide bonds within a protein 
Quasi-elastic light scattering (QLS) - noninvasisve quantitative measurement 
Relaxation time - time it takes for the protons to emit their signal 
Single photon emission computed tomography (SPECT) - imaging measurement of 
cortical metabolism similar to PET 
Tau - soluble microtubule-binding protein that plays a major role in stabilizing 
microtubules in axons 
Temporal lobe - a region in the brain that functions in smell and hearing as well as 
memory and learning and where choice is made of thoughts to express  
Transaminase - removes the amino group from the amino acid leaving behind an α-keto 
acid and converting it into an amino acid  
Transgenic - an organism that contains foreign DNA from another organism which can 
be from different species  
Ubiquitin - small protein that acts as a signal for degradation 
Unfolded protein respone (UPR) - signaling pathways that initiates the proper folding 
of misfolded or unfolded proteins. 
Voxel - volumetric pixel representing a value in 3D space 
White matter - part of the central nervous system that consists mostly of glial cells and 
myelinated axons 	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Appendix A: The Different Cleavage Pathways of Amyloid Precursor Protein (APP) 
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Appendix B: Avoidance Tests Conducted on Rats with Anti-Aβ Antibodies (anti-Aβ) 
Before or After a Training for Short-Term and Long-Term 	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Appendix C: Memory Tests Conducted on Rats using Control Monoclonal Antibody 
(mAb), Scramble (sc) Peptide, Anti-Aβ Antibodies (anti-Aβ), and β-Amyloid42 (Aβ42) 
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Appendix D: The Proper Function of Tau Protein and the Process of Neurofibrillary 
Tangle Formation 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
157	  	  
Appendix E: The Process of Storing and Erasing Memories in Relation to Calcium 
Concentrations in Normal and AD Brains 
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Appendix F: Possible Risk Factors for Alzheimer’s Disease 
Possible Risk Factors Reasoning 
Down’s Syndrome Extra copy of chromosome 21 results in an 
increase production or mutation of APP 
leading to a higher concentration of Aβ16 
Type	  II	  Diabetes	  Mellitus	   Insulin	  resistance	  promotes	  increase	  secretion	  of	  Aβ	  and	  hyperphosphorylation	  of	  tau	  proteins	  as	  well	  as	  inhibiting	  Aβ	  degrade17	  
Stroke	   Lack	  of	  blood	  flow	  damages	  the	  brain18,25	  
History	  of	  Head	  Trauma	   Damages	  the	  brain	  with	  it	  being	  more	  serious	  when	  loss	  of	  consciousness	  accompanies	  the	  head	  injury20	  
Depression	   Causes	  neuronal	  death	  in	  regions	  of	  the	  brain	  like	  the	  hippocampus13	  	  
High	  Blood	  Pressure	   Decrease	  blood	  flow	  to	  the	  brain	  resulting	  in	  hypoxia	  injuries	  and	  later	  cognitive	  decline23,24,25	  	  
Dietary	  (high	  consumption	  of	  calories,	  
cholesterol,	  saturated	  fats,	  and	  red	  
meat	  as	  well	  as	  low	  consumption	  of	  
fruits	  and	  vegetables)	  
High	  levels	  of	  cholesterol,	  calories,	  and	  saturated	  fats	  contributes	  to	  heart	  disease	  like	  high	  blood	  pressure1,	  promotes	  the	  production	  of	  Aβ425,	  aid	  in	  insulin	  resistance1,	  and	  neuronal	  degeneration5;	  high	  levels	  of	  red	  meat	  increases	  the	  level	  of	  iron26;	  low	  levels	  of	  fruits	  and	  vegetables	  provide	  low	  levels	  of	  antioxidants1	  
Vitamins	  (low	  levels	  of	  vitamin	  B,	  A,	  C,	  
and	  E)	  
Low	  levels	  of	  vitamin	  B	  increases	  the	  level	  of	  homocysteine1,5;	  low	  levels	  of	  vitamin	  A,	  C	  and	  E	  gives	  low	  levels	  of	  antioxidants1	  	  
Metals	  (high	  levels	  of	  iron,	  copper,	  and	  
zinc)	  
High	  levels	  of	  iron,	  copper,	  and	  zinc	  leads	  to	  oxidative	  stress,	  production	  of	  reactive	  oxygen	  species	  and	  later	  neuronal	  death26,27	  
Sedentary	  Lifestyles	  	   Decreases	  neurogenesis,	  hippocampal	  synaptic	  plasticity,	  and	  long-­‐term	  potentiation28,29	  
Chronic	  Stress	   Increases	  the	  production	  of	  APP	  and	  apoptotic	  enzymes	  along	  with	  enhancing	  senile	  plaques	  accumulation	  and	  tau	  phosphorylation28	  
High	  Alcohol	  Consumption	   Promotes	  oxidative	  damage	  in	  the	  brain	  leading	  to	  brain	  atrophy	  and	  causes	  mitochondrial	  dysfunction	  and	  deterioration1	  
Low	  Education	  Levels	   	   Less	  network	  of	  synapses	  and	  inefficient	  use	  of	  neural	  networks	  as	  well	  as	  a	  less	  ability	  to	  recruit	  networks30	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Appendix G: Summary of concentration of pathological alterations markers in serum and 
CSF of AD patients 
 Marker AD vs. Normal 
CSF Aβ -­‐ (9) 
Aβ autoantibodies = (2) 
Tau + (14) 
Hyperphosphorylated tau + (1) 
Combination tau + (5) 
Combination tau with Aβ42/Aβ40 
ratio 
-­‐ (1) 
β-secretase (BACE1) + (1) 
GFAP protein + (4) 
GFAP autoantibodies + (2) 
Serum/plasma Aβ + (3) 
= (2) 
Aβ40 + (with age and initial stages)(2) 
Aβ42 + (with age and initial stages)(1) 
- (1) 
GFAP autoantibodies + (4) 
Aβ autoantibodies = (2) 
Platelet APP isoforms - (2)  
+: Increased levels observed in AD patients compared to controls 
=: No difference observed in levels of AD patients compared to controls 
-: Decreased levels observed in AD patients compared to controls 
#: Number of studies conducted 
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Appendix H: Summary of concentrations of cholesterol homeostasis markers in serum 
and CSF of AD patients 
 Marker AD vs. Normal 
CSF Apolipoprotein ε4 + (1) 
= (1) 
-­‐ (1) 
24S-hydroxycholesterol + (2) 
Serum/plasma Apolipoprotein ε4 = (3) 
-­‐ (2) 
24S-hydroxycholesterol + (1) 
-­‐ (2) 
Cholesterol + (4) 
= (1) 
-(2) 
Lp(a) + (1) 
=(1) 
Homocysteine + (6) 
= (1) 
+: Increased levels observed in AD patients compared to controls 
=: No difference observed in levels of AD patients compared to controls 
-: Decreased levels observed in AD patients compared to controls 
#: Number of studies conducted 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
161	  	  
Appendix I: Summary of concentrations of oxidative stress markers in serum and CSF of 
AD patients 
 
+: Increased levels observed in AD patients compared to controls 
=: No difference observed in levels of AD patients compared to controls 
-: Decreased levels observed in AD patients compared to controls 
#: Number of studies conducted 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  	  	  
 Marker AD vs. Normal 
CSF 8-hydroxy-2’-deoxguanosine + (1) 
F2-isoprostanes + (6) 
F4-isoprostanes + (1) 
3-nitrotyrosine + (3) 
8,12-isoprostane-F2α-VI + (1) 
Serum/plasma 
 
8,12-isoprostane-F2α-VI + (1) 
F2-isoprostanes = (3) 
4-hydroxynonenal = (1) 
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Appendix J: Summary of concentrations of vitamins in serum and CSF of AD patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
+: Increased levels observed in AD patients compared to controls 
=: No difference observed in levels of AD patients compared to controls 
-: Decreased levels observed in AD patients compared to controls 
#: Number of studies conducted 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
 Marker AD vs. Normal 
CSF Vitamin A = (1) 
Vitamin C = (1) 
Vitamin E - (1) 
= (1) 
Serum/plasma 
 
Vitamin B6 -­‐ (1) 
Vitamin B12 -­‐ (1) 
= (1) 
Folic acid -­‐ (2) 
Homocysteine -­‐ (1) 
Vitamin A -­‐ (3) 
Vitamin C -­‐ (4) 
= (1) 
Vitamin E -­‐ (6) 
= (1) 
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Appendix K: Summary of inflammatory proteins in serum and CSF of AD patients 
 Marker AD vs. Normal 
CSF IL-6 + (2) 
= (8) 
-­‐ (1) 
IL-6 receptor = (1) 
-­‐ (2) 
Glycoprotein 130 = (1) 
-­‐ (1) 
IL-1β + (2) 
= (6) 
IL-1β receptor II + (1) 
TNF-α + (1) 
= (3) 
TNF-α receptors = (3) 
α-ACT + (3) 
= (2) 
Haptoglobin = (1) 
Haptoglobin fragments + (2) 
Lithostathine + (1) 
Proteinase kallikrein + (1) 
Mannan-binding lectin -­‐ (1) 
Cleavage products of kininogen -  (1) 
Serum/plasma IL-6 + (5) 
= (4) 
IL-6 receptor -­‐ (1) 
IL-1β + (1) 
= (5) 
TNF-α + (3) 
= (4) 
-­‐ (1) 
α-ACT + (5) 
= (2) 
Haptoglobin = (2) 
Haptoglobin 2-1 + (1) 
= (4) 
Proteinase kallikrein + (1) 
Histamine + (1) 
Anti-glial fibrillary acidic protein + (1) 
Anti-nerve growth factor + (1) 
Anti-histone + (1) 
Anti-double stranded DNA + (1) 
Mannan-binding lectin = (1) 
+: Increased levels observed in AD patients compared to controls 
=: No difference observed in levels of AD patients compared to controls 
-: Decreased levels observed in AD patients compared to controls 
#: Number of studies conducted 
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Appendix L: Overview of studies that assessed the diagnostic value of resting state fMRI 
(rs-fMRI) candidate biomarkers 
Study fMRI candidate biomarker Patients and subjects Diagnostic value 
Li et al. 
(2002) 
rs-fMRI (COSLOF-Index) AD (N = 14) vs. 
HC (N = 13) 
Sensitivity: 80% 
Specificity: 90% 
Greicius 
et al. 
(2004) 
rs-fMRI- 
ICA components of the DMN 
AD (N = 13) vs. 
HC (N = 13) 
Sensitivity: 85% 
Specificity: 77% 
Koch et 
al. 
(2010b) 
rs-fMRI- 
Combined functional connectivity (ROI based) and 
coactivation magnitude (ICA-based) 
AD (N = 15) vs. 
HC (N = 21) 
Sensitivity: 100% 
Specificity: 95% 
Chen et 
al. 
(2011) 
rs-fMRI- 
ROI-based pairwise product moment coefficients 
AD (N = 20) vs. 
Non-AD group (=pooled aMCI 
and HC (N = 35)) 
Sensitivity: 85% 
Specificity: 80% 
Supekar 
et al. 
(2008) 
rs-fMRI- 
Small world network properties (clustering 
coefficient) 
AD (N = 21) vs. 
HC (N = 18) 
Sensitivity: 72% 
Specificity: 78% 	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Appendix M: Summary of combined MRI and CSF studies in AD 
Study Subjects Diagnostic measures Associations 
Schönknecht et al., 
2003 
88 AD, 17 CN  In AD, CSF tau was not correlated to 
MRI. 
Wahlund and 
Blennow, 2003 
23 MCI, 24 AD  At baseline, CSF Aβ1-42 was 
correlated with MRI. During the 
follow-up period, increases in tau 
and p-tau correlated with ventricular 
increase. 
de Leon et al., 
2004 
32 stable CN, 
13 CN 
progressed to 
MCI 
Accuracy for prediction of CN 
progression to MCI: Baseline: 
MRI: 78%; CSF: 78% to 89%. 
Hippocampal volume decrease 
correlates with P-tau231 increase and 
Aβ1-42 decrease. 
Hampel et al., 
2005 
22 AD  CSF p-tau231 correlated with baseline 
hippocampus and rates of 
hippocampal atrophy. 
Schoonenboomet 
al., 2005 
39 MCI  CSF Aβ1-42 was correlated with MRI 
and not tau. 
de Leon et al., 
2006 
9 CN, 7 MCI Accuracy for separation of CN 
and MCI: Baseline: MRI: 94%, 
CSF: 63% to 88%; MRI + CSF: 
94% Longitudinal: MRI: 88%; 
CSF: 73% to 88%; MRI + CSF: 
94% 
In MCI, longitudinal hippocampal 
volume decrease correlated with P-
tau231 increase and Aβ1-42 decrease. 
Herukka et al., 
2008 
21 MCI, of 
whom 8 
progressed to 
AD 
 In all MCI, increases in tau and p-tau 
correlated with a decrease in 
hippocampal volumes. 
Schoonenboomet 
al., 2008 
32 CN, 61 AD Odds ratio between AD and CN: 
MRI: 28; CSF: 57 
There were no correlations between 
visual assessment of MRI and CSF 
biomarkers within CN and AD. 
Sluimer et al., 
2008 
23 CN, 9 MCI, 
47 AD 
 In AD, CSF p-tau181 had mild 
association with whole-brain atrophy 
rate. Only MRI was associated with 
change in cognitive measures. 
Brys et al., 2009 21 CN, 16 
stable MCI, 8 
MCI progressed 
to AD 
Accuracy for prediction of MCI 
progression to AD: MRI: 74%; 
CSF: 70%; MRI + CSF: 84% 
There were no longitudinal 
correlations between MRI and CSF. 
Chou et al., 2009 80 CN, 80 MCI, 
80 AD (ADNI) 
 CSF Aβ1-42 was correlated with 
ventricular expansion. 
Fagan et al., 2009 69 CN, 29 mild 
AD 
 In CN, decrease in CSF Aβ1-
42 correlated with brain atrophy. In 
mild AD, increases in CSF t-tau and 
p-tau181 correlated with brain 
atrophy. 
Henneman et al., 
2009 
19 CN, 25 MCI, 
31 AD 
 Baseline CSF p-tau181 was 
independently associated with 
subsequent disease progression, 
measured by hippocampal atrophy 
rate. 
Leow et al., 2009 40 CN, 40 MCI, 
20 AD (ADNI) 
 Baseline CSF correlated with 
temporal atrophy rates over the 
course of 12 months. 
Schuff et al., 2009 112 CN, 226 
MCI, 96 AD 
(ADNI) 
 In MCI, an increase in rates of 
hippocampal atrophy correlated with 
lower CSF Aβ1-42. 
Thomann et al., 
2009 
15 CN, 23 MCI 
(AACD), 16 AD 
 Increases in CSF t-tau and p-
tau181 correlated with cortical 
atrophy in temporal, parietal, and 
frontal regions. 
Vemuri et al., 2009 109 CN, 192 
aMCI, 98 AD 
(ADNI) 
AUROC separating CN, aMCI, 
and AD: MRI: 0.77; CSF: 0.68 
to 0.73; MRI + CSF: 0.81 
Within each clinical group, only MRI 
correlated with cognition in aMCI 
and AD groups. 
Vemuri et al., 2009 109 CN, 192 
aMCI, 98 AD 
(ADNI) 
Proportional hazards for 
predicting time to conversion 
from aMCI to AD: MRI: 2.6; 
Baseline MRI was a better predictor 
of subsequent cognitive and 
functional decline than baseline CSF 
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CSF: 1.7 to 2.0 was. 
Vemuri et al., 2010 92 CN, 149 
MCI, 71 AD 
(ADNI) 
Sample size required to detect 
treatment effects in AD: MRI: 
100; CSF >105. 
Longitudinal annual changes were 
observed only in MRI and not in CSF. 
Change in MRI was associated with 
change in cognitive measures. 
Walhovd et al., 
2010 
42 CN, 73 MCI, 
38 AD (ADNI) 
Accuracy for baseline separation 
of CN and AD: MRI: 85%; CSF: 
81.2%; CSF + MRI: 88.8% 
In MCIs, only baseline MRI and FDG 
were correlated to (or predictive of) 
future clinical decline during 2 years. 
Fjell et al., 2010 71 CN  Below a certain threshold, baseline 
CSF Aβ1-42correlated with ventricular 
increase and volumetric brain 
decrease over the course of 1 year. 
Fjell et al., 2010 Baseline: 105 
CN, 175 MCI, 
90 AD (ADNI) 
 In MCI and AD, baseline CSF 
measures were not related to 
baseline MRI but were related to 
longitudinal atrophy. Baseline MRI 
predicted change in cognition better 
than CSF did. 	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Appendix N: Summary of combined MRI and FDG studies in AD 
Study Subjects Diagnostic measures Associations 
Yamaguchiet 
al., 1997 
13 AD, 13 CN  Hippocampal volume and mean cortical 
cerebral glucose metabolic rates of the 
temporal lobe, temporo-parieto-occipital, and 
frontal regions were correlated. 
De Santi et 
al., 2001 
11 CN, 15 MCI, 12 
AD 
Accuracy for separation 
of MCI and CN: MRI: 
73%; FDG: 73% to 
85% AD and CN: MRI: 
83%; FDG: 100% 
FDG and MRI measures in hippocampal 
formation best characterize MCI, and 
additional neocortical damage best 
characterizes AD. 
Ishii et al., 
2005 
30 CN, 30 very 
mild AD 
 VBM: decrease in MRI in medial temporal lobes 
and decrease in FDG in posterior cingulate and 
parietal lobule 
Kawachi et 
al., 2006 
60 CN, 30 very 
mild AD, 32 mild 
AD 
Accuracy for separating 
very mild AD and CN: 
FDG: 89%; MRI: 83%; 
MRI + FDG: 94% 
VBM: decrease in MRI in bilateral 
amygdala/hippocampus complex and decrease 
in FDG in bilateral posterior cingulate and 
parietotemporal area 
Mosconi et al., 
2006 
7 CN, 7 
asymptomatic at-
risk FAD 
Accuracy for separation 
of both groups: MRI: 
43% to 86%; FDG: 
50% to 100% 
FDG showed significant decrease but little 
sMRI change in asymptomatic subjects. 
Ishii et al., 
2007 
20 very mild AD, 
20 DLB, 20 CN 
Accuracy for separation 
of DLB and AD: MRI: 
62% to 80%; FDG: 
66% to 87% 
Both MRI and FDG had a hippocampal 
decrease due to AD. 
Matsunariet 
al., 2007 
Group 1: 40 CN, 27 
AD Group 2 (early- 
and late-onset): 50 
CN, 34 AD 
Accuracy for different 
comparisons: MRI: 
74% to 92%; FDG: 
92% to 100% 
VBM: decrease in MRI in hippocampal complex 
and decrease in FDG in posterior cingulate and 
parietotemporal area 
Samurakiet 
al., 2007 
73 CN, 39 AD  VBM: FDG uptake was preserved in the medial 
temporal lobe before as well as after correction 
with MRI. 
Chetelat et 
al., 2008 
15 CN, 18 mild AD  FDG hypometabolism exceeds MRI atrophy in 
the posterior cingulate-precuneus, 
orbitofrontal, inferior temporo-parietal, 
parahippocampal, angular, and fusiform areas. 
Similar degrees of atrophy and 
hypometabolism were observed in the 
hippocampus. 
Hinrichs et 
al., 2009 
CN and AD subjects 
from ADNI: MRI: 
183, FDG: 149 
AUROC for 
discrimination of AD 
and CN: MRI: 0.88; 
FDG: 0.87 
 
Walhovdet al., 
2009 
22 CN, 44 MCI  MRI predicted diagnostic groups for most 
regions of interest, but PET did not, except a 
trend for the precuneus metabolism. 
Yuan et al., 
2009 
Meta-analysis of 24 
MCI studies (1112 
subjects) 
Odds ratio of predicting 
MCI conversion to AD: 
MRI: 10.6; FDG: 40.1 
FDG was better than MRI in predicting 
conversion of MCI to AD. 
Morbelli et al., 
2010 
12 CN, 11 stable 
MCI, 9 MCI who 
progressed to AD 
 MCI converters showed MRI changes in left 
parahippocampus and both thalami, whereas 
FDG showed MRI changes in left PCC, 
precuneus, superior parietal lobule. 
Walhovdet al., 
2010  
42 CN, 73 MCI, 38 
AD (ADNI) 
Accuracy for baseline 
separation of AD and 
CN: MRI: 85%; FDG: 
82.5% 
MRI and FDG were largely overlapping in value 
for discrimination. 	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Appendix O: Summary of combined MRI and PIB studies in AD 
Study Subjects Associations 
Archer et al., 
2006 
9 AD Positive correlation between rates of whole-brain atrophy and 
regional PIB uptake 
Jack et al., 
2008 
20 CN, 17 MCI, 8 AD aProportional odds to separate all groups: PIB: 0.75; MRI: 
0.84; MRI + PIB: 0.86. Global PIB and MRI were correlated 
with each other as well as with clinical measures. 
Jack et al., 
2009 
21 CN, 32 MCI, 8 AD Longitudinal annual change was observed only in MRI and not 
in PIB. Change in MRI was associated with change in cognitive 
measures. 
Mormino et al., 
2009 
37 CN, 39 PIB + MCI PIB and MRI were correlated with each other as well as with 
episodic memory. 
Scheinin et al., 
2009 
13 CN, 14 AD During 2 years, only longitudinal MRI change was observed but 
not in PIB. 
Strorandt et 
al., 2009 
135 CN PIB was associated with cross-sectional brain atrophy and 
longitudinal cognitive decline. 
Bourgeat et al., 
2010 
92 CN, 32 MCI, 35 AD In CN, PIB retention in the inferior temporal region and 
hippocampal volume were strongly correlated. 
Chetalat et al., 
2010 
94 CN (49 subjective 
cognitive impairment), 34 
MCI, 35 AD 
Global atrophy and regional atrophy were strongly related to 
PIB load in CN subjects with subjective cognitive impairment 
but not MCI and AD. 
Driscoll et al., 
2010 
57 CN In CN, current PIB load was not related to longitudinal MRI 
changes in the preceding years. 	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Appendix P: Weighted summary of sensitivity and specificity for each modality 
Modality Sensitivity Specificity 
FDG-PET 88.8% 84.9% 
SPECT 83.8% 70.4% 
MRI 72.8% 81.0% 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
170	  	  
Appendix Q: Table Outlining Several Risk Factors for AD and T2DM 
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Appendix R: Pathway to Show TZD Mechanism 
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Appendix S: Trisomy 21 or Down’s Syndrome 
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Appendix T: Trisomy 21 Mosaicism Model 
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Appendix U: Demographic Distribution of Caregivers for AD Patients 
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Appendix V: Risk of AD in Males vs. Females 
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Appendix W: Timeline of the Progression of AD 
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Appendix X: Cost Comparison of the Direct and Indirect Care of AD 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
178	  	  
Appendix Y: Cost vs. AD Severity in Early Detection 
	  	  
 
